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ABSTRACT 
Research on indoleamine 2,3-dioxygenase (IDO) 2 has become an area of interest in the 
domain of tryptophan (Trp) metabolism. Discovered less than a decade ago, this 
isoenzyme of IDO1 catalyses the same reaction as its isoform and tryptophan 2,3-
dioxygenase (TDO2), namely the degradation of tryptophan to N-formylkynurenine in the 
kynurenine (Kyn) pathway. Despite IDO2 possessing the ability to catabolise Trp, this 
activity is relatively low compared to TDO2 and IDO1, suggesting that this protein may 
possess alternative roles. While most mammals, including humans and mice, possess two 
homologues of IDO, lower vertebrates such as chicken and fish only possess one, and that 
enzyme is more similar to IDO2 than IDO1. Constitutive expression of IDO2 mRNA and 
protein in the mouse has been reported to be highest in the liver and the kidney, with the 
distribution apparently cytoplasmic in hepatocytes and tubules respectively. However, 
the detection of a cross-reacting protein of a similar molecular weight in the kidney 
lysates of Ido2-/- mice cast doubt upon the veracity of this observation. Over the last five 
years, possible roles for IDO2 in cancer, inflammation and autoimmunity have been 
suggested, but more research is needed before its functions in physiology and 
pathophysiology can be fully understood. 
We began this project by developing a human interferon gamma (IFNγ) bioassay based on 
the induction of IDO1 activity in human brain endothelial cells (HBECs). The focus then 
shifted to studying the distribution of IDO2 in adult mouse tissues and in developmental 
series from mouse and zebrafish. At the cellular level, we found IDO2 localised 
perinuclearly in hepatocytes, while its presence in other tissues (kidney, brain, colon, 
testis and epididymis) could not be confirmed. Its cellular localisation in the liver differed 
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to its distribution in transfected human embryonic kidney (HEK) cells, which appeared 
cytoplasmic. The distribution of ido mRNA in developing zebrafish embryos, where it was 
found localised only in the intestine, was different to that in both embryonic and adult 
mouse tissues. Ido2 mRNA was detectable in placenta and yolk sac in the mouse 
developmental series as well as in adult liver, kidney, brain, epididymis and colon 
(although IDO2 protein was found only in the liver). In zebrafish embryos, tdo2a and 
tdo2b mRNAs were detected in the liver and the intestine, while in the murine 
developmental series Tdo2 was detectable in the placenta and yolk sac but not in the 
liver. Ido1 also was detected in the yolk sac and placenta of mouse developmental 
tissues.  
Mice deficient for two Trp-catabolic enzymes were generated to complement those 
deficient in IDO1, IDO2 or TDO2 that the laboratory previously had acquired. These gene 
knockout mice were used to examine at the molecular level the relationship between the 
three enzymes. In the absence of IDO1, Ido2 mRNA was downregulated in the brain, 
kidney and epididymis. However, the expression of neither Tdo2 nor Ido1 was affected in 
the absence of one or two of the other Trp-degrading enzymes.  
Global gene expression in liver lysates deficient for IDO2 and/or TDO2 relative to their 
equivalent wild-types (WT) was analysed by microarray analysis. The expression of some 
genes subsequently was validated by RT-qPCR. By microarray analysis a total of 63 genes 
was up- or down-regulated in the liver in the absence of IDO2. The expression of 20 of 
these was further assessed by RT-qPCR, and that of Xdh, Cyp4a14, Acot1, Gdf15, Moxd1, 
Igfbp1, Fam25c and Ehd3 was found significantly dysregulated (p<0.05). In liver lysates of 
Tdo2-/- mice relative to Tdo2+/+, the expression of only two genes was validated, with 
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Cyp4a14 and Moxd1 found to be differentially regulated by RT-qPCR. In mice deficient in 
both IDO2 and TDO2, expression of four genes was found dysregulated in the liver, 
relative to Ido2+/+Tdo2+/+ animals, upon RT-qPCR analysis, namely Saa1, Lcn2, Nrep and 
Acot4. A number of the genes found differentially expressed in the absence of IDO2 
and/or TDO2 previously have been implicated in inflammation, obesity and diabetes. 
These observations led us to propose a possible role for IDO2 in averting inflammation, 
which if unchecked may lead to obesity and/or diabetes. We suggest that the absence of 
IDO2 might lead to the dysregulation of T cell proliferation and/or inflammatory 
mediators, which may contribute to an inflammatory onset in the liver.  
This is the first report demonstrating the cellular localisation of IDO2 in adult mouse liver 
with Ido2-/- mice as the negative control, as well as the mRNA expression of Trp-
catabolising enzymes in embryonic developmental series of zebrafish (tdo2a, tdo2b and 
ido) and mouse (Tdo2, Ido1 and Ido2). Both tdo2a and tdo2b were detected in zebrafish 
embryonic liver, whereas all three genes coding for Trp-catabolic enzymes were found in 
the intestine. In murine developmental tissues, Tdo2, Ido1 and Ido2 were all detectable in 
the yolk sac and placenta, with the expression of Tdo2 being the highest. Finally, we are 
the first to postulate a possible role for IDO2 in averting inflammation and metabolic 
dysregulation in the liver. 
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CHAPTER 1 LITERATURE REVIEW 
1.1 Tryptophan 
Tryptophan (Trp) is an important amino acid that makes up only about (2%) of the total 
amino acids in the body (Connick et al., 1989). As it cannot be synthesised de novo, it is 
obtained primarily through diet where Trp is present in most foods.  A striking attribute 
of this amino acid is that it is one of the few that binds to plasma albumin and its 
presence in the plasma is an interplay of balance between its bound and free forms 
(McMenamy, 1965). Most of the circulating Trp exists in its albumin-bound form (90%) in 
the resting state whereas the rest circulates in the free form (Madras et al., 1974). 
Dysregulation of Trp metabolism has been implicated in the pathogenesis of a number of 
central nervous system (CNS)-related diseases such as Alzheimer’s disease (Wu et al., 
2013), Huntington’s disease (Connick et al., 1989) and schizophrenia (Linderholm et al., 
2012),  as well as in infectious diseases such as microbial and human immunodeficiency 
viral (HIV) infections (Favre et al., 2010). Its role in autoimmune-related conditions such 
as allergy (Kawasaki et al., 2014) and cancer also has been discussed (Platten et al., 2005; 
Opitz et al., 2011; Liu et al., 2010). 
 
Non-esterified fatty acids (NEFA) are pivotal in the balance of free to albumin-bound Trp 
ratio. NEFA binds to albumin competitively with Trp and is therefore able to displace the 
amino acid from albumin, increasing the levels of free Trp in the plasma (Curzon et al., 
1973).  Conditions such as sustained exercise (Fernstrom and Fernstrom, 2006) and β-
adrenoceptor-mediated lipolysis (Cleroux et al., 1989) can result in the elevation of NEFA 
levels in the plasma. This increase in NEFA displaces Trp from albumin, increasing the 
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pool of its free form in plasma.  Some drugs are capable of eliciting similar effects, even at 
their pharmacological doses (Muller and Wollert, 1975; Spano et al., 1974). It is this 
elevation in plasma Trp levels that is believed to consequently influence brain Trp uptake 
and levels (Tagliamonte et al., 1973). However, it was demonstrated that an increase in 
brain Trp level was still evident even when the rise in plasma NEFA during exercise was 
completely blocked by nicotinic acid pretreatment (Fernstrom and Fernstrom, 1993), 
suggesting an alternative mechanism for Trp increase in the brain.  The activation of the 
sympathetic nervous system, was later shown, to have a greater influence in the 
regulation of Trp availability in the brain than the displacement of Trp from albumin by 
NEFA (Fernstrom and Fernstrom, 2006; Ruddick et al., 2006). Trp homeostasis in the brain 
also may be affected by other NEFA-independent factors, including various stress stimuli, 
carbohydrate intake, cytokines as well as some drugs (Lenard and Dunn, 2005; Curzon et 
al., 1972; Dunn, 1992; Wang and Dunn, 1998). 
Once Trp has crossed the blood-brain barrier (BBB), it can then be taken into the cells of 
the CNS system and distributed to different metabolic pathways according to the needs 
of the system. It is the regulation of Trp uptake across the BBB that ultimately controls 
serotonin synthesis (Grahame-Smith, 1971; Tagliamonte et al., 1973).  
Apart from being incorporated into proteins, Trp plays a significant role in a number of 
pathophysiological and physiological conditions as it generates neuroactive metabolites 
such as serotonin, 3-hydroxykynurenine, quinolinic acid and kynurenic acid, among 
others.  Trp can be metabolised either through the serotonin or kynurenine pathways, 
with the latter catabolising the majority of Trp obtained from the plasma. As Trp is an 
essential amino acid, its depletion acts as a strategic approach for the host to eliminate 
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pathogens by promoting nutritional competition between host cells and pathogens 
(Pfefferkorn and Guyre, 1984). This depletion of Trp in the cells invaded by pathogens 
and neighbouring cells inhibits the proliferation of the pathogen, efficiently retarding 
further pathogen growth. This mechanism has been shown to help control microbial 
infections in salmonellosis, listeriosis and toxoplasmosis (Adams et al., 2004; Durr and 
Kindler, 2013; Knubel et al., 2010; Konen-Waisman and Howard, 2007; Popov et al., 
2006).  
Evidence suggests that the depletion of Trp also modulates immune tolerance to non-self 
as in seen in the cases of transplants and allogeneic pregnancies (Munn et al., 1998; 
Uyttenhove et al., 2003; Alexander et al., 2002). More recently, it was shown that 
tolerance to non-self was not the only role of Trp catabolism as degradation of Trp also 
facilitated tolerance towards tumours (Uyttenhove et al., 2003). The depletion of Trp was 
found to modulate these effects by suppression of T cell proliferation (Munn et al., 1999; 
Lee et al., 2002) through either the activation of the GCN2 (General control 
nonderepresible 2) stress-kinase pathway (Munn et al., 2005; Zhang et al., 2002) or 
inhibition of mTOR (mammalian target of rapamycin) (Gao et al., 2002; Rohde et al., 
2001). The generation of toxic Trp metabolites through the kynurenine pathway is an 
alternative mechanism through which the immunosuppressive effects of Trp metabolism 
have been suggested to be exerted (Fallarino et al., 2002; Frumento et al., 2002; Terness 
et al., 2002).  
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1.2 Serotonin pathway 
In this pathway, Trp is hydrolysed by tryptophan hydroxylase (TPH) to 5-
hydroxytrytophan (5-HTP) (Stoll and Goldman, 1991; Grahame-Smith, 1964). 5-HTP then 
is quickly metabolised to 5-hydroxytryptamine (5-HT), also known as serotonin, by 
aromatic amino acid decarboxylase (Fig. 1.1). Serotonin, an aminergic neurotransmitter, 
then can be either packed in synaptic vesicles and stored until use or metabolised first to 
5-hydroxyindole acetaldehyde (5-HIA) and then to 5-hydroxyindoleacetic acid (5-HIAA). It 
also can be converted eventually to melatonin, a neurohormone (Ruddick et al., 2006). 
The availability of Trp itself can also, to a lesser degree, exert rate limiting effects on 
serotonin synthesis (Fernstrom and Wurtman, 1971; Richard et al., 2009). It was initially 
thought that the catabolism of Trp to serotonin in the CNS as well as the peripheral 
nervous system (PNS) was catalysed by the same enzyme, TPH. However, it was 
discovered recently that mice ablated for TPH function only had 5-hydroxytrptamine (5-
HT) deficiency in the periphery and pineal gland (Walther et al., 2003). The levels of 5-HT 
remained normal in the brain despite Tph gene ablation. This led to the discovery of a 
new, brain-specific Tph gene, now known as Tph2, which was responsible for the 
catabolism of Trp to serotonin in the brain (Walther et al., 2003). It also has been 
demonstrated that TPH2 has higher affinity for Trp than TPH1 (McKinney et al., 2005). 
Even within TPH itself, there is a difference between TPH of neural and non-neural origin 
(Hasegawa et al., 1987). Serotonin has been shown to play a role in a number of major 
organ systems as well as the CNS, with its dysregulation implicated in psychiatric and 
neurological disorders such as anxiety, depression, schizophrenia, suicidal behaviour and 
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alcohol abuse as well as in physiological activities such as arousal and sleep (Roth et al., 
2004; Berger et al., 2009; Morrissette and Stahl, 2014) .  
In peripheral tissues, only about 1% of Trp is converted to serotonin, while more than 
95% of dietary tryptophan is catabolised to kynurenines (Botting, 1995; Stone, 1993; 
Wolf, 1974). Due to the discovery of serotonin as an important neurotransmitter, the 
research focus on Trp catabolism shifted from the kynurenine pathway to the serotonin 
pathway instead. However, there has been resurgence in interest in the kynurenine 
pathway following findings on the neurological activities of kynurenine metabolites such 
as quinolinic acid and kynurenic acid. 
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Fig. 1.1 Tryptophan metabolism by tryptophan hydroxylase in serotonergic neurons 
Abbreviations: 5-HTP, 5-Hydroxytryptophan; 5-HT, 5-Hydroxytryptamine; 5-HIA, 5-
Hydroxyindole acetaldehyde; 5-HIAA, 5-Hydroxyindole acetic acid; VMAT2, Vesicular 
monoamine transporter 2; SBP, Serotonin-binding protein; BH4, cofactor 
tetrahydrobiopterin. 
Reproduced from (Ruddick et al., 2006) 
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1.3 Kynurenine Pathway 
This pathway begins with oxidative cleavage of Trp, by either indoleamine 2,3-
dioxygenase 1 (IDO1), IDO2 or tryptophan 2,3-dioxygenase (TDO2), all of which are haem-
dependent enzymes (Knox and Auerbach, 1955; Higuchi and Hayaishi, 1967; Ball et al., 
2007). The product of this step, N-formylkynurenine, is then broken down to kynurenine 
by a formamidase (Fig. 1.2). Kynurenine can then undergo different fates. It can either be 
broken down to (i) anthranillic acid by kynureninase, (ii) kynurenic acid (KA) by 
kynurenine aminotransferase or (iii) 3-hydroxykynurenine by kynurenine-3-
monooxygenase (Botting, 1995). In the case that kynurenine undergoes the first option, it 
may be used subsequently for the biosynthesis of aromatic amino acids. On the other 
hand, kynurenic acid is a rather stable compound, which can be further catalysed to 
quinolines. In the case where kynurenine follows the third route, the pathway continues 
on to contribute to the formation of NADH as the final product.  
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Figure 1.2 Schematic overview of the kynurenine pathway.  
 
Abbreviations: L-TRP, L-Tryptophan; L-KYN, IDO, Indoleamine 2,3 dioxygenase; TDO, 
Tryptophan 2,3 dioxygenase; L-Kynurenine; KAT I, II, III, Kynurenine aminotransferase; KA, 
kynurenic acid; KMO, kynurenine 3-monooxygenase; AA, anthranilic acid; 3-HK, 3-
hydroxykynurenine; XA, xanthurenic acid; 3-HAA, 3-hydroxyanthranilic acid; 3-HAO, 3-
hydroxyanthranic acid oxidase; NAD+, nicotinamide adenine dinucleotide+. 
Reproduced from (Murakami and Saito, 2013) and (Stone, 1993). 
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Furthermore, the consequence or fate of Trp in the kynurenine pathway differs according 
to tissue type, as not all cells are capable of catabolising the substrates downstream in 
the pathway (Heyes et al., 1997; Owe-Young et al., 2008). This difference is caused by the 
absence or low expression of the enzymes downstream in the pathway. For example, in 
endothelial cells, Trp is catabolised to KA constitutively, whereas in cells primed with 
Interferon gamma (IFNγ), high levels of both kynurenine and kynurenic acid was detected 
(Owe-Young et al., 2008; Wang et al., 2010). Another key observation of the pathway in 
endothelial cells was that there was little or very low quinolinic acid detected. Even in 
conditions where BBB endothelial cells were incubated with an excess of 3-
hydroxyanthranilic acid, quinolinic acid was undetectable, indicating that 3-
hydroxyanthranilinic acid (3-HAA) was not a substrate for the kynurenine pathway in BBB 
endothelial cells. Exogenous quinolinic acid added to these cells did not alter in levels, 
which showed that it is not metabolised further in the endothelial cells. The inability of 
endothelial cells to metabolise 3-hydroxyanthranilic acid, and the absence of quinolinic 
acid in these cells, suggests that it is most likely that the enzymes downstream in the 
pathway are either inactive, absent or expressed at levels too low to cause any functional 
effect (Owe-Young et al., 2008). This observation is consolidated further by the inability 
of BBB endothelial cells to metabolise exogenous quinolinic acid. Similar observations 
were reported in human foetal brain cultures and lung cells, where kynurenine 3-
monooxygenase (sometimes known as kynurenine 3-hydroxylase) activity was low and 
the production of quinolinic acid was little to none, despite stimulation with IFNγ (Heyes 
et al., 1996; Heyes et al., 1997).  In some cells types, the enzyme downstream in the 
pathway is expressed and active, and therefore downstream products are detectable. 
Quinolinic acid was detected at high levels in monocytes, microglial and liver cells, with 
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the highest accumulation observed in monocytes, indicating the capacity of these cell 
types to metabolise substrates downstream of the pathway (Heyes et al., 1992; Heyes et 
al., 1997). In the presence of IFNγ there was an even more marked production of 
quinolinic acid in these cells (Heyes et al., 1997).  
The involvement of the kynurenine pathway has been reported in some physiological 
processes, such as pregnancy, as well as pathophysiological processes such as cancer, 
dementia, schizophrenia and malaria (Munn et al., 1998; Sanni et al., 1998; Heyes et al., 
1991; Platten et al., 2012; Linderholm et al., 2012; Pfefferkorn and Guyre, 1984). This 
pathway also has been identified as the major route for NAD+ supply in rat hepatocytes 
(Bender and Olufunwa, 1988).  
The first step of this pathway is rate-limiting. Although there are three enzymes that 
catalyse this reaction, these enzymes differ in their distribution and roles. TDO2, the 
enzyme first discovered to catalyse this reaction, is a hepatic protein responsible mainly 
for the regulation of dietary Trp (Knox and Auerbach, 1955). IDO1 was first isolated from 
rabbit ileum in 1967 (Higuchi and Hayaishi, 1967). Its expression, however, was induced 
more in inflammatory conditions than constitutively (Yoshida et al., 1979; Pfefferkorn et 
al., 1986b). The third and most recently discovered enzyme that catalyses the first step of 
the kynurenine pathway is IDO2, an isoform of IDO1 (Ball et al., 2007; Metz et al., 2007; 
Yuasa et al., 2007). Although it has been implicated in inflammation and adaptive 
immunity, little is known about its role in physiological and pathological circumstances 
(Merlo et al., 2014; Metz et al., 2014). The possibility that the expression and role of IDO2 
may be influenced by, or is dependent on, the expression IDO1 also has been discussed 
recently (Metz et al., 2014) and will be further explored in Chapter 4 of this thesis. 
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1.3.1 TRYPTOPHAN 2,3-DIOXYGENASE 
Tryptophan 2,3-dioxygenase (TDO/TDO2), also known previously as tryptophan 
oxygenase, tryptophan peroxidase or tryptophan pyrrolase, is coded for by the Tdo2 
gene, which is located on chromosome 3 and 4 in mice and humans, respectively. It was 
first described by Kotake and Masayama (1936) who observed the conversion of L-Trp to 
L-kynurenine in crude extracts of rabbit liver (Knox and Mehler, 1950; Mehler and Knox, 
1950). Apart from the liver, Tdo2 mRNA is expressed constitutively in low levels in the 
epididymis, testis, pancreas, heart, brain, maternal-foetal interface and early stage 
embryos (Britan et al., 2006; Suzuki et al., 2001). However, the exact role of the enzyme 
in these tissues is not very well understood. Despite catalysing the same reaction as IDO1 
and IDO2, TDO2 shares very little sequence identity with the two, especially around the 
area pivotal for catalytic activity (Zhang et al., 2007b; Forouhar et al., 2007; Metz et al., 
2007). This difference in sequence identity also could be suggesting distinct roles for the 
three enzymes depending on the physiological or pathological condition. 
TDO2 is enantiomer-specific, cleaving highly specifically the L-isoform of Trp, a 
contrasting feature to IDO1 which has a wider substrate range (Hayaishi, 1976; Forouhar 
et al., 2007; Capece et al., 2010). The indole ring of Trp is cleaved oxidatively by TDO2, 
which has a short half-life of 2 hours in mammals (Stone, 1993). When exogenous Trp 
was administered to WT mice, the rapid degradation of TDO2 is inhibited, thereby 
facilitating the catabolism of Trp by the enzyme (Schimke et al., 1965a; Schimke et al., 
1965b). Concurrent with this observation is the finding that the activity of TDO2 is 
induced mainly by dietary Trp or its related compounds such as α-methyl tryptophan 
(Knox and Auerbach, 1955; Schimke et al., 1965b). Glucocorticoids also seem to induce 
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this enzyme, by a mechanism that results in production of more TDO2 mRNA and protein. 
Although TDO2 is known to be unresponsive to immunological signals, a striking 
difference to IDO1, a substantial inhibition of liver TDO2 activity in infectious or 
inflammatory states has been reported (Takikawa et al., 1986; Saito et al., 1993; Moreau 
et al., 2005). However, when human TDO2-transfected HeLa cells,  capable of degrading 
Trp and producing kynurenine upon stimulation with tetracycline, were infected with 
Toxoplasma gondii, Staphylococcus aureus or Herpes Simplex virus, the growth of these 
pathogens was inhibited (Schmidt et al., 2009). This suggested that TDO2 may possess 
antimicrobial properties, exerted through the depletion of Trp in the microenvironment. 
In the light of the earlier finding that TDO2 activity is suppressed during infection and 
inflammation, the antimicrobial effects seen could be a feature of extrahepatic TDO2 and 
not liver TDO2. The same publication also found that TDO2-positive cells were capable of 
suppressing T cell proliferation and IFNγ production driven by alloantigen, an 
immunoinhibitory effect that can be reversed by supplementation with Trp. This 
implicated TDO2 in a possible immunoregulatory role, especially in liver transplantation.  
Another condition in which TDO2 is suggested to play a role is cancer, as TDO2 mRNA was 
detected in a wide range of human tumour samples as well as in cancer cell lines (Pilotte 
et al., 2012; Opitz et al., 2011). In addition, when human and murine cancer cell lines 
were treated with a TDO2-selective inhibitor, a reduction in kynurenine production was 
observed, which was not seen with cells treated with the IDO1-selective inhibitor the L 
isomer of methyl-Trp (L-1-MT). In mice injected with TDO2-expressing tumour cells, a 
more rapid progression of the tumour was seen (Pilotte et al., 2012). Opitz et al. (2011) 
also showed that kynurenine constitutively generated by TDO2 of human tumour cell line 
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origin was an endogenous ligand of aryl hydrocarbon receptor (AhR). AhR is involved in a 
number of cellular processes, tumourigenesis being one of them. Both these findings are 
consistent with the suggestion that TDO2 might be mediating immunotolerance in certain 
cancer types. 
Low levels of Tdo2 have been reported in the brain (Gal, 1974). As the kynurenine 
pathway has been implicated in a number of psychiatric disorders, it has been suggested 
that TDO2 is the Trp-catabolic enzyme that plays a role in the pathology of these 
disorders. Elevated levels of kynurenic acid and kynurenine were found in postmortem 
brain samples of schizophrenic patients (Schwarcz et al., 2001), and these were later 
attributed to TDO2 (Miller et al., 2004; Miller et al., 2006). A similar upregulation of TDO2 
in post-mortem brain samples of bipolar patients with psychosis also was  reported, 
although the difference was less marked than that seen in schizophrenic patients (Miller 
et al., 2006). Interestingly, the absence of TDO2 resulted in reduced anxiety in Tdo2-/- 
mice (Kanai et al., 2009). As plasma levels of Trp and 5-hydroxyindoleacetic acid  were 
elevated in these mice, it was postulated that the absence of TDO2 increased plasma 
levels of Trp, resulting in upregulation of serotonin synthesis in the brain, which could 
cause the anxiolytic symptoms detected in the Tdo2-/- mice. Collectively, the presence of 
TDO2 in the brain, as well as the ability of TDO2 to modulate the expression of serotonin 
in its absence, suggests a possible role for TDO2 in neurological or psychiatric disorders. 
One of the outcomes of the kynurenine pathway is the generation of NAD+. Of the three 
Trp-catabolising enzymes, it is TDO2 that was proposed to be the primary enzyme driving 
this process (Badawy, 1981). This view was consolidated with more recent reports that 
TDO enzymes were able to salvage the NA-auxotrophic yeast strain, but not IDO2 (Ball et 
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al., 2014; Yuasa and Ball, 2013). Surprisingly, no difference was found in liver NAD+ levels 
between WT and TDO2-deficient mice (Terakata et al., 2013). Terakata and colleagues, 
therefore, speculated that in TDO2-deficient mice, IDO1 is essential to synthesise the 
minimum required amount of nicotinamide, suggesting extrahepatic IDO1 compensates 
for the role of TDO2 in generating niacin in these mice.  
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1.3.2 INDOLEAMINE 2,3-DIOXYGENASE 1 
IDO has been well conserved throughout evolution (Sedlmayr et al., 2014) and widely 
distributed from bacteria to metazoans. It is even found in fungi, in which TDO is absent 
(Ball et al., 2014). In some animals, IDO homologues are found. Both Ascomycota and 
Basidiomycota fungi possess multiple IDO homologues (Yuasa and Ball, 2011). In 
mammals such as mice and humans, two IDO gene homologues have been reported (Ball 
et al., 2007; Metz et al., 2007; Yuasa et al., 2007). A phylogenetic tree showing the 
distribution of IDO in different organisms is depicted in Fig 1.3. 
The first IDO gene discovered in mammals was re-classified as IDO1, following the 
discovery of the second homologue, IDO2. IDO1 is the second enzyme reported to 
catalyse the same reaction as TDO2, namely the catabolism of Trp to N-
formylkynurenine, by cleaving the 2,3-double bond of its indole ring (Higuchi and 
Hayaishi, 1967). Unlike the tetrameric TDO2, IDO1 is monomeric, despite both proteins 
containing haem molecules. IDO1 is active in its reduced form (Fe2+) but inactive in its 
oxidised form (Fe3+) (Shimizu et al., 1978). Initially, it was proposed that IDO1 is reduced 
from the Fe3+ to Fe2+ form by superoxide anion (Taniguchi et al., 1977). More recently, 
this was refuted and cytochrome b5 (cyb5) working with cytochrome P450 reductase and 
NADPH was reported to be the major physiological reductant of oxidised human IDO1 
(Maghzal et al., 2008).  
IDO1 can catalyse a greater number of indole-containing substrates than TDO2, including 
D-Trp, L-Trp, tryptamine, 5-hydroxytryptophan and 5-hydroxytryptamine catabolism 
(Shimizu et al., 1978; Thomas and Stocker, 1999). Its affinity for L-Trp also was 
significantly higher than IDO2 with a Km of about 30 µM.  
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The most well-known inhibitor of IDO1 is 1-methyltryptophan (1-MT), which has been 
used in various studies to inhibit the enzyme’s activity (Munn et al., 1998; Uyttenhove et 
al., 2003). More recently, it was reported that the L-isomer of 1-MT was more efficient in 
blocking mouse IDO1 activity than the D-isomer (Austin et al., 2010; Lob et al., 2009). 
However, in clinical studies, the D-isomer has been reported to be more effective in 
increasing survival and reducing tumour growth in mice models of cancer (Hou et al., 
2007). However, the earlier studies were reported before the discovery of IDO2 and did 
not take into account the potential targets of this inhibitor on the second isoform of IDO. 
The effects of 1-MT on IDO2 will be discussed in Section 1.3.3.4. 
In mice, IDO1 mRNA and protein are expressed constitutively at relatively low levels in 
the epididymis, gut, brain, lymph nodes, spleen, thymus, lung, and placenta, despite 
being absent from the liver (Munn et al., 1998; Yoshida et al., 1979). IDO1 protein 
localisation has been reported in the apical and principal cells of the caput epididymis 
(Britan et al., 2006; Dai and Zhu, 2010). Certain cell types such as endothelial cells, 
dendritic cells, fibroblasts and monocyte-derived macrophages also possess an inducible 
form of IDO1 (Daubener et al., 2001; Hwu et al., 2000; Munn et al., 1999; Pfefferkorn et 
al., 1986b).  
The observation that IDO1 does not catabolise excess dietary Trp led to the question of 
why IDO1 was conserved in mammals. It was only recently that IDO1 was suggested to 
play an immunomodulatory role through Trp depletion and T cell suppression (Mellor and 
Munn, 1999; Mellor and Munn, 2004). 
The role of the kynurenine pathway in antimicrobial responses is well documented (Byrne 
et al., 1986a; Pfefferkorn and Guyre, 1984; Yoshida et al., 1979). Its expression also is 
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markedly higher during inflammatory states such as cancer and cerebral malaria as well 
as neurological conditions like Alzheimer’s disease, schizophrenia and AIDS dementia 
complex (Pfefferkorn et al., 1986b; Sanni et al., 1998; Knubel et al., 2010; Gupta et al., 
1994; Yamada et al., 2009; Uyttenhove et al., 2003). Apart from cancer, IDO1 was 
reported to play a role in other autoimmune diseases, such as arthritis, colitis, 
encephalomyelitis and asthma (Criado et al., 2009; Hayashi et al., 2004; Gurtner et al., 
2003; Sakurai et al., 2002; Szanto et al., 2007). The involvement of IDO1 in pregnancy is a 
relatively new development (Munn, 1998), where the enzyme in the placenta was shown 
to prevent rejection of allogeneic foetuses. 
Its induction in inflammatory conditions is driven by a few immunological signals, namely 
lipopolysaccharide (LPS), tumour necrosis factor (TNF) and IFNγ (Higuchi and Hayaishi, 
1967; Pfefferkorn et al., 1986b; Yoshida et al., 1979). Of the three most well-known 
inducers of IDO1, IFNγ is the most potent. Type I interferons, IFNα and IFNβ were 
reported to possess stimulatory effects on IDO1 expression too, although to a lesser 
degree (Carlin et al., 1987). 
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Fig 1.3 Phylogenetic tree of known IDOs and IDO-related proteins. Reproduced from (Ball et al., 2014). The Medaka-fish, Oryzias latipes (O. lat) 
and a soft-shelled turtle, Pelodiscus sinensis (P. sin) have a putative IDO1. The tree shows that the gene duplication, generating IDO1 and IDO2, 
occurred before the divergence of vertebrates. The internal branch labels are bootstrap values with 100 replications. The scale bar 
corresponds to 0.4 substitutions per site.
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1.3.2.1 Interferons 
Interferons (IFN), first reported in 1957, derive their name from the word interfere due to 
their ability to induce virus interference, which essentially refers to the protection of host 
cells from a virus (Isaacs and Lindenmann, 1957). This family of proteins, classified as 
cytokines, have been shown to possess various cellular functions. The viral interference 
functions of IFNs were demonstrated by Isaacs and colleagues where they showed that 
chorio-allantoic membrane released IFNs with antiviral properties when challenged with 
heat-inactivated, non-infective influenza virus (Isaacs and Lindenmann, 1957; Isaacs et al., 
1957). This observation was consolidated when mice injected with anti-IFN antibodies 
exhibited greater susceptibility to viral diseases (Gresser, 1990). IFNs also were shown to 
exert immunoregulatory roles (Boehm et al., 1997; Carnaud et al., 1999; Young and 
Hardy, 1995).  
IFNs have been classified into two main groups, Type I and Type II. Type I IFNs possess 
structural similarity to each other and consist of IFNα, IFNβ, IFNω and IFNτ. Type II IFN, on 
the other hand, refers to IFNγ, which has no structural similarity to Type I IFNs. While 
IFNβ is mainly synthesised by fibroblasts, haematopoetic cells are responsible for most 
IFNα and IFNτ production. It is Type I IFNs that are often induced in the case of a viral 
infection, with IFNα and IFNβ being the more commonly expressed cytokines in the group 
(Bach et al., 1997; Jonasch and Haluska, 2001).  
IFNγ, the interferon that plays a greater role in immunomodulation, is mainly secreted by 
CD4+ Helper T (TH) cells, CD8
+ cytotoxic lymphocytes, natural killer (NK) cells, B cells and 
antigen-presenting cells (APCs) such as monocytes, macrophages and dendritic cells 
under the influence of immune or inflammatory stimuli (Frucht et al., 2001; Gessani and 
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Belardelli, 1998; Yoshimoto et al., 1998; Flaishon et al., 2000; Harris et al., 2000; Bach et 
al., 1997). Two proinflammatory cytokines, IL-12 and IL-18, have been shown to induce 
the expression of IFNγ in APCs (Munder et al., 1998; Yoshimoto et al., 1998). IFNγ acts on 
IFNγ receptors, which are distinctly different from IFNα and IFNβ receptors (Branca and 
Baglioni, 1981; Aguet et al., 1988), and is able to induce transcription of a number of 
cellular genes, leading to the translation of proteins such as major histocompatibility 
complexes (MHCs), IL-12, CXCL10, TNF and IDO1 (Akbar et al., 1996; Mosca et al., 2000; 
Luster et al., 1985; Billiau and Matthys, 2009; Collart et al., 1986; Pfefferkorn et al., 
1986a). 
The immunomodulatory effects of IFNγ  include coordinating leukocyte attraction, as well 
as influencing the growth, maturation and differentiation of various cell types such as 
human myeloid cells, B cells and NK cells (Boehm et al., 1997; Perussia et al., 1983; Young 
and Hardy, 1995). In addition, its ability to induce NK cell activity and regulate 
immunoglobulin production by influencing B cells has been documented (Boehm et al., 
1997; Carnaud et al., 1999; Finkelman et al., 1988).  
IFNγ exerts some of its immunoregulatory effects through the activation of IDO1, which 
results in Trp depletion and suppression of T cell proliferation (Pfefferkorn et al., 1986a; 
Pfefferkorn et al., 1986b; Tashiro et al., 1961). IFNγ induction of IDO1 expression was 
found to be through the IFNγ-stimulated response element (ISRE), which flanks the gene 
(Hassanain et al., 1993; Dai and Gupta, 1990). This response element makes IDO1 
inducible by IFNγ but not IFNα or IFNβ.  
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1.3.2.2 IDO1 in infections 
In infections such as T. gondii, Chlamydia pneumoniae, S. aureus, group B streptococci 
and mycobacteria, IDO1 plays a role in the innate host immune response (Byrne et al., 
1986b; Pfefferkorn et al., 1986a; MacKenzie et al., 1998; Hayashi et al., 2001; Schroten et 
al., 2001). In these infections, IFNγ-mediated induction of IDO1 resulted in Trp 
catabolism, which led to the deprivation of this essential amino acid in the local 
microenvironment. The depletion of Trp then retarded pathogen growth, an effect that 
was reversible when the growth medium was replenished with Trp. Replication of viruses 
such as cytomegalovirus and herpes simplex virus also was inhibited upon induction of 
IDO1 in vitro in infected cell lines, through a similar mechanism (Bodaghi et al., 1999; 
Adams et al., 2004).  
 
1.3.2.3 IDO1 in cancer 
IDO1 has been implicated in a number of cancer types and an upregulation of the gene 
was seen in some cancer cell lines when primed with IFNγ (Taylor and Feng, 1991; 
Uyttenhove et al., 2003; Yoshida et al., 1988). An increase in IDO1 levels resulted in worse 
prognosis in some cancer types, while in some others an improved prognosis was seen 
(Ozaki et al., 1988; Ino et al., 2006; Okamoto et al., 2005; Godin-Ethier et al., 2011).  In 
cancer cell lines such as oral carcinoma and colon adenocarcinoma cell lines, an inhibition 
of tumour growth was seen as a result of the Trp deprivation triggered by IDO1 activation 
(Ozaki et al., 1988). However, the general consensus is that IDO1 activation in cancer cells 
resulted in immune tolerance and prevented tumour rejection, while increasing the 
metastasis risk. An upregulation of IDO1 seen in endometrial, ovarian, colorectal and 
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various other carcinomas resulted in poor clinical outcomes and reduced patient survival  
(Ino et al., 2006; Okamoto et al., 2005; Uyttenhove et al., 2003; Brandacher et al., 2006; 
Inaba et al., 2009; Yoshida et al., 2008).  
There are two mechanisms through which IDO1 is suggested to contribute to the 
progression of cancer. The first is through the suppression of effector T cells in the 
tumour local microenvironment whereas the second mechanism involves the expression 
of IDO1 in the antigen-presenting cells (APCs) of tumour-draining lymph nodes (TDLN). In 
the former, suppression of CD3+ / CD8+ T cells has been observed at the site of IDO1-
expressing tumour cells (Brandacher et al., 2006; Uyttenhove et al., 2003; Inaba et al., 
2009). This led to reduced immune infiltration and antitumour response to the malignant 
cells. IDO1-expressing APCs such plasmacytoid dendritic cells (pDCs) and eosinophils in 
TDLN are proposed to be the key players in the second proposed mechanism of IDO1’s 
tolerogenic action in tumours (Munn, 2006; Sharma et al., 2007; Prendergast et al., 2010; 
Munn et al., 2004; Astigiano et al., 2005). When phorbol myristate acetate (PMA), a 
chemical that induces chronic local inflammation and thus promotes growth of 
premalignant lesions upon exposure to carcinogen, is applied topically on the skin, an 
immune stimulatory response is elicited (Muller et al., 2008). In this immune response, 
pDCs of local TDLN are activated to synthesise IDO1. As mentioned previously, IDO1 
exerts T cell suppressor activity on these pDCs, resulting in the suppression of T cell 
stimulatory activity of other DCs. Immunological signals such as IFNα, IFNβ, IFNγ 
receptors, TLR/IL-1 signalling adaptor MyD88 and GCN2 stress response kinase were 
reported to be some of the key activators of IDO1 production in pDCs. The suppression of 
T cells by IDO1 promotes tumour growth while IDO1 deficiency resulted in an aggressive 
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antitumour response in the same skin cancer model (Muller et al., 2008). Additionally, 
IDO1-positive pDCs are also reported to act by activating regulatory T cells (Tregs), which 
are generally immunosuppressive, either by converting them from naive T cells or by 
recruiting them from existing cells (Fallarino et al., 2006; Sharma et al., 2007). The 
sustained presence of regulatory T cells inhibits immune infiltration by cytotoxic T cells, 
promoting self-tolerance (Wood and Sakaguchi, 2003). 
 
1.3.2.4 IDO1 in pregnancy 
As the foetus contains both maternal and paternal genetic material, it can be considered 
partially foreign, and the maternal immune system may attack the foetus, recognising it 
as non-self. However, in a successful pregnancy, this immune response is suppressed. 
This indicates the establishment of immune tolerance to the ‘foreign’ foetus. IDO1 was 
found to contribute to this tolerance. During pregnancy, IDO1 is expressed at the foetal-
maternal interface in a human-term placenta, suggesting a possible role for this protein in 
pregnancy (Munn et al., 1998; Shayda et al., 2009; Sedlmayr and Blaschitz, 2012). 
Coinciding with this observation was the progressive decline of serum Trp seen in the first 
to the third trimester of human pregnancy (Schrocksnadel et al., 1996). Initially, this 
finding was rather contradictory to the physiology of foetal growth as IDO1 seem to be 
catabolising and causing the depletion of an essential amino acid that would be necessary 
for foetal growth. However, it was eventually shown that the activation of IDO1 in the 
microenvironment resulted in T cell suppression in the foetal-maternal interface, pivotal 
to preventing the rejection of allogeneic concepti (Munn et al., 1998). As maternal T 
lymphocytes encounter the Trp-deficient microenvironment, suppression of T cell 
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activation and proliferation occurs, preventing immune infiltration that could lead to the 
rejection of the foetus. Surprisingly, in the light of this observation, no significant 
difference was seen in the pregnancy outcome of Ido1-/- relative to wild-type mice (Baban 
et al., 2004). It was postulated that this difference in outcomes in pregnant mice when 
either IDO1 activity is inhibited in  mice naturally expressing IDO1 or IDO1 activity is 
ablated through permanent genetic alteration (Ido1-/-) mice suggests that there may be 
an alternative compensatory mechanism in genetically IDO1-deficient pregnant mice that 
induces immunosuppression to prevent pregnancy failures (Baban et al., 2004). 
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1.3.3 INDOLEAMINE 2,3-DIOXYGENASE  2 (IDO2) 
IDO2 is an enzyme of the kynurenine pathway that was identified only recently (Ball et 
al., 2007; Metz et al., 2007). It is structurally and phylogenetically very similar to IDO1 and 
catalyses the first and rate-limiting step of the kynurenine pathway, as do the two other 
Trp-catabolising enzymes, IDO1 and TDO2, as previously discussed. Phylogenetic analysis 
showed that both IDO1 and IDO2 are present in Homo sapiens (humans), Pam troglodytes 
(chimpanzees), Macaca mulatta (rhesus macaque/Nuzari monkeys), Mus musculus 
(mice), Rattus norvegicus (rats), Canis familiaris (domestic dog) and Bos Taurus (cattle). In 
chicken and fish genomes, only one IDO was detected, which bore more similarities to 
IDO2 than to IDO1 (Yuasa et al., 2007).  
Most haem enzymes have more than one isoenzyme catalysing the same reaction. This 
was the case for the IDO enzymes as well. However, unlike other haem enzymes such as 
haem oxygenase, cyclooxygenase and nitric oxide synthase, whose isoenzymes are 
located on different chromosomes although they had a common ancestral gene, both 
IDO1 and IDO2 are located on chromosome 8, adjacent to each other (Ball et al., 2007). 
This strongly supports the theory that one of the IDO enzymes arose from genetic 
duplication. Phylogenetic analysis also suggested that it is more likely that this gene 
duplication occurred before the tetrapods emerged at the end of Devonian cycle more 
than 300 million years ago (Ball et al., 2007).  As only a single IDO gene was found in 
lower vertebrates such as chicken and fish, which resembled IDO2 more than IDO1, it was 
postulated that IDO2 was the ancestral gene from which IDO1 arose by a gene 
duplication occurring in mammals (Yuasa et al., 2007). However, more recently, IDO 
homologues were detected in several species of fish and (at least two species of) turtle, 
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which possessed higher homology to mammalian IDO1 than IDO2 (Ball et al., 2014). This 
latest finding suggests that the duplication occurred early in vertebrate evolution and 
IDO1 has been lost in a number of lower vertebrate lineages. 
 
1.3.3.1 Low tryptophan-catabolic activity of IDO2 
Both IDO1 and IDO2 share striking genomic structural similarities, with only slight 
differences in their first and last exons (Ball et al., 2007). IDO1 and IDO2 shared about 
43% amino acid identity in both mice and humans (Ball et al., 2007; Metz et al., 2007). 
Despite structural similarity, the substrate specificity and biochemical characteristics of 
the two differ. IDO2 has a low Trp-catalytic activity with a high Km value (Austin et al., 
2010; Yuasa et al., 2007). This was demonstrated by the lower levels of Kyn produced by 
mammalian cells transfected with mouse IDO2 compared to IDO1 (Ball et al., 2007; Metz 
et al., 2007). Through similar experiments, it also was shown that the Trp-catabolic 
activity of mouse IDO2 was higher than human IDO2 (Metz et al., 2007; Qian et al., 2012). 
Cyb5 which was established to be a physiological IDO-reductant, also was capable of 
reducing mouse IDO2 from its oxidised form in a cell-free system (Maghzal et al., 2008; 
Austin et al., 2010). In addition to this, cyb5 was shown to also increase the Trp-catabolic 
activity of this second isoform of mouse IDO in the presence of human CPR, a 
physiological electron donor of cyb5, and an NADPH regenerating system, compared to 
the standard in vitro containing methylene blue as an electron donor (Austin et al., 2010). 
Both cyb5 and CPR needed to be present in order to activate recombinant mouse IDO2 – 
either component alone was insufficient. An increase in substrate specificity of IDO2 for 
L-Trp as well as turnover rate was observed in the presence of cyb5 (Austin et al., 2010). 
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The Trp-catabolic activity of IDO2 was too low to contribute to the generation of NAD+ as 
neither human nor mouse IDO2 was able to rescue NA-auxotrophic yeast strain in the 
same way as IDO1 (Yuasa and Ball, 2013). Despite the low enzymatic activity of IDO2, it is 
proposed that the level of activity is still capable of eliciting biological effects. This was 
suggested by knocking down human IDO2 in dendritic cells, which resulted in decreased 
Kyn levels and fewer regulatory T cells (Trabanelli et al., 2014). 
 
1.3.3.2 IDO2 Distribution in tissues and cell populations 
There have been contradictory findings regarding the distribution of IDO2 within tissues. 
When full length mRNA transcripts were assessed by reverse transcriptase polymerase 
chain reaction (RT-PCR) in human tissues, IDO2 was detected only in the brain and 
placenta (Metz et al., 2007). However, when RT-PCR was performed targeting a shorter 
IDO2 mRNA transcript, exon 10 specifically, it was detected in the liver, skeletal muscle, 
small intestine, thymus, lung, brain and placenta, suggesting that there may be other 
transcription start sites in the gene (Metz et al., 2007). Another study reported Ido2 
mRNA distribution in mouse tissues, where Ido2 mRNA was detected in the liver, kidney, 
testis and epididymis, with its expression being very low or almost undetectable in tissues 
such as brain, lung, spleen and heart (Ball et al., 2007). Fukunaga et al. (2012), on the 
other hand, observed Ido2 mRNA in the brain (cerebral cortex and cerebellum), liver, 
kidney and epididymis of mice.  
In the epididymis, IDO2 was detected in the spermatozoan tail, but not in the epididymal 
cells themselves, a different distribution pattern to IDO1, which was localised in the 
principal and apical cells of the caput epididymis. Interestingly, a compensatory role for 
 29 
IDO2 in the absence of IDO1 in the epididymis has been proposed as an upregulation of 
IDO2 was reported in Ido1-/- epididymis (Fukunaga et al., 2012). In the testis, where IDO1 
expression was undetectable, IDO2 was localised in the spermatozoan tail, similar to its 
localisation in the epididymis (Ball et al., 2007). 
Another tissue in which both IDO1 and IDO2 was detected is the kidney. IDO1 was 
detected in the blood vessels, whereas IDO2 expression was seen in the tubules (Ball et 
al., 2007). This highlighted a difference in the protein localisation of IDO1 and IDO2 in the 
same tissues, indicating that each isoform may be playing a different, specialised role, 
despite catalysing the same reaction in these tissues. Investigation of cellular and 
subcellular localisation of both IDO1 and IDO2 could shed more light on the differential 
roles of each enzyme. 
In cell populations, IFNγ-inducible IDO2 was present in antigen-presenting dendritic cells, 
macrophages, astrocytes and mesenchymal stem cells (Croitoru-Lamoury et al., 2011; Lob 
et al., 2009; Metz et al., 2007). However, in vivo, no Ido2 induction was seen the kidney 
or liver of mice infected with malaria, which are known to have high levels of circulating 
IFNγ (Ball et al., 2007). Even in IFNγ-/- mice, there was no significant differences in the 
Ido2 mRNA levels compared to wild-type mice, suggesting that IDO2 was not significantly 
inducible by IFNγ (Ball et al., 2007). It is worth considering that IDO2 may be IFNγ-
inducible in specific cell types but not necessarily throughout the system.  
Similarly, an upregulation of Ido2 mRNA in macrophages from Ido1-/- mice was detected 
when populations of macrophages were studied (Metz et al., 2007). However, when Ido2 
mRNA in Ido1-/- kidney and liver was assessed, a significant downregulation was detected. 
This difference at the mRNA level did not translate into protein as there was no 
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significant differences detected between the Ido1-/- tissues relative to the wild-type (Ball 
et al., 2007). Ido2 mRNA regulation in different cell and tissue types may warrant deeper 
study of IDO2. It could be indicative of the presence of an additional, undiscovered factor 
within tissues that regulates the expression of IDO2.  
Despite relatively higher levels of Ido2 mRNA in the kidneys of Plasmodium berghei ANKA 
(PbA)-infected C57BL/6 mice than in the same tissue in uninfected mice, this difference 
was not significant relative to uninfected animals (Ball et al., 2007). However, a significant 
reduction of Ido2 mRNA was seen in liver of PbA-infected mice compared to uninfected 
C57BL/6. There was also a down-regulation of Ido2 mRNA in kidneys from Ido1-/- mice 
compared to kidney tissues of uninfected C57BL/6 mice. In Ifnγ-/- mice, Ido2 mRNA was 
sustained at levels similar to those in wild-types (Ball et al., 2007).  
With contradictory results in the three main publications, a need to assess the expression 
levels of Ido2 mRNA in Ido2 -/- mice relative to wild type animals became pertinent. 
 
1.3.3.3 Genetic polymorphism of IDO2 and splice forms of IDO2 
Two single nucleotide polymorphisms (SNPs) that ablate the enzymatic activity of human 
IDO2 also have been reported (Metz et al., 2007). In addition to these, both human and 
mouse IDO2 have been shown to possess various splice forms (Metz et al., 2007). Even 
more recently, it was shown that in macrophages ablated for Ido1 gene expression, the 
alternatively spliced form of Ido2 is upregulated (Metz et al., 2014). This splice form gave 
rise to a truncated IDO2 protein, with diminished Trp-catabolising properties. Therefore, 
despite what seemed to be a compensatory mechanism in Ido1-/- macrophages that gives 
rise to higher levels of total Ido2 mRNA production, this compensation did not translate 
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into higher IDO2 protein activity. Indeed, the contrary was true, as IDO2 enzymatic 
activity was diminished in Ido1-/- macrophages. Whether this truncated form of IDO2 
possesses other biological catalytic properties remains to be uncovered. 
 In the liver, however, Ido1 expression did not seem to be affected by the ablation of Ido2 
gene function in Ido2-/- mice (Metz et al., 2014). The converse was also true, in that Ido2 
expression was not significantly different between murine wild-type and Ido1-/- liver 
tissues. The differences in observations between whole tissues such as liver and cell 
populations such as macrophages indicate that any regulatory or compensatory role Ido2 
plays seems to be restricted to specific cell or tissue types. As the differential regulation 
of Ido2 was seen mostly in macrophages and kidney tissue, IDO2 may play a specific role 
in the haematopoietic cells of the innate and/or adaptive immune systems. 
 
1.3.3.4 IDO2 inhibitors 
As mentioned previously in Section 1.3.2, 1-MT is a commonly used inhibitor of IDO1. D-
1-MT was reported to be the more efficient inhibitor of IDO1 clinically (Hou et al., 2007). 
However, the biochemical activity of D-1-MT as an IDO1 inhibitor was lower than that of 
L-1-MT (Hou et al., 2007). This led to the speculation that either D-1-MT targeted an IDO1 
isoform or a completely different target.  It has been demonstrated that 1-MT, more 
specifically the D-isomer of 1-MT, is also capable of inhibiting IDO2 (Metz et al., 2007). 
Subsequently, this report was challenged as some studies found L-1-MT to be a more 
potent inhibitor of IDO2 (Yuasa et al., 2010; Austin et al., 2010). Interestingly, D-1-MT did 
not only inhibit IDO2, it also was demonstrated to restore mTOR activity, which was 
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inhibited by Trp deficiency, mimicking Trp-sufficient conditions (Metz et al., 2012). This 
Trp-mimetic character of D-1-MT also was seen in L-1-MT. 
A number of selective mouse IDO2 inhibitors have been reported (Bakmiwewa et al., 
2012). Proton-pump inhibitors such as tenatoprazole, lansoprazole and pantoprazole are 
a group of inhibitors that potently and selectively inhibited IDO2. Other IDO2-selective 
inhibitors reported were retinoic acid, sildenafil, nifedipine, and troglitazone, with 
sildenafil possessing the highest IDO2-selectivity.  
 
1.3.3.5 IDO2 in autoimmune diseases 
After its discovery, there was interest in elucidating whether IDO2 could be playing a 
similar role to IDO1 in autoimmune diseases. IDO2 mRNA and protein were reported in a 
number of pancreatic cancer cell lines, which were also IFNγ-inducible (Witkiewicz et al., 
2009). Some primary human colon, gastric and renal tumours also expressed Ido2 mRNA 
(Lob et al., 2009). However, the enzyme did not seem to contribute to Trp degradation in 
these tumours, which seemed to be completely driven by IDO1. 
IDO2 was reported to be involved in the pathogenesis of arthritis, an autoimmune 
disorder in which IDO1 also has been implicated (Merlo et al., 2014; Criado et al., 2009). 
Using the KRN pre-clinical model of rheumatoid arthritis, IDO2 was demonstrated to play 
a key role in the progression of the disease (Merlo et al., 2014). Joint inflammation was 
significantly alleviated in mice deficient for Ido2 relative to wild-type. Kynurenine levels in 
the Ido2-/-mice were however unaltered compared to the levels in wild-types. The 
reductions in autoantibody production and antibody-secreting cells were attributed to 
the mitigation of the inflammatory symptoms of rheumatoid arthritis seen in joints of 
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Ido2-/- mice (Merlo et al., 2014). IDO2 was shown to be crucial for the activation of CD4+ 
helper T cells. In addition, the absence of IDO2 also resulted in lower autoantibody levels 
in the mice, although B cells from Ido2-/- themselves proliferated and produced Ig at 
similar levels to B cells from WT mice, suggesting that IDO2 is involved in B cell responses 
to autoantigens, B cell antibody responses to model antigens.  
 
1.3.3.6 IDO2 plays an essential role in inflammation  
An immunomodulatory role of IDO2 in inflammation and IDO1-dependent T cell 
regulation was discussed recently (Metz et al., 2014). IDO1-dependent T cell regulation 
was found to require activation of IDO2. The ability of Tregs to inhibit T cell proliferation 
was greatly diminished in the absence of IDO2 relative to the wild-type, as was also seen 
in the absence of IDO1 (Sharma et al., 2007). This implied that IDO2 was essential for 
IDO1-mediated T cell regulation. This evidence also pointed to possible interaction 
between IDO1 and IDO2 in regulating T cells. However, when the role of IDO2 was 
studied in another pathophysiology in which IDO1 has been implicated previously, 
namely inflammatory skin cancer (Muller et al., 2008), the outcome differed. IDO2 
deficiency did not result in the alleviated inflammatory symptoms and impedance of 
tumour progression like that seen in IDO1-deficient experimental models. The difference 
in the outcome suggested distinct biological functions for IDO1 and IDO2. Although IDO2 
did not seem to play a role in inflammatory carcinogenesis, it was proposed to play a role 
in contact hypersensitivity (CHS) (Metz et al., 2014). The susceptibility of wild-type, Ido1-/- 
and Ido2-/- mice to hapten-induced contact hypersensitivity was compared. Inflammation 
observed in the ears of Ido2-/- mice challenged with oxazolone, a contact sensitiser, was 
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reduced by about 40% compared to that in the wild-type counterparts. A similar 
reduction in inflammation was not seen in Ido2-/- mice challenged with an inflammatory 
agent that triggers an innate immunity response only. These observations implied a 
possible role for Ido2-/- in the adaptive immune system. The inflammatory response in 
Ido1-/- mouse ears also was reduced, although only by about 20%. When levels of 
cytokine expression in the CHS model of Ido2-/- and Ido1-/- were compared to wild-type, a 
clear difference was evident in the cytokine expression patterns and levels (Metz et al., 
2014). Significantly lower levels of IFNγ, TNF, IL-6, MCP-1/CCL2, GM-CSF and  
G-CSF were found in the ears of Ido2-/- mice treated with oxazolone relative to the 
similarly-treated wild-type. Increased expressions of the same cytokines were observed in 
the ears of treated Ido1-/- mice relative to wild-type animals. These differences point to a 
difference in the mechanism of actions of both IDO1 and IDO2, despite apparently 
contributing to similar outcomes in the pathophysiology of CHS. 
 
1.3.4 Tryptophan-independent signalling of GCN2/mTOR 
The depletion of Trp modulated by the kynurenine pathway leads to the suppression of T 
cells. It has been proposed that the mechanism through which Trp depletion leads to 
suppression of T cell proliferation is either by (i) the mTOR kinase pathway or (ii) the 
GCN2 stress kinase pathway. 
mTOR, is the mammalian homologue of TOR, which possesses kinase activities, that can 
be inhibited by rapamycin (Sabatini et al., 1994) Inhibition of this complex arrests cell 
cycle progression of activated T cells, which inhibits T cell proliferation, reducing the 
number of T cells (Terada et al., 1993). While amino acid availability drives the mTOR 
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pathway (Gingras et al., 2001), amino acid starvation inhibits mTOR in a similar fashion to 
rapamycin (Hannan et al., 2003). Therefore it was proposed that the depletion of Trp by 
IDO suppresses T cells by repressing its proliferation through the inhibition of the mTOR 
complex. Although earlier reports suggested that the mTOR signalling pathway is unlikely 
to be the main cause of T cell suppression since mTOR inhibitors such as rapamycin did 
not restore the proliferative arrest seen in IDO1-mediated suppression (Fox et al., 2005; 
Munn et al., 2005), a more recent publication showed that in an inflammatory 
carcinogenesis mouse model, IDO1-mediated Trp depletion inhibited mTOR kinase (Metz 
et al., 2012). This inhibition was reversible with the addition of Trp or 1-MT (IDO1 and 
IDO2 inhibitor), an observation that further consolidates the suggestion that IDO1-
catalysed Trp catabolism inhibits the mTOR pathway. 
The alternative pathway that could be driving T cell suppression by Trp depletion is the 
integrated stress response kinase GCN2 signalling pathway. GCN2 kinase is activated in 
amino acid deprivation (Zhang et al., 2002). Tryptophan catabolism initiated by IDO1 
activates GCN2, which phosphorylates eIF2α. During this process, LIP (liver inhibitory 
protein), an inhibitory isoform of the immune regulatory transcription factor NF-IL6, is 
also activated (Metz et al., 2007). GCN2 was found necessary for the suppression of T cell 
proliferation (Munn et al., 2005). In the absence of GCN2, T cell proliferation proceeded 
normally both in vitro and in vivo. It has been shown that GCN2 activation by IDO1 led to 
cell cycle arrest and anergy in CD8+ T cells, while suppressing the differentiation of T 
helper 17 (TH17) and promoting maturation of Tregs suppressor activity in CD4
+ T cells 
(Fallarino et al., 2006; Munn et al., 2005; Sharma et al., 2007; Sundrud et al., 2009). Upon 
supplementation of the culture medium with Trp, the immunosuppressive effect of IDO1 
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was reversed. The mechanism through which IDO1 activates GCN2 has not yet been 
ascertained. An increase in uncharged tRNA is an established stimulus of GCN2 (Dong et 
al., 2000). Tryptophanyl-tRNA synthetase, an enzyme responsible for ligating Trp to its 
specific tRNA, has been shown to be induced by IFNγ, as is IDO1 (Bange et al., 1992). In 
the absence of Trp, an increase in uncharged tRNA would naturally result. It has been 
proposed that IDO1 could be activating the GCN2 kinase signalling pathway through the 
increase in uncharged tRNA (Mellor and Munn, 2004; Munn et al., 2005).  
Although IDO2 was found to similarly activate this pathway, its effect could not be 
rescued by supplementation of tryptophan. This suggests that IDO2 may produce a 
tryptophan-independent signal, distinct from that which is elicited by IDO1 (Metz et al., 
2007).  
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Fig. 1.4 Possible mechanisms of immune suppression through IDO1-induced tryptophan 
deficiency. IDO, indoleamine 2,3-dioxygenase; DC, dendritic cell; MФ, macrophage; KYN, 
Kynurenine; TRP, Tryptophan; AhR, aryl hydrocarbon receptor; Treg, regulatory T cells; 
GCN2, General control nonderepresible 2; mTOR, mammalian homologue of target of 
rapamycin 
Reproduced from (Munn and Mellor, 2013) 
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1.4 Organ development 
1.4.1 Trp-degrading activity in placenta 
Placenta is an important tissue in embryonic development, upon which the growth and 
survival of a foetus depend. By forming the foetal-maternal interface, it plays a pivotal 
role in metabolite and gas exchange as well as foetal waste disposal. In addition, the 
placenta secretes hormones that prepare maternal physiology for pregnancy while 
forming an immunity barrier between the mother and foetus. 
Both human and rodent placenta are comprised of three layers: the outer maternal layer, 
the middle junctional region and an inner layer (Watson and Cross, 2005). The outer layer 
is made up of decidual cells of the uterus and maternal vasculature that transports blood 
between the implantation site and the maternal circulation. The middle junctional region, 
on the other hand, is comprised of the trophoblast cells of foetal-placental origin, 
permeating the uterine wall and maternal vessels. It is also this layer which adheres the 
placenta to the uterus. The third layer, the inner layer, facilitates efficacious nutrient 
exchange through its highly branched villous layer. In mice, placental development begins 
as early as embryonic day (E) 3.5 in the blastocyst, during which the trophectoderm 
separates from the inner cell mass. When implantation takes place on E4.5, the mural 
trophectoderm differentiates to become trophoblast giant cells (TGC). These cells 
become polypoid as their DNA continues replicating, although the cells themselves have 
stopped dividing. TGCs facilitate the physical attachment of the embryo to the uterus, a 
step essential to the development of the embryo (Cross et al., 1994). During this process, 
TGCs stimulate uterine lining to develop and evolve functionally (Hu and Cross, 2010). 
TGCs also increase in number in the uterine stroma (Hu and Cross, 2010; Bevilacqua and 
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Abrahamsohn, 1989). Together with underlying parietal endoderm cells, they also form 
the parietal yolk sac, a transitory structure that facilitates nutrient and endocrine signal 
interchange in the early stages of pregnancy (Hu and Cross, 2010) Welsh and Enders 
1987. The parietal yolk sac permeates  the uterine epithelium and connects them to 
maternal blood spaces, to mediate this exchange (Bevilacqua and Abrahamsohn, 1989). 
Following implantation, TGCs adapt a more endocrine role, synthesising hormones, 
growth factors and cytokines that are pivotal for the adaptation of maternal physiology to 
support pregnancy as well as growth of the foetus (Hu and Cross, 2010; Cross et al., 
1994). An example of such hormones is prolactin, whereby genes from the 
prolactin/placental lactogen/prolactin-like protein family, except pituitary prolactin, are 
secreted only by the placenta (Hu and Cross, 2010; Simmons et al., 2008). A remarkable 
change in the pool of uterine immune cells is also evident during pregnancy (Hu and 
Cross, 2010). This modification is pivotal to avert the immune system of the mother from 
rejecting  allogeneic concepti. However, the exact mechanism that modulates this 
immune tolerance was not fully understood. It was proposed that perhaps progesterone, 
which is highly expressed during pregnancy may contribute to this tolerance, as it was 
found to activate Type II helper T cells (TH2) (Szekeres-Bartho and Wegmann, 1996; Hu 
and Cross, 2010).  
High Trp-catabolising activity has been ascribed to human placental tissue, and this was 
attributed to IDO1 (Yamazaki et al., 1985). IDO1 in murine placental tissues was shown to 
facilitate immune tolerance, which prevented allogeneic foetal rejection (Munn et al., 
1998). IDO1 expression in various foetal-maternal tissues has been described previously 
(Blaschitz et al., 2011; Yamazaki et al., 1985; Sedlmayr et al., 2002; Ligam et al., 2005). In 
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humans, IDO1 was not detected in placental villi in the first trimester, albeit being 
observed in subtrophoblastic capillaries and glandular epithelium of the decidua 
(Sedlmayr et al., 2002; Sedlmayr et al., 2014; Blaschitz et al., 2011). During mid-gestation, 
the expression of IDO1 was restricted to foetal TGC (Baban et al., 2004). In a term human 
placenta, expression of IDO1 was found in the mesenchymal core and 
syncytiotrophoblasts (Sedlmayr et al., 2002). While IDO1 remains undetectable in the 
umbilical cord of term placenta, endothelium in the tissues closest to the foetal-maternal 
interface in humans, such as the large vessels in stem villi as well as arteries and veins of 
the chorionic plate, have been reported to be IDO1-positive (Blaschitz et al., 2011; 
Sedlmayr et al., 2002). 
Although initially IDO1 expression also was reported in trophoblast cells (Kudo et al., 
2004; Sedlmayr et al., 2002; Honig et al., 2004), contradictory reports that followed 
subsequently challenged this observation (Blaschitz et al., 2011; Wang et al., 2011). Wang 
et al. (2011) showed that IDO1 expression is induced in trophoblasts only upon viral 
infection and is not constitutively expressed in these cells (Kudo et al., 2004; Ligam et al., 
2005). 
Also, the kynurenine-to-Trp ratio in the blood of term placenta at delivery was found to 
be significantly higher than that of peripheral blood of healthy adults, suggesting that 
IDO1-mediated Trp-catabolic activity remains high even after the arrest of placental 
blood circulation (Blaschitz et al., 2011). Blaschitz and colleagues assumed that the Trp-
catabolic activity seen in term placenta is mediated by IDO1 as an earlier report found 
that the expression of TDO2 in murine placenta decreased as the embryo grew (Suzuki et 
al., 2001) as will be discussed in the next paragraph.  
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 TDO2 has been detected in both murine and human placenta (Suzuki et al., 2001; 
Dharane Nee Ligam et al., 2010). Suzuki and colleagues also demonstrated that the high 
Trp-degrading activity in early murine gestation (from E6.5 dpc) was attributable to TDO2 
and not IDO1, as the latter was not detected at such an early stage. The expression of 
IDO1 during the developmental period was shown to be transient as it was absent in the 
early developmental stages and detected only between two to three days from E8.5 to 
12.5 dpc, whereas TDO2 was detected from E6.5 to E18.5 dpc although the levels were 
lower in the older embryos (Suzuki et al., 2001). This observation led some to suggest 
that TDO2 also may be involved in immune tolerance to prevent rejection of allogeneic 
foetuses during pregnancy, to a greater extent than IDO1 (Suzuki, 2001; Britan, 2006).  
IDO2 RNA and protein have been reported in human placenta (Lob et al., 2008; Metz et 
al., 2007). However, its localisation and possible role in pregnancy has not been explored 
previously. 
 
1.4.2 Trp catabolising activity in the yolk sac 
Another important extraembryonic tissue during pregnancy is the yolk sac, which is 
responsible for the transport of various substances in mammals, such as vitamins, 
immunoglobulins, and plasma proteins (Jollie, 1986). While being the primary membrane 
for placental exchange in lower vertebrates, the role of the yolk sac in mammals may not 
necessarily be placental (Jollie, 1986). In some eutherian mammals, placental function is 
played by the choriovitelline placenta in early stages of development and is eventually 
taken over by the chorioallontois. It forms the choriovitelline placenta by fusing with the 
inner surface of the chorion. In rodents and insectivores, the placental function is 
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performed by a more intricate mammalian yolk sac-placenta (Jollie, 1986). In these 
organisms, the parietal yolk sac comprises of the non-vascularised wall of the membrane, 
the chorion to which it is apposed and the decidua capsularis to which these membranes 
are attached. This structure eventually breaks down, exposing the vascularised 
membrane, known as visceral yolk sac (VYS), to uterine substances. While the parietal 
yolk sac is transitory, visceral yolk sacs remain until term. The VYS is central in supplying 
amino acids and nucleotides for embryonic protein synthesis to the growing foetus by 
driving protein degradation and absorption at the membrane (Freeman and Lloyd, 1983; 
Beckman et al., 1990; Beckman et al., 1991; Rowe and Kalaizis, 1985).  
The role of yolk sac in providing or catabolising the essential amino acid Trp to the 
growing murine embryo and the expression or role of any of the three Trp-degrading 
enzyme in the yolk has not been discussed previously. Whether Trp-catabolic activity is 
present in the yolk sac, which Trp-degrading enzyme drives this activity and the possible 
roles of Trp catabolism in this tissue remain to be elucidated. 
 
1.4.3 Trp-catabolic activity in embryonic and neonatal liver 
Despite being expressed in high levels in adult liver, neither TDO2 RNA nor protein was 
detected in embryonic liver (Franz and Knox, 1967; Nakamura et al., 1987). Constitutive 
Trp-catabolic activity was reported in neonatal liver as young as 2 weeks old, which was 
initially attributed to TDO2 (Franz and Knox, 1967). However, with the recent discovery of 
another liver Trp-catabolising enzyme, IDO2, the expression and role of this enzyme in 
Trp catabolism in the liver during development need to be further investigated. 
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1.5 Zebrafish as an experimental model in biomedicine 
The zebrafish (Danio rerio) is becoming a popular study model organism in the field of 
biomedicine, with it being used in the fields of developmental genetics, neurophysiology, 
organogenesis and disease processes, and more recently in drug screening (Kinth et al., 
2013; Meeker and Trede, 2008; Renshaw and Trede, 2012; Schlegel and Gut, 2015; 
Tavares and Santos Lopes, 2013). This tropical fresh water fish species was first reported 
in the Ganges region in eastern India, by a surgeon with the British East India company 
stationed in West Bengal (Spence et al., 2008). Zebrafishes are relatively small with the 
adults rarely exceeding 40mm in length. Domesticated zebrafishes have an average life 
span of 42 months. Fertilisation occurs outside the mother’s body, where female fishes 
can spawn every couple of days, and contain several hundreds of eggs per clutch (Spence 
et al., 2008). The embryos continue to develop ex utero and can be observed from their 
earliest developmental stages. Zebrafish embryos are relatively large compared to other 
fishes with a diameter of 0.7mm at fertilisation. (Kimmel et al., 1995).  Their rapid 
development, with precursors to all major organs developing within 36 hours, can be 
followed easily due to the optical transparency of the embryos (Kimmel et al., 1995).  
One of the earliest studies using zebrafish as a model research organism was by 
Streisinger and colleagues who paved the way for the use of zebrafish for the study of 
molecular genetics in vertebrate embryology (Streisinger et al., 1981). To date, the 
zebrafish has been used as a human disease model for cancer (Stanton, 1965; Taylor and 
Zon, 2009; Spitsbergen et al., 2000), diabetes (Gleeson et al., 2007; Andersson et al., 
2012; Moss et al., 2009), cardiovascular disease (Holden et al., 2011; Sabeh et al., 2012; 
Dahme et al., 2009), neurodegeneration (Xi et al., 2011) and drug screenings (Rubinstein, 
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2003) (Tavares and Santos Lopes, 2013). Physiology of lipid metabolism in the digestive 
system also has been studied, where phospholipid processing in the digestive system was 
investigated using fluorescently-tagged lipid (Farber et al., 2001). Some of these will be 
discussed more thoroughly in the following paragraphs. 
Fishman described the zebrafish as the canonical vertebrate due to its similarities to 
mammalian biology (Fishman, 2001). Due to the optical transparency of the zebrafish 
embryo, phenotypical changes that take place in mutants are identifiable at the level of 
individual cells (Fishman, 2001). One is able to discover the role of a protein before the 
gene coding the protein is deciphered as phenotypes of randomly induced mutations are 
recognised first in genetic screens before the gene sequence is decoded.  
Zebrafish have been used as a human disease model in cancer. Innately, they possess a 
low frequency of inherent tumour growth, with only 10% of the fish developing cancer 
over their lifetime (Tavares and Santos Lopes, 2013). However, they develop malignant 
tumours when exposed to carcinogens, although the responsiveness to carcinogenic 
stimulus was most evident among embryos and fry while older zebrafishes appeared 
resistant to such treatment (Spitsbergen et al., 2000). An exciting aspect in cancer 
research in zebrafish is the potential to follow tumour cell fate within the system, after 
transplanting human tumour cells into zebrafish embryos (Taylor and Zon, 2009).  
Zebrafish models for diabetes and lipid-related disorders also have been reported. 
Destruction of pancreatic β cells led to hyperglycaemia in zebrafish, a condition that 
reversed with time and normoglycaemia returned without the administration of 
exogenous insulin (Andersson et al., 2012; Moss et al., 2009). This restoration of 
normoglycaemia was attributed to the regeneration of insulin-positive β cells. The 
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simplicity of organ structures within the zebrafish enabled investigators to follow the 
development of the pancreas and study signalling pathways that may be involved in the 
regeneration process (Andersson et al., 2012). In addition, the zebrafish experimental 
model also allowed for the screening of about 7000 compounds that could support or 
stimulate pancreatic regeneration in the hope of finding new therapeutic approaches for 
treatment of, in particular, Type I diabetes (Andersson et al., 2012). 
The optical transparency of the embryo also has enabled the investigation of various 
vascular processes. The assessment of cardiovascular pacemaking, rhythm and 
contractility is one example (Baker et al., 1997). Molecular control of vascular 
development also has been studied extensively using this model as the developing heart 
and blood vessels can be observed across timepoints (Holden et al., 2011). The use of 
fluorescent markers further intensifies the visualisation of vasculatures in these studies. 
As oxygen is delivered to zebrafish embryos by surface diffusion in the first week of 
development, embryos with cardiovascular defects can still develop through 
embryogenesis and into the larval stages. This allowed for the comprehensive 
phenotyping of blood flow velocity, electrocardiograms and determination of cardiac 
atrial and ventricular shortening fraction (Dahme et al., 2009). 
To put it succinctly, zebrafish embryos are optically transparent animals that develop ex 
utero. They are genetically amenable and breed in high numbers while taking a shorter 
period to develop to maturity. These features make it a highly desirable experimental 
model that has been used in the study of various pathological and physiological 
processes. 
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1.5.1 D. rerio embryonic developmental stages 
There are seven broad periods in zebrafish embryogenesis that occur from the point of 
the unfertilised egg to its hatching (Kimmel, 1995). The first period is the formation of the 
zygote, which involves the fertilisation of the egg by the sperms of male fish (Fig. 1.4) 
(Kimmel et al., 1995). At the one-cell stage, cytoplasmic streaming occurs towards the 
animal pole from the yolk (also known as the vegetal pole), to form the blastodisc. At this 
stage, the formed embryos are in the one-cell stage for about 0.75 hours, before cleavage 
occurs, marking the second period of embryogenesis.  
During this second period, cell cycles occur rapidly resulting in a 64-cell stage embryo, 
just prior to the growth of the egg to form a blastula (128-cell stage embryo). During the 
blastula (third) period, epiboly commences and asynchronous, lengthened cell cycles 
occur at the midblastula region (Kimmel et al., 1995). The achievement of 50% epiboly 
marks the beginning of the fourth period, the gastrula period. During this period, the 
thickness of the blastoderm is maintained and the germ ring begins to form from the 
animal pole. The shield begins to appear from about six hours-post-fertilisation (hpf), and 
the gastrula period ends with the formation of the tail bud and 100% epiboly occurring. 
The fifth period, the segmentation period, begins after the tenth hour, during which the 
polster becomes noticeable while the optic and Kupffer’s vesicle begins to form. It is 
during this period when primary organogenesis occurs, the tail begins to appear and early 
movements can be detected in the embryos. 
The body axis begins to unbend and the development of fins, circulation and 
pigmentations can be seen during the pharyngula (sixth) period (24 to 42 hpf), 
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Morphogenesis of the primary organs is completed during the seventh and final period, 
accompanied by the cartilage formation in the head and pectoral fin.  
It should be noted that D. rerio embryos of a single clutch can develop at different rates 
(Kimmel et al., 1995). Hence, the final stage, which is the hatching, also occurs 
asynchronously. During the early larval stage (72 hpf onwards), the swim bladder inflates 
and the embryos exhibit distinct behaviours including food-seeking and active avoidance. 
The development of the embryo is depicted in Fig. 1.4. 
Liver and intestinal development during zebrafish embryogenesis has been studied 
previously (Field et al., 2003; Ng et al., 2005). The budding phase begins after the 
aggregation of hepatocytes around 24 hpf, during which the liver buds off the intestinal 
rod (Field et al., 2003). The formation of the hepatic duct at 50 hpf marks the end of this 
phase. The second phase is marked by a voluminous modification of liver shape and size. 
A reasonable increase in liver size is seen by 72 hpf, although no change in shape is seen. 
Following this growth is the medial expansion of the liver.  
The zebrafish gut, on the other hand, is segmented into pharynx, oesophagus, intestinal 
bulb, mid-intestine and posterior intestine (Field et al., 2003; Ng et al., 2005). In zebrafish, 
the intestine is joined directly to the oesophagus as zebrafish does not have a stomach. 
The characterisation of the endoderm cells takes place between 26 to 126 hpf, after the 
primitive gut is formed by the convergence of the endoderm precursor. During the first 
half of this process, the whole intestinal endoderm is rapidly dividing. Stage I of zebrafish 
gut development involves lumen formation, which occurs between 26 to 52 hpf and, by 
the end of this stage, cell masses related to the developing gut are evident (Ng et al., 
2005). By about 74 hpf, the second stage of gut development, characterised by epithelial 
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cell polarisation, is noticeable. The third and final stage of gut development involves the 
most complex and elaborate processes where remodelling and differentiation of 
intestinal epithelium take place. This stage is characterised by the compartmentalisation 
of the intestinal tract into intestinal bulb, mid-intestine and posterior intestine. While the 
epithelial cells in the posterior intestine remain highly proliferative, diminished 
proliferation was documented in the mid-intestinal region. This diminished proliferation, 
however, is accompanied by increased differentiation in this region. Distinct folds begin 
to form in the intestinal bulb and mid intestine at this stage. Proliferation and 
differentiation of goblet and enteroendocrine cells that are restricted to mid-intestine 
also can be seen. By 5 dpf, a digestive system made up of mouth, pharynx, oesophagus, 
intestinal bulb, mid-intestine, posterior intestine and anal opening is distinct. The yolk 
also is completely resorbed by this stage. 
Studying the development of zebrafish shows that its embryogenesis occurs rapidly, with 
hatching occurring by the third dpf. The development of the organs can be observed and 
imaged live during embryogenesis, rendering it a highly favourable model organism to 
study disease and physiological processes. As TDO2 and IDO2 have been reported in 
murine liver whereas IDO1 has been detected in murine intestine, the zebrafish embryo 
can be an excellent model to study the role these enzymes may play in zebrafish 
embryonic development. 
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1.5.2 Tryptophan-catabolising enzymes in Danio rerio (zebrafish) 
As mentioned previously (Section 1.3.3), in mammals and most vertebrates two 
homologues of IDO genes were found. However, in lower vertebrates such as chicken and 
fish, only a single IDO gene was found (Ball et al., 2007; Yuasa et al., 2007). This gene 
shared greater genomic similarity with the IDO2 gene in mammals than with IDO1. Due to 
this characteristic of the IDO gene in fish and chicken, studying the expression patterns 
and role of the IDO gene in fish may shed light on the possible roles that IDO2 may play in 
more complex mammalian systems.  
In the zebrafish, there are three Trp-catabolising proteins, namely tryptophan 2,3-
dioxygenase 2a (Tdo2a), tryptophan 2,3-dioxygenase 2b (Tdo2b) and indoleamine 2,3-
dioxygenase (Ido). Despite the similarity in the nomenclature of the first two enzymes, 
they are located on different chromosomes, tdo2a on Chromosome 14 and tdo2b on 
chromosome 11.  
To date, there are only sparse data on the RNA expression of tdo2b in zebrafish embryos 
(> 5 dpf), a direct data submission to ZFIN, which showed tdo2b RNA expression in the 
liver and posterior intestine (Thisse and Thisse, 2004). 
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Fig. 1.5. Sketches of zebrafish embryos at selected stages of development. In the earlier 
stages, the animal pole is to the top while, in the later stages, the anterior is to the top. 
Diagram taken from Kimmel et al. (1995). 
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1.6 Scope of the thesis 
The general aim of this thesis is to investigate the distribution of IDO2 and its possible 
role in mouse and fish physiology. Three Trp-catabolising enzymes have been found in 
zebrafish, namely Tdo2a, Tdo2b and Ido. Unlike mammalian systems, only one IDO 
homologue is known in zebrafish, which is more similar to IDO2 than IDO1. Therefore, we 
aimed to investigate the distribution of tdo2a, tdo2b and ido expression as well as the 
possible roles these enzymes, especially Ido, may play in zebrafish. We also were 
interested to elucidate possible interactions or interdependency between the three Trp-
catabolising enzymes present in the mouse. The downregulation of IDO2 activity in the 
absence of IDO1 in macrophages (Metz et al., 2014) as well as the upregulation of Ido2 
mRNA in the epididymis of mice deficient for IDO1 has been reported previously 
(Fukunaga et al., 2012). At the functional level, the absence of IDO2 affected IDO1-
dependent T cell regulation (Metz et al., 2014). These were the first pieces of evidence 
for a non-redundant role of IDO2 as well as a possible interaction between two Trp-
catabolic enzymes in mammals, namely IDO1 and IDO2. In some tissues, the expression 
of two enzymes that catalyse the metabolism of Trp through the kynurenine pathway has 
been reported. Despite catalysing the same reaction, it was speculated that the role of 
the two may differ and be specialised.  
In the beginning of the project, we aimed to develop a simpler, easier IFNγ 
spectrophotometric bioassay based on the observation that endothelial cells express 
inducible-IDO1. Due to the unavailability of the downstream enzymes of the kynurenine 
pathway in this cell type, the pathway is retarded at the level of kynurenine production. 
As spectrophotometric detection of kynurenine is relatively easy using Ehrlich’s reagent, 
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we aimed to develop an IFNγ bioassay based on the ability of the enzyme to induce IDO1 
expression and activity, thereby increasing kynurenine formation. 
Therefore, in this thesis, we aimed to:   
1. Develop an improved human IFNγ spectrophotometric bioassay utilising 
endothelial cells. 
2. Investigate the expression of the three Trp-catabolising enzymes present in 
zebrafish by in situ hybridisation as well as elucidate possible roles they may play 
in zebrafish embryonic development using the morpholino knockdown approach. 
3. Identify the cellular distribution of IDO2 in various murine tissues as well as the 
intracellular distribution of IDO1 and IDO2 in transfected cells. 
4. Examine possible interactions between the three Trp-catabolising enzymes in 
various murine tissues by examining mRNA expression of Ido1, Ido2 and Tdo2 in 
these tissues. We developed mutant mice deficient in two of the three Trp-
degrading enzymes alongside their equivalent wild-types (Ido1-/-Tdo2-/-, Ido2-/-
Tdo2-/- and Ido1+/+Ido2+/+Tdo2+/+) to complement the mutant mice deficient in one 
Trp-catabolic enzyme that we already had in our laboratory (Ido1-/-, Ido2-/- and 
Tdo2-/-).  
5. Determine global gene expression in the liver of mice deficient in one or both the 
Trp-catabolic enzymes (Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/-) relative to their 
equivalent wild-types. 
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CHAPTER 2 HUMAN INTERFERON GAMMA (IFNγ) BIOASSAY 
2.1 INTRODUCTION 
The major mechanism through which tryptophan is catabolised is via the kynurenine 
pathway. The conversion of tryptophan into N-formylkynurenine is the first and rate-
limiting step in this pathway and is catalysed by the enzymes IDO1, IDO2 or TDO2. 
Structurally, TDO2 and IDO1 differ significantly, as TDO2 is a homotetrameric haem B-
containing protein whereas IDO1 is a monomeric protein with a single haem B protein. 
The second isoform of IDO1, now known as IDO2, has similar genomic structures to IDO1 
but possesses different tissue distribution patterns and substrate specificity (Ball et al., 
2007; Ball et al., 2009). Despite possessing tryptophan-catabolising properties, IDO2 has a 
much lower affinity for tryptophan than IDO1 with a Km more than 400 times higher than 
IDO1 (Austin et al., 2010). Due to the low enzymatic activity of IDO2, it is uncertain 
whether IDO2 performs a tryptophan-catabolic role physiologically or if it possesses an 
alternative role, independent of its tryptophan-catabolising capacity (Section 1.3.3.1). 
While TDO2, which is expressed constitutively at high levels in the liver, is induced by 
glucocorticoids and is involved more with the regulation of dietary tryptophan, the 
expression of IDO2 has been reported in the liver (Ball et al., 2007) and is known to be 
moderately induced by IFNγ in certain cell types (Metz et al., 2007; Lob et al., 2009; 
Croitoru-Lamoury et al., 2011; Witkiewicz et al., 2009). 
IDO1, on the other hand, is stimulated in inflammatory conditions such as viral or 
bacterial infections, schizophrenia, dementia and cancer, with low constitutive expression 
only in the epididymis, intestine and lung. High expression of IDO1 was detected in the 
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placenta, which led to the discovery of the role of IDO1 in preventing allogeneic foetal 
rejection (Munn et al., 1998). Inflammatory cytokines such as IFNγ (Taylor and Feng, 
1991), TNF (Babcock and Carlin, 2000) and LPS (Fujigaki et al., 2001) are established to be 
potent inducers of IDO1.  
IFNγ, one of the most potent inducers of IDO1, belongs to a family of interferons, which 
act as immunomodulators as well as antivirals (Bach et al., 1997; Schroder et al., 2004). 
Previously, human IFNγ has been assayed by anti-viral assays (Green et al., 1981; Sato et 
al., 1984), enzyme-linked immunosorbent assay (ELISA) (Gibson and Kramer, 1989; 
Mazurek et al., 2001) and high performance liquid chromatography (HPLC) (Byrne et al., 
1986a; Mailankot and Nagaraj, 2010). While antiviral assays were technically demanding, 
ELISAs did not reflect the actual activity of the protein in its measurement. HPLC, the 
more commonly used method in the recent years, is laborious. In the work reported in 
this chapter in the form of a published manuscript, we demonstrate an improved 
spectrophotometric approach to assaying human IFNγ using the Ehrlich’s reagent assay of 
kynurenine as a measure of IDO1 activity in a human brain endothelial cell line (HBEC). 
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CHAPTER 3: GENES CODING FOR TRYPTOPHAN-CATABOLISING ENZYMES IN ZEBRAFISH 
DURING DEVELOPMENT 
3.1 INTRODUCTION 
Tryptophan (Trp) is an essential amino acid that can be metabolised through either the 
serotonin or kynurenine (Kyn) pathways. Most dietary Trp is catabolised through the Kyn 
pathway, which can exert biological effects through depletion of Trp and/or generation of 
biologically-active metabolites (Opitz et al., 2007). The Kyn pathway has been implicated 
in a number of pathological conditions such as cerebral malaria, cancer, microbial 
infections, dementia and schizophrenia, as well as the physiological process of pregnancy 
(Romani et al., 2008; Sanni et al., 1998; Chang et al., 2011; Okamoto et al., 2005; Ino et 
al., 2006; Muller and Schwarz, 2007; O'Connor et al., 2009; Linderholm et al., 2012; Munn 
et al., 1998). 
The first step in the Kyn pathway is the catabolism of Trp to N-formylkynurenine. This 
step can be catalysed by either tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3-
dioxygenase (IDO) enzymes (Higuchi and Hayaishi, 1967; Knox and Auerbach, 1955). TDO 
is found in most metazoan species and some bacteria, but not in fungi, and its enzymatic 
activity is well conserved (Ball et al., 2014). In humans and mice, TDO is highly expressed 
in the liver, can be stimulated by dietary Trp and is involved in regulating plasma Trp 
levels (Kanai et al., 2009; Knox and Auerbach, 1955).  
IDO is present in some bacteria, fungi, invertebrates and all vertebrates. The evolution of 
IDO enzymes is complex, with multiple gene duplication events giving rise to species 
possessing two or more IDO enzymes with distinct enzymatic activities and expression 
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patterns (Ball et al., 2014; Ball et al., 2009). For example, the first IDO enzyme to be 
described in mammals, now known as IDO1, has high efficiency for Trp catabolism and is 
expressed constitutively in the intestine, epididymis and placenta (Britan et al., 2006; 
Hayaishi, 1996; Munn et al., 1998). IDO1 expression is induced in inflammatory conditions 
by cytokines such as IFNγ, TNF and LPS (Taylor and Feng, 1991; Yoshida et al., 1981). IDO1 
activity has been implicated in microbial infections and CNS-related disorders such as 
depression and schizophrenia. More recently a second IDO enzyme, IDO2, was described 
(Ball et al., 2007; Metz et al., 2007; Yuasa et al., 2007) that has a lower efficiency for Trp 
metabolism and is expressed in mouse liver and dendritic cells (Austin et al., 2010; Ball et 
al., 2007). Certain cytokines trigger its expression in specific cell types and studies 
employing Ido2-/- mice suggest a role in autoimmunity (Merlo et al., 2014; Metz et al., 
2007).  
IDO2 is found in all vertebrates while IDO1 is present in mammals and several species of 
fish and turtles. This suggests that IDO1 and IDO2 arose via gene duplication in an 
ancestor of the vertebrates. IDO1 has been lost in many lower vertebrate lineages while 
IDO2 is well conserved (Yuasa et al. manuscript submitted). An IDO2 orthologue, but not 
IDO1, is present in the model organism, zebrafish (Danio rerio). The optical transparency 
of zebrafish embryos enables the study of gene expression in whole embryos as well as 
the progression of organogenesis in embryos. Therefore the zebrafish represents a model 
organism where the function and expression of Ido2 can be examined in the absence of 
Ido1. In addition, gene duplication has generated two Tdo2 enzymes in zebrafish, with the 
genes having been named as tdo2a and tdo2b. To date, only the expression of tdo2b in 5 
days-post-fertilisation (dpf) old embryos has been reported (Thisse and Thisse, 2004), 
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being detected in the liver and posterior intestine. That work was a preliminary screen of 
tdo2b expression, and an in-depth analysis of the expression of Trp-catabolising enzymes 
remains lacking in zebrafish.  In the light of IDO2 and TDO being highly conserved, 
understanding the role of Trp-catabolising enzymes in the biology of lower vertebrates 
may also shed light on their function in mammals. Thus, in the present study we aimed to 
determine the expression patterns of the three Trp-catabolising genes (tdo2a, tdo2b and 
ido) in a zebrafish developmental series and to examine the effects of suppressing the 
gene expression of these three enzymes. 
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3.2 METHODS 
3.2.1 Enzymatic activity of Trp-catabolising enzymes 
The ido expression construct was prepared as previously described (Yuasa et al. 2009). 
The coding sequences of tdo2a and tdo2b were amplified from cDNA clones MGC:171678 
and MGC:63488 and blunt-end ligated into the pcDNA3.1 vector (Life Technologies). The 
sequences of all primers used for amplifications are listed in Table 3.1. Human Embryonic 
Kidney 293T (HEK293T) cells were grown in phenol red- and antibiotic-free DMEM 
supplemented with 10% (v/v) foetal bovine serum (FBS). Reverse transfection was 
performed in a 96 well plate with Lipofectamine 2000, according to the manufacturer’s 
instructions (Life Technologies). Each well contained 0.4 µL Lipofectamine 2000, 0.32 µg 
plasmid DNA and 5 x 105 cells.  Enzyme activity was measured as described in Chapter 2 
(Jusof et al., 2013). Briefly, the medium was replaced 24 h following transfection with 
culture medium supplemented with 400 µmol/L of Trp and incubated for a further 24 h. 
Protein was precipitated from the medium with the addition of trichloroacetic acid (4% 
w/v final concentration) and centrifugation. The supernate was mixed with an equal 
volume of 2 % (w/v) p-dimethylaminobenzaldehyde in acetic acid and the absorbance 
measured at 485 nm in a spectrophotometer. 
 
3.2.2 Fish husbandry 
Wild type TAB zebrafish were maintained at 28.5°C under standard conditions 
(Westerfield, 2000). Embryos were collected after natural spawning as described 
previously (Kimmel et al., 1995) and raised in embryo medium (Westerfield, 2000). All 
husbandry and experimental procedures were approved by the Animal Ethics Review 
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Committee, University of Sydney (NSW, Australia) and the Animal Ethics Committee, 
Macquarie University (N.S.W., Australia).   
 
3.2.3 Reverse Transcriptase Polymerase Chain Reaction 
Embryos were anaesthetised with 4 g/L Tricaine MS-222 (Sigma-Aldrich) in embryo 
medium prior to RNA extraction. Total RNA from 8 - 10 pooled embryos was extracted 
using Trizol (Life Technologies) according to the manufacturer’s instructions and pellets 
were resuspended in RNase-free water.  RNA concentrations were determined using a 
Nanodrop spectrophotometer (Nanodrop 2000, Thermo Scientific). For cDNA synthesis, 1 
µg of RNA was denatured (70 °C, 5 min) and primed with random hexamers (0.5 µg) 
followed by cDNA synthesis (37 ºC, 45 min) with a Tetro Reverse Transcriptase kit 
(Bioline) and heat denaturation (92 °C, 2 min). Gene expression was assessed using the 
Phusion High-Fidelity DNA Polymerase kit (New England Biolabs) according to the 
manufacturer’s instructions. Each reaction contained cDNA equating to 50 ng of RNA 
starting material and 0.8 µmol/L each of reverse and forward primers. Amplification was 
performed on Eppendorf Mastercycler Personal with initial denaturation at 98 °C for 30 s, 
followed by 35 cycles of denaturation at 98 °C for 10 s, annealing at 60 °C for 30 s and 
elongation at 72 °C for 30 s per kb. The final elongation was at 72 °C for 5 min and 
amplified products were run on an agarose gel and visualized using 1 X SYBR Safe DNA gel 
stain (Life Technologies). For RT-quantitative PCR, amplification was performed with a 
Rotorgene Q (QIAGEN) using the same reaction mix and conditions, with the addition of 
0.1 µL of 10 X SYBR Safe DNA gel stain to each reaction. The purity of the PCR products 
was assessed by melting curve analysis and expression was normalised to the β-actin 
gene. 
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No. Gene Primer design 
1.  tdo2a  
(pcDNA 3.1) 
5’ ATGAGCGGATGTCCGTATTTTC 3’ 
5’ CTGTATATATGTATACTCTTTA 3’ 
2.  tdo2b 
(pcDNA3.1) 
5’ ATGAGTGGATGTCCATTTTTG 3’ 
5’ GGAAAGAGTTTAGCATTTAT 3’ 
3.  ido 
(pCS2) 
5’ CTCGGATCCGATAATATGGGTACCGAAGTGAAA 3’ 
5’ CTCGGATCCTTATTCTATGGTGAGCTC 3’ 
4.  tdo2a 
(ISH) 
5’CATTAACCCTCACTAAAGGGAAATTTCAGCCATGAGCGGATG 3’ 
5’ TAATACGACTCACTATAGGGAAGCCTGAAGCTGGTGAGAG 3’  
5.  tdo2b 
(ISH) 
5’ CATTAACCCTCACTAAAGGGAAGAGGAATCATCTACGGAGAC 3’  5’ 
TAATACGACTCACTATAGGGCGATGTTAGCCTGCAGTTTA 3’ 
6.  ido 
(ISH) 
5’ CATTAACCCTCACTAAAGGGAATCCCTCCATATTCTACGGCGTT’ 3’  
5’ TAATACGACTCACTATAGGGCACGGGACGCTGGTATTGTG 3’.  
7.  ido  
exon 1 
5’ ACCGAAGTGAAAGCTACAAGGAA 3’  
5’ CTTTGACCTCCAGGCAACGA 3’ 
8.  ido 
exon 9 
5’ TTCCCAGCGAGCTCATCAAGG 3’ 
5’ TGGGAGGGAGGCATGTAGTC 3’ 
9.  tdo2a  
exon 6 
5’ CTCTCACCAGCTTCAGGCTT 3’ 
5’ TTCCTCTCCGAGGCTGGT TT 3’ 
10.  tdo2a 
exon 3 
5’ CTCAGGTGCTTCAAAGTGAGC 3’ 
5’ ATGGTTTCCAGAACGGCGAA 3’ 
11.  tdo2b 
exon 6 
5’ GCTTGACAAGGTGCTGAATGC 3’ 
5’ GTCTGCGATTGTACGGGACT 3’ 
12.  β-actin 
(reference) 
5’ ACG AGA GAT CTT CAC TCC CCT 3’ 
5’ GATTCAGGGGAGCCTCAGTG 3’. 
Table 3.1. Primers used to amplify zebrafish tdo2a, tdo2b and ido mRNA and cDNA from zebrafish 
genome for cloning into expression vectors (1-3), for synthesis of probes for ISH (4-6) and for RT-PCR 
(7-12). 
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3.2.4 In situ hybridisation  
Primers amplifying tdo2a, tdo2b and ido coding sequences were designed with a T7 or T3 
promoter sequence (Table 3.1). mRNAs amplified from the zebrafish genome were run on 
agarose gel and purified using a QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s instructions. RNA transcription was performed in a 40 µL reaction with 
500 ng of template DNA, 1 X DIG labelling mix (Roche,), 2 µL of T7 Polymerase for 
antisense riboprobes or T3 Polymerase (20 U/µL) for sense riboprobes (Thermo 
Scientific), 1 X Transcription Buffer (supplied with the polymerase) and 1 µL Ribosafe 
RNAse inhibitor (Bioline). After 3 h incubation at 37 °C, the reaction was stopped by the 
addition of 4 µL of 0.2 mol/L EDTA. Riboprobes were purified using the ISOLATE II RNA 
micro clean up kit (Bioline) according to the manufacturer’s instructions. The 
concentration of RNA was measured using a Nanodrop (Nanodrop 2000, Thermo 
Scientific) and the probes stored at -80 °C until further use. The hybridisation procedure 
was performed according to Thisse in situ hybridisation protocol (Thisse and Thisse, 2008) 
with minor modifications, which included hybridising the embryos in 250 µL hybridisation 
medium containing 500 ng DIG-labelled RNA probe and performing both hybridisation 
and post-hybridisation washes at 68 °C. After staining, embryos were rinsed in Phosphate 
Buffered Saline with 0.1 % (v/v) Tween 20 (PBST) and fixed in 4 % (w/v) paraformaldehyde 
for 2 h. At the end of fixation, embryos were rinsed in PBST twice before they were stored 
at 4 °C in the same solution until imaged. 
 
 
 
 71 
3.2.5 Morpholino and ido mRNA microinjections   
Splice-site morpholinos directed to the ido, tdo2a and tdo genes, as well as standard 
control oligonucleotides, were purchased from Gene-Tools (Table 3.2). The ido coding 
sequence for the generation of ido RNA transcript (rescue) was amplified using primers 
with BamH1 sequences and a Kozak consensus sequence upstream of the start codon 
(Table 3.2). After BamH1 digestion, the fragment was ligated into the pCS2 vector, then 
sequenced, and ido mRNA was transcribed finally using the SP6 mMACHINE mMESSAGE 
kit (Life Technologies). The mRNA was purified with the ISOLATE II RNA micro clean up kit 
(Bioline) according to manufacturer’s instructions and the concentration of RNA 
measured using the Nanodrop (Nanodrop 2000, Thermo Scientific). Morpholinos were 
prepared with or without ido mRNA in RNase-free water with 10 % (v/v) phenol red and 
Oregon green fluorescent dye. One-cell stage D. rerio embryos were injected with 1.5 
pmol morpholino + 300 pg ido mRNA in an approximately 3 nL bolus. Efficiency of 
knockdown was assessed using RT-qPCR, according to the procedures mentioned above.  
No. Gene Morpholino design 
1.  ido 
exon 1 
5’ AAAGAAATGACCTACAGAGATGTGA 3’ 
2.  ido 
exon 9 
5’ TTCCATCTAACAACCACAAGCAGAA 3’ 
3.  tdo2a 
exon 3 
5’ TTAGTGTTTGCGAAGCTCACCTTGA 3’ 
4.  tdo2a 
exon 6 
5’ GATGGTTTCCTCAGGTTTTACCTCTA 3’ 
5.  tdo2b 
exon 6 
5’ AGATACTCCCTATAACATTCAAACA 3’ 
Table 3.2. Morpholino sequences targeting splice sites to knock-down gene expression  
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Figure 3.1. Morpholino injection protocol on one-cell stage D. rerio embryos. Diagram 
redrawn using images from (Langenau and Zon, 2005) and personal collection. 
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3.2.6 Microscopy and image acquisition 
For live embryo imaging, embryos anaesthetised 24 hours post-fertilisation were mounted 
onto 3 % (w/v) methylcellulose (Sigma Aldrich) or 1 % (w/v) low melting point agarose gel 
(Sigma-Aldrich) and subsequently imaged. Embryos were returned to the petri dish and 
allowed to grow up to 5 days post-fertilisation (dpf).  
For imaging of fixed embryos treated by in situ hybridisation, embryos were dehydrated in 
increasing concentrations of methanol (25, 50, 75 % v/v methanol) for 15 min each, before 
the final dehydration (100 % methanol, 1 h). The methanol solution was then removed and 
replaced with 500 µL of methysalicylate (AJAX Finechem). Embryos were allowed to sink to 
the bottom of the microcentrifuge tubes before they were removed and mounted in 
dibutylphthalate in xylene (DPX) on glass slides. These slides were imaged promptly using a 
Leica M165 FC stereo microscope (Leica).  
 
3.2.7 Statistical analysis for mortality rate 
The mortality rate observed in the morphants relative to uninjected wild-types and rescued 
morphants were analysed using repeated measures ANOVA with the Tukey post-test 
(GraphPad Prism) as embryo clutches differ from experiment to experiment (Kimmel et al., 
1995). Therefore, the mortality rates were treated as repeated measures of different 
populations.
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3.3 RESULTS 
3.3.1 Zebrafish have three genes that encode Trp-catabolising enzymes  
Amino acid sequence alignment shows that Tdo2a and Tdo2b share 76 % amino acid 
identity (Fig. 3.2), with their genes situated on chromosomes 11 and 14, respectively. 
Database searching revealed that Astyanax mexicanus (Mexican tetra) also has two tdo 
genes, like D. rerio. Interestingly, in the phylogenetic tree (Fig. 3.3), one of A. mexicanus 
tdo genes is clustered with zebrafish tdo2b.  
When introns of Tdo2a and Tdo2b were compared, it is evident that they occurred at 
identical positions within the coding regions of the tdo2a and tdo2b genes, suggesting that 
the two genes arose via a gene duplication event (Fig. 3.4A). In contrast, Ido, encoded by a 
gene located on chr 8, has no significant homology to the Tdo proteins. The position of 
introns within the coding sequence is different to the tdo genes, suggesting that ido and 
tdo do not share a common ancestral gene (Fig. 3.4A). HEK293T cells were transfected with 
each of the zebrafish cDNAs encoding the Tdo or Ido enzymes or with mouse IDO1, as a 
positive control. All of the zebrafish enzymes exhibited Trp-catabolising properties as they 
converted Trp in the culture medium to Kyn (Fig. 3.4B). Thus, zebrafish possess three 
enzymes with the ability to catabolise Trp. It is likely that the two Tdo enzymes arose 
through a gene duplication event while the Ido enzyme has independently evolved to have 
the same enzymatic activity. 
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Tdo2a  1    MSGCPYFQRKFLSTSKQHLKEEENDEAQTGINKASKGGLIYGDYLQLDKIVTSQVLQSEL  60 
 MSGCP+        S    + EE D +Q G+NKA+KGG+IYGDYLQLDK++ +QVLQSE  
Tdo2b  1    MSGCPFLGGTLQLLSSNPRQAEEEDGSQGGVNKAAKGGIIYGDYLQLDKVLNAQVLQSEQ  60 
 
Tdo2a  61  KGNKIHDEHLFIVTHQAYELWFKQVLWELDSVREIFISGHVRDERNMLKVNTRIHRIVMI  120 
             KGNKIHDEHLFIVTHQAYELWFKQ+LWELDSVR++FI  HVRDERNMLKV +RIHRI MI 
Tdo2b  61  KGNKIHDEHLFIVTHQAYELWFKQILWELDSVRDLFIKKHVRDERNMLKVVSRIHRITMI  120 
 
Tdo2a 121 FRLLLDQFAVLETMTALDFYDFRGYLSPASGFQSLQFRLLENKIGVPHNQRVPYNRRHYR  180 
             F+LL+DQFAVLETMTALDF+DFR YLSPASGFQSLQFRLLE KIGV  + RVPYNRRHYR 
Tdo2b 121 FKLLVDQFAVLETMTALDFFDFREYLSPASGFQSLQFRLLEQKIGVADHLRVPYNRRHYR  180 
 
Tdo2a 181 DNFRDQESELLLHSEQEPTLLQLVEQWLERTPGLEEDGFNFWGKLEKNIFEGLRREKEHI  240 
             DNF  +ESE LL SEQEPTLLQLVEQWLERTPGLE+DGFNFWGKL+ NI EGL+REK  + 
Tdo2b 181 DNFHGEESETLLSSEQEPTLLQLVEQWLERTPGLEKDGFNFWGKLQANIEEGLKREKHQV  240 
 
Tdo2a 241 EQKPASERKEEMLAELIKQRDIFLSLFDEKRHDHLVSTGQRRLSYKALQGALMIYFYREE  300 
             E+   +E K+E+L +L KQ + F +LFD KRH+HL+S G+RRLSYKALQGALMI FYREE 
Tdo2b 241 EKMEDTEVKQELLEDLNKQMETFTALFDSKRHEHLLSKGERRLSYKALQGALMINFYREE  300 
 
Tdo2a 301 PRFQVPFQLLTSLMDIDTLMTKWRYNHVCMVHRMIGRKDGTGGSSGYQYLRSTVSDRYKV 360 
             PRFQVPFQLLT+LM+IDTLMTKWRYNHVCMVHRMIG K GTGGSSGY YLRSTVSDRYKV 
Tdo2b 301 PRFQVPFQLLTALMEIDTLMTKWRYNHVCMVHRMIGSKAGTGGSSGYHYLRSTVSDRYKV  360 
 
Tdo2a 361 FVDLFNLATFLIPRDWVPKLDPSEHTFLYMAECCDSSYCS-SSDDSD  406 
             FVDLFNLATFL+PR WVPKL+P+ H F Y AEC DSSY S SS+DSD 
Tdo2b 361 FVDLFNLATFLVPRSWVPKLNPNIHKFPYTAECYDSSYNSCSSEDSD  407 
 
 
Fig. 3.2. An alignment of D. rerio Tdo2a (NP_001096086.1) and Tdo2b (NP_956150.1 ) 
proteins using T-Coffee using their FASTA sequences. Identical residues are highlighted in 
the middle row. The ‘+’ sign denotes that the amino acid is conserved in charge. 
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Fig. 3.3. Phylogenetic tree (maximum likelihood tree) of vertebrate TDOs. TDO is widely distributed among vertebrates, both tetrapod 
(highlighted in blue) and teleost fishes (highlighted in red). Each species possesses only one TDO basically, a few fishes (Danio and Astyanax) 
have two TDO isoforms, TDOa and TDOb. Amino acid sequences of amphioxus TDO is employed as an outgroup. The internal branch labels  
are bootstrap values with 100 replications. The scale bar corresponds to 0.08 substitutions per site. The tree was constructed with a help of Dr 
Yuasa, Kochi University, Japan.
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A. 
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Fig 3.4. Enzymatic activity, but not sequence homology, is common to zebrafish Ido and 
Tdo2 proteins. A. A schematic representation of the intron positions in tdo2a 
(NP_001096086.1), tdo2b (NP_956150.1) and ido (NP_001077323.1) proteins and their 
shared homology. The vertical black lines represent the position of introns within the 
protein sequence. Protein sequences were aligned using T-Coffee (Notredame et al., 
2000) and 76% amino acid identity was found between Tdo2a and Tdo2b. A full alignment 
of the Tdo2 sequences is found in Fig. 3.2. B. Tryptophan-catabolising enzymatic activities 
of zebrafish Tdo2a, Tdo2b and Ido assessed by measuring Kyn formation in the medium of 
transfected HEK293T cells using a spectrophotometric assay. Data shown are the mean ± 
SEM from a single experiment with 6 replicates.  
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3.3.2 Genes coding tryptophan-catabolising enzymes are expressed in the liver and 
intestine of zebrafish embryos. 
Expression of the three enzymes in embryonic development was examined in RNA 
extracted from pooled embryos by both endpoint RT-PCR and RT-qPCR (Fig. 3.5A and 
3.5B).  Abundant tdo2a mRNA expression was detected in embryos as young as 3 dpf and 
mRNA levels almost tripled from 3 dpf to 5 dpf.  tdo2b mRNA was only detected from 4 
dpf onwards, with approximately a 50 % increase in its expression levels from 4 to 5 dpf. 
The expression of ido was detected from 3 dpf onwards, similar to tdo2a. However its 
levels did not increase significantly from 3 to 5 dpf.   
The localisation of mRNA encoding the three enzymes was examined in D. rerio embryos 
using in situ hybridisation. tdo2a mRNA was detected throughout the intestine from 3 dpf 
onwards, but the expression of tdo2a mRNA was detected in the liver only from 4 dpf 
(Fig. 3.6A). Likewise, tdo2b mRNA was detected in the liver from 4 dpf and in the intestine 
from 3 dpf onwards, although its expression was limited to the posterior intestine (Fig. 
3.6B). ido, on the other hand, was detected throughout the intestine from 3 dpf onwards 
(Fig. 3.6C) and it was not detected in the liver (Fig. 3.6C).  
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Fig. 3.5. All three genes coding for tryptophan-catabolising enzymes are expressed in zebrafish 
embryonic development. A. Expression of the three tryptophan-catabolising genes in 2 to 5 dpf 
D. rerio embryos assessed by end-point RT-PCR. A representative experiment from 10 pooled 
embryos is shown. B. tdo2a (left), tdo2b (middle) and ido (right) mRNA expression relative to 3 
(tdo2a, ido) or 4 (tdo2b) dpf levels, at which point expression is first detected. Data shown for 3 to 
4 dpf are from pooled samples of 10 embryos in 3 experiments whereas data shown for 1 and 2 
dpf is from a single experiment. The expression of mRNA levels was relative to its own mRNA 
levels when it was first detected i.e the standard for tdo2a and ido were the expression levels of 
their respective mRNA at 3 dpf whereas the standard for tdo2b was the expression level of tdo2b 
mRNA at 4 dpf.   
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Fig 3.6. Genes coding Trp-catabolising enzymes are expressed in the zebrafish embryo 
intestine and liver. Images are representatives of n = 3 independent experiments in 
replicates of 5. A. tdo2a mRNA expression is seen in the liver and throughout the 
intestine from 4 and 5 dpf  D. rerio embryos treated with tdo2a antisense 
probes, whereas no expression was seen in the negative control treated with tdo2a sense 
probes. B. tdo2b mRNA expression is seen in the liver and posterior intestine when 
treated with antisense probes but not with the equivalent negative control. C. ido mRNA 
expression is seen throughout the intestine when treated with antisense probes but not 
with the equivalent negative control. ISH was performed in 2 to 5 dpf embryos. However, 
specific staining was only evident from 4 dpf onwards. The arrows point to the tissue 
where targeted mRNA is detected. 
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3.3.3 Knocking down the ido gene resulted in higher mortality in the embryos. 
To further investigate the Trp-catabolising genes in the D. rerio system, we employed the 
morpholino approach to transiently knockdown the expression of target genes. 
An ido morpholino targeting exon 1 splice site successfully knocked down ido mRNA 
expression by almost 70 % relative to the uninjected wild-type embryos at 3 dpf (Fig. 
3.7A). Although the levels of mRNA increased slightly at 4 and 5 dpf, they never exceeded 
50 % of the mRNA levels in uninjected controls. Morphants (embryos in which target gene 
expression has been knocked down) that were rescued by injection with ido mRNA 
transcript had similar knockdown efficiency at 3 dpf (~70%) but the mRNA levels  climbed 
to ~70% relative to the wild-type after 4 dpf (Fig. 3.7A). When the expression of tdo2a in 
ido morphants was assessed, a similar trend to ido expression was observed, where tdo2a 
mRNA levels were downregulated in the morphants relative to WT embryos (Fig. 3.7B). 
The mortality rate was recorded on each day and the results at 5 dpf are presented in 
Table 3.3 (mean ± SEM, n = 3 experiments).The morphants exhibited the highest mortality 
rate among the groups (55.4 ± 10.5 % from 181 morphants at 5 dpf ). The mortality rate 
of the rescued morphants was less than half that of the morphants (21.4 ± 4.2 % in 154 
embryos). There were no significant differences between the mortality rate of rescued 
morphants, the rescue RNA-injected embryos (22.6 ± 12.5 % in 151 embryos) and the 
uninjected embryos (10.1 ± 3.8 % in 307 embryos ) (Fig. 3.8). Gut oedema was exhibited 
by 25 % (n = 20) of the ido morphants surviving until 5 dpf (Fig. 3.9).  
Knockdown of ido expression in zebrafish embryos was also attempted using an 
alternative ido morpholino targeting exon 9. ido morphants exhibited cardiac oedema 
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and a general developmental retardation (Fig. 3.10A). All of the morphants also did not 
survive past 5 dpf. When the level of knockdown was assessed by RT-PCR and gel 
electrophoresis, a complete knockdown of ido expression was seen (Fig. 3.10E). However, 
alongside this knockdown, an ablation of tdo2a gene expression was also seen while the 
expression of reference gene β-actin remained normal. When the morphants were 
injected with ido RNA transcript (rescue), the general developmental retardation, cardiac 
oedema and premature death still remained (Fig. 3.10B). None of these phenotypes were 
observed in the rescue RNA only-injected and uninjected embryos (Fig. 3.10C & D). 
 
3.3.4 Knocking down the tdo2a and tdo2b genes in zebrafish embryos 
We successfully reduced the expression of tdo2a mRNA in D. rerio with a morpholino 
targeting exon 3 and 6 (Fig. 3.11A & B). However, no differences in phenotype or 
mortality rate were observed in the morphants compared to the wild-type uninjected 
embryos (Fig. 3.12). On the other hand, morpholinos designed to target splice sites in 
tdo2b mRNA were unsuccessful in knocking down gene expression (Fig. 3.11C).     
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Fig. 3.7. A. ido gene expression can be knocked down using morpholinos. Validation of 
the efficiency of ido knockdown by morpholinos targeting exon 1 of the ido gene was 
assessed by RT-qPCR analysis in ido morphants, relative to uninjected wild-type embryos, 
at 3, 4 and 5 dpf. Ido expression in morphants rescued using ido mRNA as well as wild-
type embryos injected with ido mRNA is also shown. B. tdo2a gene expression in ido 
morphants was assessed by RT-qPCR relative to WT embryos at 3, 4, and 5 dpf. 
Data are from pooled samples of 8 embryos from a single experiment.  
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Treatment  
 
Total embryos 
alive (%) 
Total embryos 
dead (%) 
Average Mortality 
rate (%) 
ido Exon 1 morpholino  80 (44) 101 (56) 55.4 ± 10.5 
ido Exon 1 + ido rescue  119 (77) 34 (23) 21.4 ± 4.2 
ido rescue only  116 (77) 35 (23) 22.6 ± 12.5 
WT uninjected  274 (89) 33 (11) 10.1 ± 3.8 
Table 3.3. Percentage of mortality in ido Exon 1 morphants, ido morphants rescued with 
ido mRNA, embryos injected with ido mRNA alone, and uninjected wild-type controls. 
Data shown are the total mortality rate as well as the mean mortality rate from 3 
independent experiments ± SEM. 
 
 
 
 
 
 
 
Fig. 3.8. Knockdown of ido gene expression increases the mortality rate in zebrafish 
embryos. Survival rate over 5 dpf of ido morphants, morphants rescued with ido mRNA, 
embryos injected with ido mRNA alone and uninjected wild-type embryos. Values 
represent the mean survival rate from 3 independent experiments. One-way repeated 
measures ANOVA with Tukey post-test statistical analysis showed significant differences 
(p< 0.05) in the survival rate on 5 dpf between morphants and rescued morphants (*) as 
well as between morphants and both rescue mRNA-injected embryos and uninjected 
embryos (not marked). There were no significant differences in the survival rates of 
uninjected embryos, rescue mRNA-injected embryos and rescued morphants (ns). 
Standard error of mean is not shown for clarity but were <12% of the mean values. 
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Fig. 3.9. Surviving ido ex 1 morphants had deformities including gut oedema. A. ido 
morphants, B. rescued morphants, C. ido mRNA-injected wild-type embryos and D. 
uninjected wild-type embryos. Images are representative of 3 independent experiments. 
Uninflated swim bladder (denoted by ‘*’), heart and gut oedema was seen in 20 % of the 
ido morphants (n=20) and was not present in the rescues.  
 
 
 
 
 
 
 87 
 
 
    
 
 
 
 
Fig. 3.10. Zebrafish embryos injected with ido exon 9 morpholino only (A) as well as ido 
morpholino and ido RNA transcript (B) at 3 dpf showed cardiac oedema (denoted by the 
square). Mortality rate was 100% for both ido morphants and rescue injected-morphants, 
likely indicating toxic off-target effects of the morpholino. ido mRNA only-injected wild-
type embryos (C) and uninjected wild-type embryos (D) showed normal, healthy 
phenotypes. Images are representative of a single experiment.  
Knockdown efficiency of ido exon 9 morpholino was assessed by RT-PCR and agarose gel 
electrophoresis (E). Although it appeared as though ido gene expression has been fully 
knocked down in ido morphants, the ablation of tdo2a gene expression in these 
morphants was also found. Expression of β-actin, an ubiquitously expressed gene, was 
normal in the morphants. 
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Fig. 3.11. Efficiency of tdo2a exon 6 (above), tdo2a exon 3 (middle) and tdo2b exon 6 
(below) knockdown in morphants compared to blank-injected (RNase-free water) and 
uninjected embryos as assessed by RT-PCR and gel electrophoresis.  
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Fig. 3.12. Morphology of tdo2a ex 6 (A) and ex 3 (B) morphants compared to blank-
injected wild-type (C) and uninjected wild-type (D) embryos at 5 dpf. No specific 
phenotypes seen in the morphants compared to the controls.  
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3.4 DISCUSSION 
3.4.1 Phylogenetic analysis of tryptophan-catabolising enzymes in aquatic animals. 
Ido2 is conserved throughout vertebrate evolution while Ido1 is present in all mammals 
and some species of fish and turtle (Yuasa et al. manuscript submitted). D. rerio has lost 
the Ido1 homologue but possesses an Ido2 homologue as well as two Tdo homologue 
genes (tdo2a and tdo2b). Almost all fishes seem to have only one Tdo gene, showing 
higher identity with tdo2a than tdo2b. As one of the two A. mexicanus tdo genes is 
clustered with zebrafish tdo2b (Fig. 3.3), gene duplication might have occurred in an 
ancestor of the teleosts and, similar to Ido1, tdo2b has been lost in many lineages of fish. 
However, the unavailability of tdo sequences of many other fish species in the database 
makes it hard to ascertain the timing of the gene duplication. D. rerio and A. mexicanus 
are rather closely-related species, so the tdo gene duplication might have occurred in 
their common ancestor. 
 
3.4.2 Enzyme kinetics of the three tryptophan-catabolising enzymes in zebrafish 
Although the enzyme kinetics of the zebrafish TDO enzymes have not been determined, 
in general TDO enzymes, from invertebrates to mammals, possess a high efficiency for 
catabolising Trp (Yuasa & Ball, in press). In contrast, IDO2 enzymes demonstrate 
low/moderate efficiency for the catabolism of Trp (Km of ~50 mM in mouse; Km of ~30 
mM in zebrafish); high efficiency for catabolising Trp, similar to TDO enzymes, has only 
evolved in mammalian IDO1 enzymes (Km of ~20 µM in mouse) (Yuasa et al., 2009; Yuasa 
et al., 2007); Yuasa et al. manuscript submitted). Although the results from the Kyn assay 
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(Fig. 1B) show similar quantities of Kyn formation by zebrafish Ido and the Tdo enzymes, 
this assay was performed over 24 h with a single, high concentration of L-Trp. Thus, while 
the assay demonstrated that each of the zebrafish enzymes has the capacity to catabolise 
Trp, it cannot be used to infer the enzyme kinetics of the proteins. Previous studies on the 
enzyme kinetics of IDO2 enzymes demonstrate that zebrafish Ido has a low efficiency for 
Trp catabolism compared to mammalian IDO1 enzymes (Yuasa et al, 2009). Although we 
have not performed a direct comparison, on the basis of these previous studies, we 
expect that the Trp-catabolising efficiency of zebrafish Ido would also be low compared to 
the zebrafish Tdo enzymes. 
 
3.4.3 RNA expression onset and distribution of ido, tdo2a and tdo2b in zebrafish 
The overlap in the onset of expression and distribution of tdo2a, tdo2b and ido in D. rerio 
is consistent with a collaborative role between the three enzymes, though this remains to 
be tested. Beginning at 3 dpf, all three genes were expressed in the intestine, although 
tdo2b was localized to the posterior intestine while tdo2a and ido were expressed 
throughout the intestine. The localisation of tdo2b in the posterior intestine is in 
agreement with a previous study (Thisse, B., Thisse, C., 2004). Both IDO1 and IDO2 have 
been reported to be expressed in the human intestine (Metz et al., 2007). More recently, 
we found Ido2 mRNA in the mouse colon but not in the duodenum (Section 4.3.2). In 
contrast, ido mRNA was detected throughout the intestine in zebrafish.  
 
Both tdo2a and tdo2b were found in the D. rerio liver from 4 dpf onwards, however ido 
was not detected in the liver. These results point to a difference in the expression of Trp-
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catabolising genes between mammalian and zebrafish liver. Both Tdo and Ido2 are 
expressed in the liver of humans and mice (Ball et al., 2007; Ball et al., 2014), whereas in 
D. rerio only tdo2a and tdo2b were detected in the liver. It is possible that Ido2 enzymes 
have evolved to have a role in the mammalian liver that does not exist in zebrafish. 
 
3.4.4 Knocking down the expression of ido, tdo2a and tdo2b in zebrafish using the 
morpholino knockdown approach  
3.4.4.1 Knocking down ido expression in zebrafish 
The morpholino knockdown approach was used to explore the role of ido in zebrafish 
development. Morpholinos produce a transient knockdown of the targeted gene 
expression and are known to be stable for an average of 3 - 5 days. However, its highest 
knockdown efficiencies have been noted in the first two days of development (Nasevicius 
and Ekker, 2000). It is rare for morpholinos to be completely penetrant beyond 2 dpf. 
Most studies employing the morpholino knockdown approach reveal a phenotype by 3 
dpf, although there have been reports of the phenotypes being stable for up to 5 days 
(Bill et al., 2009; Kloosterman et al., 2007; Nutt et al., 2001). Even if some percentage of 
knockdown is seen, the subsisting level of target mRNA can still be sufficient to produce 
protein with biological significance and hence, a normal phenotype may be seen (Eisen 
and Smith, 2008). Additionally, heterozygous mutations are unlikely to produce 
phenotypes (Ekker and Akimenko, 2010; Kettleborough et al., 2013). Although the ido 
gene knockdown efficiency in morphants was ~70 % on 3 dpf, this had reduced to 50 % by 
4 dpf, suggesting that knockdown efficiency was decreasing and ido mRNA production 
was increasing (Fig. 3.7). In morphants injected with ido RNA transcript (rescue), 
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knockdown efficiency was ~70 % (i.e. 30 % of uninjected WT ido mRNA levels) on 3 dpf, 
but on 4 dpf onwards the levels of ido mRNA climbed to 70 % of WT RNA expression. 
These observations seem to indicate that the statistically significant higher mortality seen 
in ido morphants (Fig. 3.8), compared to the rescued morphants and the uninjected 
embryos, may be due to an off-target effect of the morpholino. There are a few 
indications that the apparently on-target effect of ido loss is likely to be off-target.  
First, the significantly higher mortality rate in the morphants relative to rescued 
morphants and WT uninjected embryos was evident from 1 dpf onwards, a time point at 
which ido was undetectable (Fig. 3.8). This could be an off-target effect of the morpholino 
that causes increased mortality in the morphants, even at a time ido is not expressed. 
Although this increased mortality was rescueable by injection of ido RNA transcript, this 
does not necessarily indicate the rescue of an on-target effect. The presence of 
exogenous ido RNA could result in the improvement of the general well-being of the 
embryo that resulted in the reduced mortality in the rescued morphants and not 
necessarily be due to rescue of an on-target effect.  
Secondly, both morpholino only-injected and morpholino + rescue RNA-injected embryos 
had high knockdown efficiency at 3 dpf and the efficiency of knockdown only diverged at 
4 dpf onwards (Fig. 3.7A). In the embryos injected with both ido RNA transcript and 
morpholino, a higher level of ido mRNA was detected. Exogenous rescue RNA is suitable 
for rescuing developmental phenotypes seen in the first 24 to 48 hpf as it degrades within 
two to four dpf (Bill et al., 2009; Link and Megason, 2008). Therefore, the increasing levels 
of ido mRNA indicates that the knockdown effects are beginning to wear off and the 
significantly lower mortality rate seen in the rescued morphants is more likely due to 
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lower levels of morpholino in these embryos to begin with than in the morpholino only-
injected embryos. In addition, the level of another gene expressed in the intestine, tdo2a, 
also was reduced (Fig. 3.7B). One could opine that this could be a result of ido-tdo2a 
interaction since both genes code Trp-catabolising enzymes that are expressed in the 
intestine. However, considering the former argument on the increased mortality even at 
1 dpf, this reduction in tdo2a gene expression could be a result of an off-target effect that 
is affecting the development of the intestine. This could explain the gut oedema observed 
in the morphants. 
The final observation that consolidated the finding as likely being an off-target effect was 
the protruding lower jaw and heart oedema seen in the morphants. These phenotypes 
are common off-target effects of the neural crest (Eisen and Smith, 2008). The presence 
of other off-target effects in tissues in which ido is not known to be expressed is a cause 
for concern and further strengthens the likelihood that the increased mortality seen in 
morphants is an off-target effect.  What initially seemed like a ‘successful’ rescue of 
morphant phenotype of increased mortality, suggesting ido to play a role in the normal 
development of the embryos, was elucidated to be more likely an off-target effect.  
Another morpholino targeting a different exon, 9, of the ido gene was also used to obtain 
knockdown of ido expression in zebrafish embryos. The attempt to knockdown the ido 
gene using exon 9 resulted in off-target mortality in all the injected embryos, which were 
not rescuable by the injection of ido RNA transcript (Fig. 3.10A & B). As the off-target 
effect included general developmental retardation, it was difficult to establish knockdown 
efficiency in the morphants. ido mRNA expression was undetectable in these morphants 
even from 3 dpf, while being detectable in uninjected and blank-injected zebrafish 
 95 
embryos (Fig. 3.10E). The expression of tdo2a gene also was undetectable in these 
morphants. Reference gene β-actin, which is ubiquitously expressed in all cells and 
tissues, was measurable in the morphants. This outcome is similar to the morphants 
injected with ido morpholino targeting exon 1, where a knockdown of tdo2a also was 
seen in these morphants (Fig. 3.7B). Although it is possible that ido was knocked down 
efficiently in these morphants and the expression of tdo2a is reduced in them because of 
the effect of Ido deficiency on the intestinal growth or on tdo2a expression directly, the 
failure of ido RNA transcript to rescue the morphants suggests that the overall 
developmental retardation and mortality observed is an off-target effect of the 
morpholino. 
Despite using two morpholinos targeting different exons, we were not able to elucidate 
the possible role of Ido in zebrafish development due to the various technical challenges 
encountered. 
 
3.4.4.2 Knocking down tdo2a and tdo2b expression in zebrafish 
When we attempted to knockdown tdo2a expression in zebrafish embryos, we were able 
to achieve a reduction in tdo2a expression by microinjection of morpholinos, but yet 
again we could not completely abolish gene expression. No phenotypic effects were 
observed as a result of knocking down tdo2a.  As mentioned previously (Section 3.4.4.1), 
reduction in mRNA levels does not always translate into an equal reduction in protein 
levels (Eisen and Smith, 2008) and it is possible that the levels of tdo2a mRNA present 
translated into sufficient Tdo2a enzymatic activity. Alternatively, it is possible that there 
was loss of Tdo2a activity but either Trp catabolism is not important in embryonic 
 96 
development or the loss of Tdo2a activity is compensated for by the presence of the 
other two enzymes. Another morpholino targeting exon five of tdo2a also was employed 
to attempt to knockdown tdo2a gene expression. Both these morpholinos were not able 
to produce sufficient mRNA knockdown to result in a phenotype. Due to the strong 
expression of tdo2a in zebrafish, transient gene knockdown approaches may be 
unsuitable for studying the role of Tdo2a within the zebrafish. Generating mutant fish 
lines using the TALENs (transcription activator-like effector nucleases), ZFN (Zinc finger 
nucleases) or CRISPR (clustered, regularly interspaced, short palindromic repeats)-
associated Cas systems may be better alternatives, but there was insufficient time to 
attempt this during the current project. 
The morpholinos targeting tdo2b were not successful in knocking down its expression. As 
the expression of tdo2b only appears at 4 dpf onwards, the morpholino approach may be 
unsuitable for studying the possible role of tdo2b in D. rerio embryos.  
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3.5 CONCLUSION 
In this work, the different expression patterns of the three Trp-catabolising genes in 
zebrafish embryos were elucidated. However, knocking down the gene using the 
morpholino approach rendered misleading off-target effects which posed technical 
challenges to ascertaining unambiguously the possible role of the three Trp-catabolising 
genes in lower vertebrates. 
These data point to an evident and common complication of using the morpholino 
approach for knocking down gene expression. Off-target effects of morpholinos are 
common and often can be misleading (Eisen and Smith, 2008). Even with the use of 
appropriate controls such as rescue RNA, blank-injected embryos or uninjected WT 
embryos, there is still a chance that the effects observed are off-target. A possible way to 
rule out off-target effects would be stringent control of the amount of morpholino 
delivered per embryo and the use of a number of morpholinos targeting different sites on 
the target gene. However, the former approach would require a more technologically 
advanced morpholino delivery system that does not depend on human labour for 
injections of the embryos, which was not available in the local zebrafish facilities. The 
latter suggestion, on the other hand, would be laborious and time consuming. Even with 
the use of multiple morpholinos, off-target effects of the morpholinos cannot be 
definitively avoided or resolved. In the face of an off-target effect, the remaining choice 
would be to utilise a different morpholino design targeting a different exon. This 
approach, unfortunately, could be counterproductive considering that the phenotypical 
changes seen in the morphants can only be ruled out as being off target after optimising 
and validating the knockdown itself. 
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The recent discovery of a double-stranded genome-editing approach, CRISPR could be a 
promising alternative to morpholino gene knockdown approach (Hwang et al., 2013b; 
Hwang et al., 2013a). However, this method also has been reported to induce a high level 
of off-target mutagenesis (Fu et al., 2013).  Off-target effects remain a confounding 
aspect in more than one genome-editing approach in zebrafish. Studies to define 
parameters that may contribute to off-target effects may help to better refine zebrafish 
genome-editing approaches. More recently, a software tool to guide the selection of 
target sequences and validation of on- as well as off-target effects observed was 
developed (Hsu et al., 2013). This could help reduce the possibility of off-target effects in 
zebrafish genome-editing studies. Whilst the zebrafish is an excellent experimental model 
for fundamental localisation, developmental and organogenesis-related research, the 
limitation of the genome-editing techniques currently available would need to addressed 
and overcome to successfully and validly answer pivotal research questions.  
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CHAPTER 4 EXPRESSION OF IDO2 IN VARIOUS ADULT AND 
EMBRYONIC MURINE TISSUES 
4.1 INTRODUCTION 
There are three tryptophan-catabolising enzymes that catalyse the first and rate-limiting 
step in the kynurenine pathway, namely TDO2, IDO1 and IDO2. These three enzymes are 
regulated by different factors and are expressed in different tissues, despite catalysing 
the same reaction. In physiological conditions, TDO2 expression is high in the liver (Knox 
and Auerbach, 1955), whereas IDO1 expression has been detected constitutively in 
epididymis, colon and placenta, although its expression is mainly induced in inflammatory 
conditions by IFNγ, TNF and LPS  (Higuchi and Hayaishi, 1967; Pfefferkorn et al., 1986b; 
Yoshida and Hayaishi, 1978; Werner-Felmayer et al., 1990). IDO2 expression, on the other 
hand, has been reported in the liver and kidney (Ball et al., 2007; Metz et al., 2007). 
All three enzymes have been implicated in various types of cancer. Increased TDO2 
expression was detected in gliomas and colon, breast, ovarian and lung carcinomas (Opitz 
et al., 2007), whereas IDO1 expression has been detected in various human tumours such 
as prostatic, colorectal, pancreatic, ovarian and breast carcinomas as well as in sarcomas, 
lymphomas and melanomas (Uyttenhove et al., 2003). The existence of IDO2 was first 
reported in 2007 (Ball et al., 2007; Metz et al., 2007) and to date has been found to be 
associated with human pancreatic, colon, renal and gastric cancer, as well as in arthritis 
(Merlo et al., 2014; Witkiewicz et al., 2009; Lob et al., 2009). IDO1 also has been 
implicated in pregnancy, and is suggested to prevent allogeneic foetal rejection by 
breaking down Trp (Munn et al., 1998). It was speculated that the catabolism of Trp 
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resulted in the induction of maternal T-cell tolerance, which prevented allogeneic foetal 
rejection by inhibiting the expansion of T lymphocyte populations. 
The cellular localisation pattern of TDO2 within the liver has not been reported thus far. 
On the other hand, IDO1 has been reported to be localised in the columnar epithelial cells 
in the caput of the epididymis (Dai and Zhu, 2010; Fukunaga et al., 2012). In the digestive 
tract, IDO1 was detected constitutively throughout most of the tract, with the highest 
expression of mRNA detected in small intestine (duodenum, jejunum and ileum) (Dai and 
Zhu, 2010). As assessed by immunohistochemistry (IHC), IDO1 was detected in the lamina 
propria of villi and the glands in the duodenum, whereas in the jejunum and ileum it was 
found in the interstitial space of villi or the mucosal layer. The expression of IDO1 in colon 
and caecum was mainly in the connective tissues between the glands in the mucosal 
lamina propria (Dai and Zhu, 2010). A predominantly cytosolic localisation of IDO1 in 
syncytiotrophoblasts in the placenta also has been reported (Dai and Zhu, 2010). 
Previously, IDO2 had been described in the epididymis and testes (Ball et al., 2007). 
Although TDO2, IDO1 and IDO2 were all expressed in the epididymis, the pattern of 
cellular localisation differed (Ball et al., 2007; Britan et al., 2006; Dai and Zhu, 2010; 
Fukunaga et al., 2012).  Some information on the possible cellular distribution of IDO2 in 
the liver, brain, kidney and epididymis also has been reported (Fukunaga et al., 2012). 
However, the lack of a definitive negative control in the form of Ido2-/- gene knockout 
mouse liver may have been a disadvantage for ascertaining accurate patterns of IDO2 
cellular localisation in previous studies, as will be discussed later in this Chapter. The 
cellular localisation of TDO2, IDO1 and IDO2 in various tissues is summarised in Table 4.1. 
 102 
To date, interactions between the expression of TDO2, IDO1 and IDO2 have not been 
investigated in detail. One observation is that inhibiting TDO2 enzyme activity did not 
alter kynurenine production by IDO1 (Opitz et al., 2007). There also have been findings 
indicating that IDO2 expression may be regulated by IDO1, as there were reduced levels 
of functional IDO2 protein, whilst alternatively-spliced IDO2 protein levels were 
increased, in the macrophages of Ido1-/- mice (Metz et al., 2014). Upregulation of IDO2 in 
the epididymis of Ido1-/- mice also has been reported (Fukunaga et al., 2012). Conversely, 
IDO1-mediated regulatory T cell generation was impaired in Ido2-/- mice, suggesting a 
possible interaction between the two proteins (Metz et al., 2014). Although skin contact 
hypersensitivity responses were impaired in both Ido1-/- and Ido2-/- mice, a reduction in 
immune regulatory cytokines was only detected in Ido2-/- mice, suggesting that despite an 
interaction between IDO1 and IDO2, there was a difference in the mechanism through 
which these enzymes effect change in immunity and inflammation  (Metz et al., 2014).  
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Tissue TDO2 IDO1 IDO2 
Epididymis  Spermatozoan head 
(Britan et al., 2006) 
Caput of epididymis 
(Ball et al., 2007; Britan 
et al., 2006; Fukunaga 
et al., 2012) 
Stereocilia of the apical 
epithelial epididymal 
cell (Dai and Zhu, 2010) 
 
Spermatozoan tail (Ball 
et al., 2007) 
Caput, corpus and 
cauda (Fukunaga et al., 
2012) 
Testes  Intertubular tissue 
and late 
differentiating germ 
cell (Britan et al., 
2006) 
Undetected in testes 
(Ball et al., 2007; Britan 
et al., 2006) 
Spermatozoa (Ball et al., 
2007) 
Liver Information on 
cellular localisation of 
TDO2 has not been 
reported. 
Undetected (Britan et 
al., 2006; Fukunaga et 
al., 2012; Dai and Zhu, 
2010) 
Liver hepatocyte 
(Fukunaga et al., 2012) 
Kidney Not reported Localised in the blood 
vessels (Ball et al., 
2007) 
Smooth muscle layer of 
small blood vessel (Dai 
and Zhu, 2010) 
Tubules (Ball et al., 
2007; Fukunaga et al., 
2012) 
 
Brain Not reported Cerebral cavity region 
(Dai and Zhu, 2010) 
Purkinje cells of 
cerebellum cortex and 
neuronal cells of 
cerebrum cortex 
(Fukunaga et al., 2012) 
Digestive tract Not reported Detected constitutively 
throughout tract. 
Highest expression 
detected in the small 
intestine (duodenum, 
jejunum and ileum) 
(Dai and Zhu, 2010) 
Detected in human 
small intestine and 
colon (Metz et al., 2007) 
Table 4.1. Summary of tissue and cellular distribution of Trp-catabolising enzymes in 
different tissues. 
 
 104 
In embryonic tissues, TDO2 mRNA and protein expression have been observed as early as 
5.5 days-post-coitus (dpc) in mouse concepti (embryos and extra embryonic tissues) and 
this was maintained up to 10.5 dpc.  It also was detected strongly from 10.5 to 16.5 dpc in 
the placenta (Suzuki et al., 2001). In humans, TDO2 mRNA has been reported in placental 
explants (Dharane Nee Ligam et al., 2010). However, the role of this enzyme in the 
placenta remains unknown. The expression of TDO2 in embryonic or neonatal livers has 
been studied in rat models where it was first detectable only in the liver of 2-week old 
rats (Franz and Knox, 1967).  IDO1 protein has been detected in both human and mouse 
placenta (Suzuki et al., 2001; Yamazaki et al., 1985). The third enzyme, IDO2, has been 
reported only at the mRNA level both in human and mouse placenta (Metz et al., 2007; 
Ball et al., 2009). 
Based on these earlier findings of others, we aimed to investigate more thoroughly the 
cellular localisation of IDO2 within different tissues of wild-type mice. We also were 
interested in uncovering possible interactions between the three enzymes by looking at 
mRNA levels of the three genes in different tissues of various single and double gene 
knockout mouse strains. Additionally, we examined Tdo2, Ido1 and Ido2 expression in 
tissues from a murine developmental series, namely the placenta, yolk sac and liver, in 
order to determine their patterns of expression in relation to the development of the 
organism. 
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4.2 METHODS 
4.2.1 Mouse strains 
C57BL/6 wildtype (WT) was the background strain of mouse used in this project. The mice 
were acquired from the Australian Animal Resources Centre (Perth, Australia) and were 
also used as the Ido1-/- wildtype-equivalent. Ido1-/- mice (back-crossed to C57BL/6J) were 
obtained from Dr Andrew Mellor (Institute for Molecular Medicine and Genetics, Medical 
College of Georgia) (Baban et al., 2004). Ido2-/- mice, on the other hand, were generated 
in our laboratory by crossing C57BL/6J mice expressing Cre recombinase (Cre-Tg) under 
the influence of the Cytomegalovirus (CMV) promoter, courtesy of Prof. R. Harvey (Victor 
Chang Cardiac Research Institute), with C57BL/6J mice having loxP sites incorporated to 
either side of the exon 3 of the Ido2 gene (courtesy of Dr. George Prendergast, Lankenau 
Institute of Medical Research, Philadelphia, USA). Exon 3 of the Ido2 gene that was 
flanked by loxP genes was cleaved under the control of the CMV promoter, causing non-
functional IDO2 enzyme production.  Ido2-/- litters were verified by genotyping.   
The Tdo2-/- mouse and its equivalent WT controls (Tdo2+/+) consist of a mixed genetic 
background of C57BL/6NCr Slc x DBA/2 and were generated by intercrossing 
heterozygotes. The heterozygotes were obtained through germ-line transmission of the 
knockout allele by crossing the F1 male chimaeras (C57BL/6NCr Slc and DBA/2 parents) 
containing the knockout allele with C57BL/6NCr Slc females, and were obtained courtesy 
of Toshikazu Nakamura and Hiroshi Funakoshi (Kanai et al., 2009). 
Outbred wild-type QS strain mice were courtesy of Dr Stuart Fraser (Department of 
Physiology, The University of Sydney). 
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All mice, with the exception of wild-type C57BL/6J, were bred in the Medical Foundation 
Building, The University of Sydney. They were housed two to five mice per cage under a 
12 hour light-dark cycle with food and water available ad libitum. 
For immunohistochemistry (IHC), liver, kidney, brain, epididymis, testes and colon tissues 
were collected from 8-week-old Ido2-/- mice and the equivalent wild-type animals.  
Assessment of mRNA expression in a developmental series was performed using 
embryos, neonates and adult tissues of outbred QS and inbred Cre transgenic mice. To 
study the possibility of interaction between the three genes for Trp-catabolising enzymes, 
the expression levels of these genes were studied in mice with single genes knocked out, 
Ido1-/-, Ido2-/- and Tdo2-/-, alongside two double gene knockout strains (Ido1-/- Tdo2-/- and 
Ido2-/- Tdo2-/-) that were generated by Dr Helen Ball in the laboratory. The mRNA analysis 
was performed in these single and double gene knockout strains alongside their 
equivalent wild-type strains as shown in Table 4.2. 
All studies were carried out in accordance with the New South Wales legislation 
governing research with animals. The protocols were approved by the University of 
Sydney Animal Ethics Committee.
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Knockout strain Wild-type equivalent 
Ido1-/- 
C57BL/6J 
Ido2-/- 
Transgenic Ido2+/+ with Cre-loxP system (C57BL/6J). 
Also referred to as Cre-Tg. 
Tdo2-/- 
Tdo2+/+ (DBA x C57BL/6NCr Slc) 
Ido1-/- Tdo2-/- Ido1+/+ Ido2+/+ Tdo2+/+ 
Ido2-/- Tdo2-/- 
 Table 4.2. shows the list of knockout strains with their wild-type equivalents used for mRNA 
assessment of Trp-catabolising gene expression 
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4.2.2 Tissue collection and homogenisation 
For the assessment of gene and protein expression in adult mice, tissues were collected 
from two, three and eight-week-old mice. For the study of gene expression in a 
developmental series, tissues were collected from murine embryos of outbred QS and 
inbred Ido2+/+ strains. Embryonic tissues such as the yolk sac and liver, as well as placenta, 
were collected at E12.5, E16.5, E17.5 and E18.5 dpc whereas neonatal tissues were from 
P1, P2, P3 and P7 neonates, i.e. days 1, 2, 3 and 7 post-partum. Tissues were collected in 
2 mL screw-cap tubes and snap-frozen immediately in liquid nitrogen. These were stored 
at -80°C until processing. 
On the day of homogenisation, tissues were transferred into liquid nitrogen flasks, where 
they were kept until they were homogenised. Tissues were transferred from the 2 mL 
screw cap tubes into 2 mL tubes, where 500 to 1000 µL of PBS was added to the tissue 
(depending on the tissue size) and homogenised using a Polytron Tissue homogeniser (PT 
2100) for about 20 sec or until they were fully homogenised. Homogenates were 
immediately placed on ice. Subsequently, 30 µL of the homogenate was added to 350 µL 
RNA Lysis Buffer from the ISOLATE II RNA Mini Kit (BIOLINE). Another 400 µL of the tissue 
homogenate was added to another tube with an equal volume of 2X RIPA buffer for 
protein extraction. The remaining homogenate was aliquoted into separate tubes for 
other uses. All aliquots were kept frozen at -80 °C until further processed. 
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4.2.3 RNA extraction 
RNA extraction and cDNA synthesis was performed as described previously in Chapter 2 
with the exception that the RNA extraction was done using the BIOLINE ISOLATE II kit, 
according to the manufacturer’s protocol (Jusof et al., 2013). 
 
4.2.4 Protein extraction  
An equal volume of tissue homogenate was added to 400 µL of 2X RIPA buffer containing 
50 mmol/L Tris pH 7.4, 150 mmol/L NaCl (Sigma Aldrich), 1 mmol/L EDTA (Sigma Aldrich), 
1% v/v Triton X-100, 1 % w/v sodium deoxycholate (Sigma Aldrich), 0.1 % w/v sodium 
dodecyl sulphate (SDS) and 1:100 protease inhibitor (Sigma Aldrich) and allowed to sit on 
ice (4 °C) for 30 min, after which the solution was spun down at 16000 rcf at 4 °C for 15 
min. The supernate was pipetted into new, clean 1.5 mL microcentrifuge tubes whereas 
the pellet was discarded.  
 
4.2.5 Anti-IDO2 antibody specificity 
Anti-IDO2 antibodies were obtained either commercially or from other laboratories 
studying IDO2. Rabbit polyclonal anti-IDO2 antibodies were obtained from Dr. Ursula 
Grohmann from the University of Perugia, Italy, as well as Prof. Yasuko Yamamoto from 
the University of Kyoto, Japan. In addition to the rabbit polyclonal anti-IDO2 antibody 
generated by Genscript, NJ, USA (Ball et al, 2007), two commercial anti-IDO2 antibodies 
were purchased from Santa Cruz Biotechnologies, one mouse monoclonal and a rabbit 
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polyclonal antibody. The specificity of these antibodies was tested on liver protein lysates 
from Ido2+/+ and Ido2-/- mice by Western blotting. 
 
4.2.6 SDS-PAGE and Western Blotting 
Concentration of protein in the lysates was determined by bicinchoninic acid (BCA) 
protein assay (Pierce, IL, USA), according to the manufacturer’s instructions. Once 
determined, the concentration of the protein was standardised to 5 µg/µL by the addition 
of water, before an equal volume of 2X loading buffer was added to the lysates. This was 
placed on a heating block at 95 °C for 2 min and 10 µL (25 µg) was transferred onto the 
wells of 10 % w/v SDS-Polyacrylamide Electrophoresis gels. The samples were run 
alongside 2 µL of pre-stained protein ladder (Pierce Life Technologies) on a MiniGel Tank 
in 1X Tris-Glycine-SDS electrophoresis buffer at 100 V for 110 min or until the dye front 
reached the bottom of the gel. The protein bands on the gel were transferred onto 
polyvinylidene difluoride membrane (GE Healthcare), before the membrane was 
incubated in 4 mL of primary antibodies (0.2 µg/mL) overnight. This was followed by 1 h 
incubation in 1:4000 secondary antibody (IRDye, Li-Cor) wrapped in foil. Every incubation 
was followed by 3 washes of the membrane in PBS with 0.1 % v/v Tween 20. The density 
of bands on the membrane was read on an Odyssey Infrared Imaging System (LI-COR 
Biosciences). 
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4.2.7 Immunoprecipitation and Western Blot 
To every tube, 50 µL of Protein A was added and the solution was rotated at 4 °C for 1 h, 
before spinning down at 6000 rcf for 3 min. The supernates were retained and frozen at -
80 °C until further analysis. For immunoprecipitation, Protein A was first equilibrated by 
spinning tubes at 6000 rcf for 3 min (40 µL of Protein A per sample). The supernate was 
discarded and the pellet was resuspended in 100 µL of 1X RIPA buffer (per sample). 
Protein lysates (200 µL) were added to 100 µL of Protein A, with 2.5 µg of IDO2 antibody. 
These samples were prepared alongside controls with no anti-IDO2 or an irrelevant 
mouse IgG antibody. The preparations were rotated overnight at 4 °C before they were 
spun at 6000 rcf for 3 min at 4 ºC. The supernates were carefully removed and the pellet 
was resuspended in 1 mL cold 1X RIPA buffer. This wash step was repeated twice before 
the pellets were finally resuspended in 1X Loading buffer and run on an SDS-PAGE gel. 
The antibody used for detection in the Western Blot was a different anti-IDO2 antibody, 
raised in a different animal species. 
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Figure 4.1. Flow chart of the protocol of Western Blot detection using immunoprecipitated protein lysates. 
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4.2.8 Immunohistochemistry on formalin-fixed mouse tissues using the M.O.M. 
ImmPRESS system 
The sections of formalin-fixed tissue were stored at 4 °C. The sections were 
deparaffinised by immersing them twice in xylene for 10 min each, followed by 
immersion in decreasing concentrations of ethanol (absolute, 95 % x 2, 70 % v/v) for 2 
min each. Finally the slides were immersed in water for 2 min. Upon deparaffinisation, 
antigen retrieval was performed by incubating the slides in 600 mL of 0.2 mol/L citrate 
buffer ph 6.0 (Sigma Aldrich) at 90 ° to 95 °C for 12 min. The beaker was left to cool for 20 
min in a water bath before slides were washed in 50 mmol/L TRIS-buffered saline with 0.1 
% v/v Tween-20 (TBS-T) for 2 min. All subsequent washes were performed for 2 min with 
TBS-T unless mentioned otherwise. Peroxidase blocking was performed thereafter with 3 
% v/v hydrogen peroxide (H2O2) in methanol for 5 min. After the slides were washed, 
peptide blocking was performed using Mouse on Mouse (M.O.M.) blocking reagent 
(Vectorlabs) for 30 min. Slides were then washed twice, and incubated with 2.5 % v/v 
normal horse serum (NHS) for 5 min. Primary IDO2 antibody (Santa Cruz Biotechnnology) 
at a final concentration of 1 µg/mL, prepared in 2.5 % v/v NHS, was added to each section 
and incubated in a humidified container at 4 °C overnight. The next morning, the sections 
were washed twice before the Vector M.O.M.™ ImmPRESS reagent (Vectorlabs) was 
added to the sections and incubated for 10 min. Sections were then washed twice for 5 
min. Dinitrophenyl (DNP) amplification reagent from the TSA™ DNP (HRP) System (Perkin 
Elmer) was prepared in DNP amplification reagent (from the kit) in a 1:50 v/v dilution . 
This was added to the sections and incubated for 5 min. Sections were washed thrice 
with agitation before 1:100 v/v anti-DNP-HRP (from the kit), diluted in TNB blocking 
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reagent, was added prior to incubation for 20 min. Sections were washed thrice with 
agitation before diaminobenzidine (DAB) substrate (Dako) was added and the sections 
incubated for 4 to 8 min (depending on the tissue type). After thorough rinsing in water, 
sections were stained using haematoxylin for about 2 min, subsequently washed in 
water, and dipped briefly in acetone before they were counterstained in Scott’s blue 
stain. The slides were brought through an ascending concentration of ethanol (75 %, 90 % 
v/v and absolute ethanol for 30 sec each) and finally dipped in Histolene (2 min in each 
solution) before they were coverslipped and observed. All washes were performed with 
TBS-T for 2 min. Stained surface area and nuclei count were quantified using the 
MetaMorph software (Molecular Devices), after which Student’s t-test was used to 
ascertain statistical significance using GraphPad Prism.  
During the optimisation of the IHC method, various different antigen retrieval approaches 
were used including the pressure cooker method and water bath on a hotplate method 
for fixed sections with the former not being optimal for IDO2 antigen retrieval. Staining 
on frozen sections also was attempted. However, this method had high background 
staining. Despite the different approaches used, only the hotplate antigen retrieval 
method on formalin-fixed sections, followed by IHC with Vector M.O.M. complemented 
with TSA strategy yielded positive signals. Therefore, this method was used subsequently 
to study IDO2 expression in different tissues. 
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Figure 4.2. Protocol flow of IDO2 protein localisation in tissues by IHC using the Vector 
M.O.M. ImmPRESS kit.   DNP, dinitrophenyl; Tyr, Tyramide; HRP, horse radish peroxidase; 
DAB, diaminobenzidine 
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4.2.9 Immunofluorescence 
Prior to seeding with cells, Nunc 8-well permanox slides were coated with 300 µL of Poly-
D-lysine (Sigma Aldrich, 25 µg/mL) and allowed to dry overnight. The next day, DNA-
lipofectamine complexes were prepared in the transfection medium OPTIMEM (GIBCO) 
according to the ratio 80 µL OPTIMEM : 0.33 µL Lipofectamine 2000 (Invitrogen) : 0.5 µg 
plasmid DNA per reaction. Once the complexes had formed for 15 to 20 min, they were 
added to the wells – approximately 75 µL/well. A total volume of 225 µL Human 
Embryonic Kidney (HEK) cells at a concentration of 5 x 105 cells/mL was added to each 
well and swirled gently. The cells were incubated overnight to allow attachment before 
immunofluorescence was performed. The medium was then removed and cells were 
washed with 200 µL of PBS before fixation in 200 µL of 4 % v/v paraformaldehyde for 15 
min. The cells were then permeabilised with 0.2 % v/v Triton-X100 (Packard Instruments) 
in PBS for 5 min. Protein blocking was done using 5 mg/mL BSA in PBS for 1 h. Primary 
antibody prepared in PBS was added to each well and incubated for 60 to 90 min. Double 
5 min washing steps preceded incubation with 90 min Alexa 488 secondary antibody 
prepared at a concentration of 1:1000. Washing was performed similarly to the previous 
washing step but the chambers were incubated in the dark. The silicon beading that 
fastens the chamber to the slide was pulled off and chamber edges were squeezed to lift 
them from the surface of the slide. The gasket was gently peeled off. As much liquid as 
possible was removed without disturbing the cells. Finally, slides were treated with three 
drops of Fluoroshield mounting medium with DAPI (Sigma Aldrich) and coverslipped. The 
slides were refrigerated, wrapped in foil. Images were captured on a Zeiss LSM 510 
Confocal Microscope at the Advanced Microscopy Facility of the Bosch Institute. Pinhole 
 117 
size, detector gain, amplifier gain and amplifier offset were all standardised for each 
probe. 
4.2.10 RT-qPCR using the standard curve method 
Expression of Ido2 was determined by the standard curve method, with normalisation to 
the Ywhaz reference gene for adult tissues and Rpl13a for tissues from the 
developmental series. These genes have similar amplification efficiencies, as assessed 
using serial dilutions of cDNA, and the purity of the PCR products was assessed by melting 
curve analysis. For the standards, cDNA for Ido1, Ido2, Tdo2, Ywhaz and Rpl13a genes 
were cloned into plasmid. Standards were serially diluted and amplified products from 
test samples were plotted against the standard curve to determine the relative amounts 
of genes of interest in the test samples.  
The RT-qPCR reaction (20 µL) contained 8 µL cDNA, 0.1 µmol/L of each primer in 1x KAPA 
SYBR Fast Universal qPCR Master Mix (KP-KK4602). Amplification was performed in a 
Rotorgene 3000 (Corbett Research) with (40 cycles of 95 °C for 15 sec followed by 60 °C 
for 45 sec). Initially, the reference gene that was used for assessment of gene expression 
in tissues of murine developmental series was Ywhaz. However, a high variability was 
seen between samples. Rpl13a was tested and deemed to be a better reference gene for 
studies of embryonic tissues due to greater consistency in copy number across tissue 
types and age. 
The primers for Tdo2, Ido1, Ido2, Ywhaz and Rpl13a are listed in Table 4.3. 
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Ywhaz 5’ TGTCACCAACCATTCCAACTTG 3’ 
5’ ACACTGAGTGGAGCCAGAAAGA 3’ 
Rpl13a 5’ CTTAGGCACTGCTCCTGTGGAT 3’ 
5’ GGTGCGCTGTCAGCTCTCTAAT 3’ 
Tdo2 5’ CTATGAGTGGGTGCCGTTT 3’ 
5’ CACTCTGAAGTTCTTGCGCATT 3’ 
Ido1 5’ AGATGAAGATGTGGGCTTTGCT 3’ 
5’ GGCAGATTTCTAGCCACAAGGA 3’ 
Ido2  
(To detect transcript coding for 
full length protein) 
5’ CAAAGTCAGAGCATGACGCTG 3’ 
5’ CGCTGCTCACGGTAACTCTTTA 3’ 
Ido2  
(detects C-terminus of the gene) 
5’ CTACATGCCGCCTTCCCATA 3’ 
5’ AGGACCAGAGGCCAGTATGT 3’ 
 
Table 4.3. Primer sequences of genes coding Trp-catabolising enzymes and reference 
genes. 
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4.3 RESULTS 
4.3.1 Detection of IDO2 protein in murine liver and kidney tissues using anti-IDO2 
antibodies  
In order to find a suitable antibody for the study of IDO2 protein localisation in various 
tissues by IHC, 5 different anti-IDO2 antibodies were tested by Western Blot on liver 
lysates. The rabbit polyclonal anti-IDO2 antibody from Santa Cruz Biotech (SC-292212) 
detected a specific IDO2 protein band at the expected band position (~44 kDa) in the 
wild-type liver lysates that was not present in the liver lysates of the Ido2-/- mice (Fig. 
4.3AIII). However, this antibody also detected non-specific protein bands at 50 and 85 
kDa that were present in both the wild-type and Ido2-/- liver lysates. The mouse 
monoclonal anti-IDO2 antibody, on the other hand, detected a single band at ~45kDa 
(Fig. 4.3 A-D II, which is the estimated molecular weight of IDO2 protein (Ball et al., 2007). 
This was present in the wild-type liver lysate but not in the corresponding Ido2-/- lysate 
(Fig. 4.3AI, II). The rabbit polyclonal anti-IDO2 Ab generated by Genscript, NJ, USA (Ball et 
al., 2007) detected a faint band at the expected protein band location in the wild-type 
liver lysate but not in that of Ido2-/-  mice (Fig. 4.3BIII). However, this antibody also 
detected a band of a similar molecular weight to IDO2 in Ido2-/- kidney lysates. 
Unexpectedly, a protein band at the position of 85 kDa was detected in both wild-type 
and Ido2-/- liver lysates by the rabbit polyclonal anti-IDO2 antibody from Italy (Fig. 4.3CIII). 
Finally, the anti-IDO2 antibody from Prof Yasuko Yamamoto, Japan, detected a protein 
band at the approximate location of ~45 kDa. However, this band was present in both the 
wild-type and Ido2-/- liver lysates, suggesting that the band detected is a cross-reacting 
protein with a similar molecular weight to that of IDO2 (Fig. 4.3DIII). 
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Mouse monoclonal anti-IDO2 antibody (Santa Cruz Biotech), the most specific and robust 
anti-IDO2 antibody of the 5 that were tested, was used to assess the presence of IDO2 
protein in kidney lysates. No protein band of IDO2 was detected in wild-type or Ido2-/-  
kidney lysates (Fig. 4.4) immunoprecipitated with rabbit polyclonal anti-IDO2 antibody 
(Genscript, NJ, USA, generated for Dr Helen Ball), despite the positive detection of IDO2 
protein in the immunoprecipitated liver lysates (positive control).
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Fig 4.3. Detection of IDO2 protein in liver of Ido2+/+ mice using 5 different anti-IDO2 antibodies. The first column is the combined image with 
both red and green detection system (AI, BI, CI and DI). The red channel (AII, BII, CII and DII) represents detection using mouse monoclonal 
anti-IDO2 antibody (Santa Cruz Biotech.) AIII. Green channel shows detection by rabbit polyclonal anti-IDO2 Ab (Santa Cruz). BIII. Green 
channel shows detection by rabbit polyclonal anti-IDO2 Ab from the Hunt laboratory (Ball et al., 2007). CIII. Green channel is rabbit polyclonal 
anti-IDO2 Ab from Dr. Ursula Grohmann, University of Perugia, Italy. DIII. Green channel shows detection by anti-IDO2 rabbit polyclonal 
antibody from Prof. Yasuko Yamamoto of the University of Kyoto, Japan. Lanes 1-3 are protein lysates from Ido2+/+ liver from 3 individual mice, 
whereas lanes 4-6 represent protein lysates from Ido2-/- liver of 3 individual mice. Lane 7 is immunoprecipitated protein lysate from Ido2+/+ 
mouse (Images A, B and C) whereas Lane 8 is immunoprecipitated Ido2-/- mouse liver lysate (Images A, B and C). In D, Lane 7 is 
immunoprecipitated Ido2-/- mouse liver lysate whereas Lane 8 is immunoprecipitated protein lysate from Ido2+/+ mouse. Lane L shows 120 kDa 
pre-stained protein ladder (Pierce, Thermoscientific). Arrow indicates the expected IDO2 protein band (~44 kDa). 
 
Figure on the next page 
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Fig. 4.3 
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Fig 4.4. Expression of IDO2 protein in kidney lysates of Ido2+/+ (wild-type) and Ido2-/- 
mouse. Specific IDO2 protein bands were detected in immunoprecipitated-protein Ido2+/+ 
mouse lysates from liver of 3 individual mice (lanes 1-3), whereas no bands were 
detected in immunoprecipitated protein lysates from Ido2+/+ mouse kidney (n=3) lanes 4-
6 and Ido2-/- mouse kidney lysates (n=3) lanes 7-9. Lane L shows 120 kDa pre-stained 
protein ladder (Pierce, Thermoscientific) with the arrow indicating the expected IDO2 
protein band (~44 kDa). Mouse monoclonal anti-IDO2 antibody (Santa Cruz Biotech) was 
used for detection. 
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4.3.2 IDO2 protein localisation in murine tissues 
The mouse monoclonal anti-IDO2 antibody was subsequently used to study the 
localisation of IDO2 protein in various murine tissues by immunohistochemistry (IHC). 
This was carried out using a staining system (Vector M.O.M.  ImmPRESS kit) specialised 
for the detection of proteins in mouse tissues using mouse monoclonal antibodies.  
In the liver, IDO2 protein appeared to be localised around the nuclei of the hepatocytes 
(Fig. 4.5). Though not all the nuclei were stained with a similar intensity, a significantly 
higher number (p<0.005) of hepatocyte nuclei was stained in the wild-type liver 
compared to Ido2-/- mouse liver tissue. The average nuclei surface area that was stained in 
the wild-type liver tissue was also significantly higher (p<0.001,) than that in Ido2-/- liver 
sections (Table 4.4).  
When kidney tissues were analysed, no specific staining was seen in the wild-type 
sections, although faint non-specific staining was seen in the tubular cells of the kidney in 
both the wild-type and Ido2-/- mouse tissue sections (Fig. 4.6). Staining was seen in what 
appears to be neuronal projections in the cerebral cortex in the wild-type mouse tissue, 
and this was absent in the isotype control-stained wild-type tissues (Fig. 4.7).  
However, the presence of a similar staining pattern and localisation in the cerebral cortex 
hemisphere of an Ido2-/- mouse brain section indicates that this is likely to be a result of 
non-specific staining. Similarly, in the colon, non-specific staining in the goblet cells along 
the intestinal mucosal layer was seen in both wild-type and Ido2-/- mouse tissues and this 
was absent in the isotype control-stained tissues (Fig. 4.8). Despite low levels of IDO2 
mRNA transcript being detected in testes, no specific protein staining was seen in wild-
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type mouse testis sections by IHC (Fig. 4.9). A non-specific staining of the differentiating 
germ cells was seen both in wild-type and Ido2-/- testes.  
IDO2 mRNA was detected in substantial amounts in the epididymis.  However, the 
epididymis showed no specific staining for IDO2 protein in this tissue (Fig. 4.10). Histology 
showed smaller epididymal tubules and scarcer levels of spermatozoa within the tubules 
in the Ido2-/- mice compared to the equivalent wild-type animals (Fig. 4.10). 
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Fig. 4.5 Localisation of IDO2 protein in mouse liver. Representative image of IDO2 protein 
detected around the nuclei of hepatocytes in Ido2+/+ mouse liver sections (A) whereas no 
staining was seen in Ido2-/-  (B) when treated with mouse monoclonal anti-IDO2 antibody. 
No staining was seen in Ido2+/+ (C) and Ido2-/- (D) liver sections treated with monoclonal 
IgG2A isotype control antibody. Scale bars represent 42.0 µm.  
 
 
Liver section  Ido2+/+ Ido2-/-  p-value  
Average stained surface 
area  
1731 + 104   108 + 108   Significant, 0.0004 
Count  13 + 2   0.0 + 0.0   Significant, 0.0038 
Table 4.4. Stained nuclei count and average surface area in livers of Ido2+/+ and Ido2-/- 
mice showed a significantly higher number of stained nuclei and average stained surface 
area in Ido2+/+ liver than in the knockout. All values in arbitrary units. n=3 in each group 
with 6 random fields of view counted from each wild-type mouse liver section and 4 
random fields of view from each Ido2-/- liver section. 
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Fig. 4.6. Representative image of kidney sections stained with anti-IDO2 mouse 
monoclonal antibody. No specific staining seen in Ido2+/+ mouse (A) or Ido2-/-  mouse (B) 
kidney sections treated with mouse monoclonal anti-IDO2 antibody or in Ido2+/+ (C) and 
Ido2-/- (D) mouse kidney sections treated with monoclonal IgG2A isotype controls. Scale 
bars represent 42.0 µm. 
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Fig. 4.7. Representative image of brain sections stained with anti-IDO2 antibody. 
Non-specific staining seen in Ido2+/+ sections (A) and Ido2-/- (B) treated with mouse 
monoclonal anti-IDO2 antibody. No staining seen in Ido2+/+ (C) and Ido2-/- (D) brain 
sections treated with monoclonal IgG2A isotype controls. Scale bars represent 42.0 µm. 
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Fig. 4.8. Representative image of colon sections stained with anti-IDO2 antibody. 
Non-specific staining seen in Ido2+/+ mouse (A) and Ido2-/-  mouse (B) colon sections 
treated with mouse monoclonal anti-IDO2 antibody. No staining seen in Ido2+/+ (C) and 
Ido2-/- (D) colon sections treated with monoclonal IgG2A isotype controls. Scale bars 
represent 42.0µm. 
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Fig. 4.9. Representative image of testis sections stained with anti-IDO2 antibody. 
Non- specific staining seen in Ido2+/+sections (A) and Ido2-/- (B) testis sections treated with 
mouse monoclonal IDO2 antibody. No staining seen in Ido2+/+ (C) and Ido2-/- (D) testis 
sections treated with monoclonal IgG2A isotype controls. Scale bars represent 63.0 µm. 
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Fig. 4.10. Representative image of epididymis sections stained with anti-IDO2 antibody. 
No staining seen in Ido2+/+ (A) and Ido2-/- (B) mouse sections treated with mouse 
monoclonal IDO2 antibody or in Ido2+/+ (C) and Ido2-/- (D) epididymis sections treated with 
monoclonal IgG2A isotype controls. Scale bars represent 63.0µm. 
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4.3.3 IDO1 and IDO2 protein intracellular localisation in transfected Human Embryonic 
Kidney (HEK) cells  
When HEK cells transfected with plasmids containing mouse Ido1 and Ido2 cDNA were 
assessed by immunofluorescence, both IDO1 (Fig. 4.11) and IDO2 (Fig. 4.12)  transfected-
HEK cells exhibited a similar protein expression pattern, which was cytoplasmic. This 
cytoplasmic expression pattern of both IDO1 and IDO2 in transfected HEK cells was seen 
in cells cultured in both Trp-deficient medium and Trp-rich medium (250 µM), similar to 
that in cells cultured in physiological plasma levels of Trp (~45 µM). 
To try to clarify this observation by examining the expression patterns of IDO1 and IDO2 
protein in primary cells, we isolated hepatocytes from the liver of Ido2+/+ mice and 
cultured them for subsequent immunofluorescence study. However, in several 
experiments we found that Ido2 mRNA expression plummeted drastically within the first 
24 hours of isolation and culture (data not shown). This occurred despite variations in the 
isolation and culture media employed. Thus it was impossible to pursue that line of 
investigation. 
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Fig. 4.11. Representative images of HEK cells transfected with plasmid carrying mouse Ido1 cDNA. 
IDO1 protein expression in the transfected cells is shown on column 1, whereas column 2 shows 
nuclear staining (DAPI) and the third column is the merged image showing the IDO1 expression 
pattern along with nuclear staining. IDO1 protein expression in HEK cells grown in Trp-deficient 
medium (A1 – A3). The expression pattern was maintained in both HEK cells (B1 – B3) grown in 
medium containing physiological levels of Trp (45 µmol/L) and medium with (C1 – C3) excess Trp 
(250 µmol/L). Mock plasmid-transfected HEK cells treated with anti-IDO1 Ab were used as the 
negative control (D1 – D3).  
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Fig. 4.12. Representative images of HEK cells transfected with mouse Ido2 cDNA plasmid. IDO2 
protein expression in HEK cells cultured in Trp-deficient medium (A1 – A3). The expression 
pattern was maintained in both HEK cells (B1 – B3) grown in medium containing physiological 
levels of Trp (45 µmol/L) and medium with (C1 – C3) excess Trp (250 µmol/L). First column shows 
IDO2 protein expression whereas second column shows nuclear (DAPI) staining. The third column 
is the combined image exhibiting both IDO2 and nuclear staining patterns. 
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4.3.4 Expression of genes for tryptophan-catabolising enzymes in tissues in murine 
developmental series 
4.3.4.1 Expression of genes for tryptophan-catabolising enzymes in the placenta of 
developing embryos of QS strain outbred mice  
The mRNA expression of all three Trp-catabolising enzymes was detected in the placenta 
of embryos as early as E14.5 dpc. The levels of Ido1 (Fig. 4.13A) and Ido2 (Fig. 4.13B) 
mRNA were maintained in the placenta with no significant changes throughout 
development. Tdo2 mRNA, however, showed a significant increase (p=0.0017) between 
E14.5 to E16.5 dpc in placenta (Fig. 4.13C). The expression of Tdo2 mRNA was then 
maintained in E17.5 dpc placenta at a similar level to that of E16.5 dpc placenta. When 
the ratios of the expression of Ido1, Ido2 and Tdo2 relative to reference genes were 
compared (Fig. 4.14), Tdo2 had the highest mRNA expression in the placenta. The mRNA 
expression of both Ido1 and Ido2 was relatively low. However, Ido1 was still more highly 
expressed than Ido2. 
 
4.3.4.2 Expression of genes for tryptophan-catabolising enzymes in the yolk sac of 
developing embryos of QS strain outbred mice  
In the yolk sac, Ido1 and Tdo2 mRNAs were detected as early as E12.5 dpc (Fig. 4.15). 
There was a significant increase in the expression Tdo2 (Fig. 4.15C) mRNA in the yolk sac 
from E17.5dpc to E18.5 dpc, although expression of Ido1 (Fig. 4.15A) and Ido2 (Fig. 4.15B) 
remained relatively constant throughout development. Amongst the three Trp-
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catabolising genes, Tdo2 was the most highly expressed gene in the yolk sac, more than 
30-fold higher than Ido1 and Ido2 (Fig 4.16). 
 
4.3.4.3 Expression of Ido2 and Tdo2 in the liver of developing embryos, neonates and 
adult QS outbred and Ido2+/+ (Cre-Tg) transgenic mice 
Due to the crossreactivity of IDO2 antibody seen in Section 4.3.2, it is best that any IDO2 
protein study undertaken uses Ido2-/- mice as the negative control. With this in mind, the 
later studies examining Ido2 mRNA expression in the developmental series were done 
using Cre-Tg to accommodate protein studies if found necessary. However, due to 
relatively low levels of Ido2 mRNA in the developmental series, protein expression studies 
were not pursued. The mRNA expression studies were undertaken on outbred QS strain 
mice as they are commonly used as the strain for studying developmental series by the 
collaborating laboratory (Dr. Stuart Fraser), so that gestational timing was well-
established.  Tdo2 mRNA was not detected in embryonic liver in either the outbred QS 
(Fig. 4.17A) or inbred Cre-transgenic (Fig. 4.17B) mouse strain. The developmental stage 
at which Tdo2 mRNA was first detected was P1 (neonatal liver). However, the expression 
level of Tdo2 at this stage was only about 2% of adult liver expression levels. Tdo2 mRNA 
expression climbed to about 10% of adult liver mRNA levels in the liver of a one-week-old 
neonate, before increasing almost 4-fold in the liver of 2-weeks old mice. This level was 
maintained in the liver of 3-week old mice before doubling in that of 8-week old mice 
(Fig. 4.17B).  
Similarly, no Ido2 mRNA transcript coding for full length IDO2 protein was detected in 
embryonic livers. Ido2 mRNA was detected in neonatal livers, albeit at low levels (<1% of 
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its expression level in adult livers). In one-week old neonatal liver, Ido2 mRNA levels were 
less than 5% of that in adult liver. In the following week, the mRNA expression level 
increased almost 6-fold. By the third week, the level of Ido2 mRNA in the liver was about 
45% of that in the adult liver. This level then doubled in the liver of adult (8-week old) 
mice. 
 138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13. Trp-catabolising genes Ido1 (A), Ido2 (B) and Tdo2 (C) mRNA expression in placenta of 
developing QS strain embryos at 14.5, 16.5 and 17.5 days-post-coitus (dpc) relative to expression 
of the respective genes at 14.5dpc, as detected by RT-qPCR (standard curve method). Data shown 
are the mean percentage of expression from N>5 individual placenta; error bars represent 
standard error of mean. Statistical analysis by one-way ANOVA with Tukey post-test, p<0.05. 
Double asterisks denote p<0.01 whereas triple asterisks denote p<0.001. 
 
 139 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.14. Ratio of expression of Trp-catabolising genes Ido1, Ido2 and Tdo2 mRNA 
expression in placenta of developing QS strain embryos relative to the reference gene 
Rpl13a, assessed by RT-qPCR using the standard curve method. Data shown are the mean 
ratio of expression from N >5 individual placenta; error bars represent standard error of 
mean. Statistical analysis by one-way ANOVA with Tukey post-test, p<0.05. Triple asterisks 
denote p<0.001. 
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Fig 4.15. Trp-catabolising genes Ido1 (A), Ido2 (B) and Tdo2 (C) mRNA expression in  yolk sac of 
developing QS strain embryos at 12.5, 16.5, 17.5 and 18.5 dpc relative to expression of the 
respective genes at 16.5dpc, as detected by RT-qPCR (Standard curve method). Data shown are 
the mean percentage of expression from N >5 individual yolk sacs for 16.5, 17.5 and 18.5 dpc. 
Percentage expression at 12.5 dpc is a result of pooled samples from n=3 individual yolk sacs. 
Statistical analysis by one-way ANOVA with Tukey post-test, p<0.05 and error bars represent 
standard error of mean. Single asterisk denotes p<0.05.
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Fig. 4.16. Ratio of Trp-catabolising genes Ido1, Ido2 and Tdo2 expression in yolk sac of 
developing embryos relative to the reference gene Rpl13a, assessed by RT-qPCR using the 
standard curve method. Data shown are the mean ratio of expression from N>5 
individual yolk sacs for 16.5, 17.5 and 18.5 dpc. Percentage expression at 12.5 dpc is a 
result of pooled samples from n=3 individual yolk sacs. Statistical analysis by one-way 
ANOVA with Tukey post-test, p<0.05 and error bars represent standard error of mean. 
Single asterisk denotes p<0.05. 
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Fig. 4.17. Trp-catabolising genes Ido2 and Tdo2 mRNA expression in liver of embryos, neonates 
and adults of outbred QS mice strain (A) and inbred Cre transgenic mice strain (B) relative to the 
expression of the respective genes in 8-week-old adult mouse liver, as detected by RT-qPCR 
(standard curve method). Data shown are the mean percentage of expression from n=6; error 
bars represent standard error of mean. The gender of the mice at early neonatal stages (P1, P2 
and P3) was not discerned. The compositions of genders for the rest of the analysis were 1-week 
old neonates (3♂ 3♀), 2-week old mice (2♂ 4♀), 3-week old (4♂ 2♀) and 8-week old (6♂). 
Statistical analysis by one-way ANOVA with Tukey post test, p<0.05. Single asterisk denotes 
p<0.05, double asterisks denote p<0.01, triple asterisks denote p<0.001 and quadriple asterisks 
denote p<0.0001. 
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4.3.5 Expression of genes for tryptophan-catabolising enzymes in various transgenic 
mouse tissues deficient for one or two tryptophan-catabolising enzymes 
As mentioned previously, there have been reports suggesting possible interactions 
between IDO1 and IDO2in terms of their expression. As this was of great interest, 
transgenic mice deficient in two Trp-catabolising enzymes were generated (in addition to 
the single gene knockouts) for the purpose of this study. 
 
4.3.5.1 Liver  
Both Ido2 and Tdo2 mRNA were detected in liver tissues, whereas no Ido1 mRNA was 
detected. As expected, the expression of Ido2 was ablated in the single Ido2-/- as well as 
the double knockout Ido2-/-Tdo2-/- mice.  Ido2 mRNA expression levels were similar in 
Ido1-/- and Tdo2-/- mice and double knockout Ido1-/- Tdo2-/- mice to those of their wild 
type equivalent (Fig. 4.18A). The pattern of Tdo2 mRNA levels in the various gene 
knockout animals was similar to that of the equivalent wild-types, with the absence of 
neither Ido1 nor Ido2 affecting Tdo2 expression (Fig. 4.18B). No Ido1 mRNA was detected 
in the liver tissues of these strains. 
 
4.3.5.2 Kidney  
Kidney was the tissue with the most abundant Ido2 mRNA, after the liver. When Ido2 
mRNA expression level was assessed across single and double gene knockout mouse 
kidney tissues, significantly lower levels of Ido2 mRNA were detected in both the single 
Ido1-/- (p<0.0001) and double Ido1-/- Tdo2-/- (p<0.0001) kidney tissues relative to the 
equivalent wild types (Fig. 4.19). This pattern of lower Ido2 mRNA in the gene knockout 
mice, however, was not seen in Tdo2-/- compared to its equivalent wild-type, Tdo2+/+. 
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4.3.5.3. Brain 
Ido2 mRNA was detected in the brain, albeit in low levels, across the single and double 
gene knockout mice alongside their equivalent wild-types. A similar downregulation of 
Ido2 mRNA in single Ido1-/- (p<0.0001) and double Ido1-/-Tdo2-/- (p=0.0117) mice to that 
seen in the kidney (Section 5.3.5.2) was observed in brain tissue (Fig. 4.20A). The other 
Trp-catabolising gene detected in the brain was Tdo2, at low levels. The expression of 
Tdo2 mRNA in single Ido1-/- and Ido2-/- mice was similar to that of their equivalent wild 
types, C57BL/6J and Cre transgenic respectively (Fig. 4.20B). However, Ido1 mRNA was 
not detected in the brain. 
 
4.3.5.4 Testis 
The two Trp-catabolising genes expressed in the testes were Ido1 (Fig. 4.21A) and Tdo2 
(Fig. 4.21B). Both genes were detected at low levels in the testes, and their expression 
patterns were maintained at a similar level in the mouse strain in which their counterpart 
Trp-catabolising gene had been knocked-out to that in the equivalent wild-type. 
 
4.3.5.5 Epididymis 
Both Ido1 (Fig. 4.22A) and Ido2 (Fig. 4.22A) mRNA were detected in the epididymis. The 
expression of Ido2 in single Ido1-/- (p<0.0001) and double Ido1-/-Tdo2-/- (p < 0.0001) gene 
knockout mice was significantly lower than in their respective wild-types. Ido1 mRNA 
expression relative to the reference gene in the epididymis also was significantly higher  
(p < 0.0001) than that of Ido2.  
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Fig. 4.18. The relative mRNA expression of Ido2 (A) and Tdo2 (B) in the liver tissue of nine 
different transgenic mouse strains, including double knockout strains Ido1-/-Tdo2-/- and  
Ido2-/-Tdo2-/-, relative to the equivalent wild-type mouse as assessed by RT-qPCR using 
the standard curve method. Error bars represent standard error of mean, n>5. 
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Fig. 4.19. The relative mRNA expression of Ido2 in kidney tissues of nine different 
transgenic mouse strains, including double knockout strains Ido1-/-Tdo2-/- and  
Ido2-/-Tdo2-/-, relative to the equivalent wild-type mice as assessed by RT-qPCR using the 
standard curve method. Ido2 mRNA was significantly downregulated in Ido1-/- (p<0.0001) 
and Ido1-/-Tdo2-/- (p<0.0001) mice relative to their respective wild-types. No Ido1 and 
Tdo2 mRNA were detected in kidney tissues. Error bars represent standard error of mean, 
n>5 whereas triple asterisks denote p<0.001. 
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Fig. 4.20. The relative mRNA expression of Ido2 (A) and Tdo2 (B)  in brain tissues of nine different 
transgenic mouse strains, including double knockout strains Ido1-/-Tdo2-/- and Ido2-/-Tdo2-/-, 
relative to the equivalent wild-type mouse as assessed by RT-qPCR using the standard curve 
method. Ido2 mRNA was significantly downregulated in Ido1-/- (p<0.0001) and Ido1-/-Tdo2-/- 
(p=0.0117) relative to their respective wild-types. No Ido1 mRNA was detected in brain tissues. 
Error bars represent standard error of mean, n>5. Single asterisk denotes p<0.05 whereas triple 
asterisks denote p<0.001.
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Fig. 4.21. The relative mRNA expression of Ido1 and Tdo2 in testes tissues of nine 
different transgenic mouse strains, including double knockout strains Ido1-/-Tdo2-/- and 
Ido2-/-Tdo2-/-, relative to the equivalent wild-type mouse as assessed by RT-qPCR using 
the standard curve method.  No Ido2 mRNA transcript coding for full length IDO2 protein 
was detected in testis tissues. Error bars represent standard error of mean, n>5. 
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Fig. 4.22. The relative mRNA expression of Ido1 (A) and Ido2 (B) in epididymis of nine different 
transgenic mouse strains, including double knockout strains Ido1-/-Tdo2-/- and Ido2-/-Tdo2-/-, 
relative to the equivalent wild-type mouse as assessed by RT-qPCR using the standard curve 
method. .Ido2 mRNA was significantly downregulated in Ido1-/- (p=0.0001) and Ido1-/-Tdo2-/- 
(p<0.0001) relative to their respective wild-types. No Tdo2 mRNA was detected in epididymis. 
Error bars represent standard error of mean, n>5. Triple asterisks denote p<0.001. 
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4.4 DISCUSSION 
In this chapter, we aimed to investigate the tissue and cellular distribution of IDO2 within 
adult and developmental series murine tissues and to elucidate possible interactions 
between the three Trp-catabolising genes within various murine adult tissues. 
 
4.4.1 IDO2 protein detection in Western Blot 
Five different anti-IDO2 antibodies were tested by Western Blot on liver lysates of wild-
type and Ido2-/- mice to validate their specificity (Section 4.3.2). Although four out of five 
anti-IDO2 antibodies detected a band with a molecular weight of ~45 kDa (the estimated 
molecular weight of IDO2), two out of these four antibodies detected similar bands in 
livers from Ido2-/- mice. Notably, the two non-specific anti-IDO2 antibodies were rabbit 
polyclonal antibodies. The detection of a non-specific band of a similar molecular weight 
in the liver tissues of both wild-type and Ido2-/- mice indicates an issue of antibody cross-
reactivity, which only became evident in the presence of a true negative control in the 
form of gene knockout mouse tissues. The use of a cell line or tissue known to not 
express the protein, or loading buffer without the sample, are commonly used as 
negative controls in Western blotting and IHC. However, based on the current 
observations, the best negative control to determine specificity of an antibody, for 
Western Blot or IHC, is protein lysates or sections from the same tissue of the appropriate 
gene knockout mice. The anti-IDO2 antibody made for the Hunt laboratory by Genscript 
(USA), while being specific on liver lysates, was not specific for kidney, as it detected a 
similar-sized band in Ido2-/-  kidney lysates. This adds to the complexity of validating the 
presence of IDO2 in tissues by Western Blot and IHC as antibodies may be specific for 
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some tissues, but not so for others. This issue of non-specificity did not arise for IDO2 
detection in HEK cells transfected with IDO2 plasmids (data not shown), using the same 
antibodies. As HEK cells are of human origin, it is possible that the anti-IDO2 does not 
react with other proteins in human cells but does do so in murine cells. Apart from that, 
there could be a difference in terms of cellular expression, whereby no cross reacting 
protein is present in embryonic kidney cells that may be present in other cell types. In 
addition, this could be an issue more relevant to testing the presence of proteins in whole 
tissue lysates. Therefore, when elucidating the presence of a protein in whole tissues 
using Western Blot, it is highly desirable to have a negative control in the form of an 
equivalent tissue from a gene knockout mouse. Obviously, this is not feasible for other 
mammalian species. 
The antibody that was specific, whereby no bands were detected in Ido2-/- mouse liver, 
was a commercial mouse monoclonal anti-IDO2 antibody (Santa Cruz). This antibody, 
however, did not detect any IDO2 protein in kidney lysates. This suggests a higher 
specificity of mouse monoclonal antibodies compared to polyclonal antibodies, as would 
be expected, and, therefore, better applicability to protein detection, especially for IHC. 
Despite higher specificity of mouse monoclonal antibodies, technical challenges that arise 
when using mouse monoclonal antibodies on mouse tissues in IHC will need to be 
overcome before analysis can be done, as is described in the next section. 
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4.4.2 Cellular distribution of IDO2 within various murine tissues 
4.4.2.1 IHC techniques for detecting mouse protein using mouse monoclonal antibody 
As the only antibody that was specific for IDO2 was a mouse monoclonal antibody, IHC 
techniques to detect the subcellular localisation of IDO2 within mouse tissue required a 
more specialised approach to prevent high background and/or non-specific staining. The 
Vector M.O.M. (Mouse-on-mouse) kit gave no staining initially. When the Vector M.O.M. 
approach was complemented with tyramide signal amplification (TSA) there was a 
detectable positive signal in the tissue (Section 4.3.2). This shows that although a 
relatively abundant level of Ido2 mRNA was detected in liver tissues by RT-qPCR (Section 
4.3.1), this did not seem to translate into protein detection, when assessed by IHC. IDO2 
protein was not detectable by conventional IHC and required the TSA approach for the 
expression pattern to become evident. The relatively low and detectable IDO2 protein 
signal in the liver sections could be due to a number of possible reasons. I. The antigen 
retrieval method is not optimal and antigen epitopes remain masked by formalin fixation. 
II. Limitations of the Vector M.O.M. method, in that the blocking Fc segments of 
endogenous mouse antibodies in the method could also block the Fc segments of the 
primary IDO2 antibodies, which are necessary for the binding of the secondary 
antibodies. III. Low levels of IDO2 protein in the liver 
With regard to the first possibility, various different antigen retrieval approaches were 
used (as mentioned in Section 4.2.8) and none but the hotplate antigen retrieval method 
on formalin-fixed sections, followed by IHC with Vector M.O.M. complemented with TSA 
strategy yielded positive signals. This indicates that it is more likely that IDO2 protein was 
absent in the liver or was present at a low level that was not detectable by conventional 
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IHC methods. While reason (II) is a possibility, this method has been optimised with its 
own specialised secondary antibody, which has been reported to yield specific staining 
with its secondary without affecting its ability to bind to the Fc segment of the primary 
mouse antibody, rendering it highly specific without affecting the binding effectiveness of 
the secondary antibody. Due to this, we conclude that low levels of IDO2 protein (III) in 
the liver are the most likely cause for the weak staining seen in the liver tissues. 
 
4.4.2.2 Cellular localisation of IDO2 in various tissues 
IDO2 protein was detected in the liver, often located around the nuclei of hepatocytes. 
However, not all hepatocytes showed this staining. There also was variability in the 
intensity of staining between different cells. Its localisation around and over the nuclei 
could suggest that IDO2 is either a nuclear protein or is stored around the nucleus until its 
use is triggered by other factors. Although the preliminary data on intracellular 
localisation of IDO2 in transfected HEK cells showed a cytoplasmic distribution (Section 
4.3.3), the localisation of IDO2 may differ according to tissue type. An in vitro system also 
may not necessarily represent the distribution of IDO2 in vivo as the gene is artificially 
expressed in a cell line in which it would not otherwise be expressed. Although the mouse 
monoclonal IDO2 antibody did not detect any non-specific bands of a similar molecular 
weight to IDO2 in Ido2-/- mouse liver lysates, while detecting a specific band in the wild-
type by Western Blot, it did bind to other non-specific proteins of higher molecular 
weight. Non-specific staining by IHC was seen in a number of other tissues from Ido2-/- 
mice. No staining was seen in the kidney and epididymis. However, in the brain, colon 
and testes, staining was seen in the wild-type and Ido2-/- sections treated with anti-IDO2 
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antibody that was absent in the sections treated with mouse monoclonal IgG2A isotype 
control. Within the brain, what seemed like positive staining of cells with the 
characteristics of nerve fibres in the wild-type, was actually non-specific staining that was 
also present in the Ido2-/- mouse brain. Similarly in the colon, staining was seen in the 
goblet cells along the crypts of the colon in both the wild-type and Ido2-/- mouse sections, 
despite being absent in sections treated with an isotype control antibody. Positive 
staining was observable in the differentiating germ cells within the testes. However, as 
was seen in the case of brain and colon tissue, similar staining was observable in testis 
sections from Ido2-/- mice. No staining was observed in the small intestine of any mouse 
(data not shown). This non-specific staining could be high molecular weight proteins 
detected by the mouse monoclonal IDO2 antibody (Fig. 4.3). This outcome is one of the 
limitations of using mouse monoclonal antibodies on mouse sections as cross reactivity is 
a common issue. While the Vector M.O.M. system uses a blocking approach that 
significantly reduces this, it is possible that some cross-reactivity still occurs resulting in 
the staining of non-specific proteins. Without the knockout tissue, the staining patterns 
observed could easily have been interpreted as specific staining denoting IDO2 
expression within the different tissues, as the staining pattern observed in the wild-type 
mouse tissue treated with anti-IDO2 antibody was absent in the sections treated with 
isotype control. Both previous papers reporting the cellular localisation of IDO2 within 
tissues (Ball et al., 2007; Fukunaga et al., 2012) did not have the advantage of tissues 
from gene knockout mice as negative control. Therefore, the results reported in these 
two papers will need to be validated with tissues from knockout mice. Ball et al. (2007) 
reported IDO2 by IHC in the epididymis, testis and kidney and Fukunaga et al. (2012) 
found IDO2 in the brain, liver, kidney and epididymis. Both publications agreed that the 
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distribution of IDO2 within the kidney was localised to the tubules. However, the data on 
cellular distribution of IDO2 in the epididymis differed between the two publication as 
the earlier paper reported IDO2 localised in the tail of spermatozoa (Ball et al., 2007) 
whereas the latter found it expressed in the caput, corpus and cauda cells of the 
epididymis (Fukunaga et al., 2012). Another consideration is that the antibody was indeed 
staining for IDO2, but a truncated version of the protein that might or might not be 
enzymatically active. Both the mouse and human IDO2 genes have various alternatively 
spliced transcripts (Metz et al., 2007; Ball et al., 2007). These possess the potential to 
translate into variant forms of IDO2 proteins. More recently, a truncated version of IDO2 
has been reported that possesses lower Trp-catabolising activity (Metz et al., 2014). The 
IDO2 antibodies available commercially do not distinguish between full-length and 
variant forms of IDO2 that may exist.  It is possible that the protein we detected both by 
Western Blots and IHC is one of the variant forms of the IDO2 protein. With this in mind, 
for future directions, it will be necessary to generate antibodies that are either specific to 
the enzymatically active protein or the truncated protein. 
 
4.4.3 Intracellular localisation of IDO1 and IDO2 within transfected HEK cells 
We hypothesised that the intracellular localisation of IDO1 and IDO2 may differ, and that 
this might change in different conditions (Trp-rich vs physiological Trp vs Trp-deficient 
medium). We initially explored this question by transfecting HEK with plasmids containing 
Ido1 and Ido2 cDNA. When assessed by immunofluorescence, no gross differences 
between the distribution pattern of IDO1 and IDO2 within the cells in the three different 
conditions tested were observed (Fig 4.11 and 4.12). This lack of difference need not 
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necessarily be a true representation of the distribution pattern of these two enzymes. As 
HEK cells were transfected with plasmids expressing these enzymes, we would not expect 
to be able to detect meaningful differences in levels of IDO1 and IDO2 expression. It is 
possible that IDO1 or IDO2 expression in primary cells would be influenced by 
extracellular Trp concentration. In addition, HEK cells are embryonic kidney cells in which 
IDO1 and IDO2 proteins are not detectable constitutively. In vivo, only IDO2 has been 
detected in adult kidney cells (Ball et al., 2007; Fukunaga et al., 2012). IDO1, on the other 
hand, is not present in kidney cells constitutively (Section 4.3.2) (Theate et al., 2015). 
Furthermore, as mentioned previously, the localisation of IDO2 within transfected HEK 
cells differed to that in hepatocytes since the intracellular localisation of IDO2 in the 
former appeared cytoplasmic whereas in the liver hepatocytes, it had a perinuclear 
localisation (Section 4.3.2). Therefore, the apparent cytoplasmic intracellular localisation 
of both IDO1 and IDO2 needed to be validated by assessment of the distribution pattern 
of these proteins in primary cells. 
When we attempted to study intracellular localisation in primary hepatocytes, isolated 
from wild-type and Ido2-/- liver tissues, we encountered a number of obstacles. First, the 
expression levels of Ido2 mRNA dropped drastically within the first 24 hours of isolation, 
conforming with previous reports of a marked loss of DNA and of protein expression in 
hepatocyte monocultures during the first 48 hours (Bissell and Guzelian, 1980; Crane and 
Miller, 1977; Clayton and Darnell, 1983). Secondly, the long-term stability of functional 
primary hepatocytes has been difficult to establish (Hewitt et al., 2007; Martinez et al., 
2010).  This made studying the expression pattern of the protein unfeasible unless a way 
to extend the stability of hepatocytes could be found. Different approaches, such as co-
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culturing hepatocytes with liver endothelial cells or fibroblasts (Ukairo et al., 2013; Fraslin 
et al., 1985) or culturing the hepatocytes in a sandwich collagen gel formation (Choi and 
Choi, 2013), have been recommended. Although we attempted to co-culture the 
hepatocytes with fibroblasts, overgrowth of the fibroblasts impeded the growth of the 
hepatocytes. Due to all these technical challenges, this aspect could not be further 
pursued. 
  
4.4.4 Expression of genes for tryptophan-catabolising enzymes in murine 
developmental series 
Although the expression of Trp-catabolising genes in embryonic developmental tissues 
has been investigated before, all the studies (Suzuki et al., 2001; Yamazaki et al., 1985; 
Dharane Nee Ligam et al., 2010) focused primarily on placenta, and most did not 
compare the expression of the three genes in embryonic tissues. One group reported the 
expression patterns of TDO2 and IDO1 in embryonic and extraembryonic tissues (from 
5.5 to 9.5 dpc) as well as in placenta (10.5 to 18.5 dpc), comparing protein levels and 
activity and semi-quantitative analysis of mRNA levels by Northern Blot (Suzuki et al., 
2001). High Trp-degrading activity was detected in early concepti (5.5 dpc), which was 
attributed to TDO2. This high activity was not maintained throughout embryonic 
developmental stages and dropped after 6.5 dpc to basal levels comparable to those 
detectable in placenta. On the other hand, neither IDO1 mRNA nor protein was 
detectable in the early developmental stages (5.5 to 9.5 dpc) (Suzuki et al., 2001). 
However, IDO1 has been reported in both human and mouse placenta, specifically in the 
endothelial cells of villous chorion in the placental vasculature (Blaschitz et al., 2011; 
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Metz et al., 2007). Unlike earlier suggestions that IDO1 plays a key role in preventing 
allogeneic foetus rejection by depriving the microenvironment of Trp and, thus, 
suppressing T-cell proliferation (Munn et al., 1998), it was proposed that TDO plays this 
role (Suzuki et al., 2001).  
In this study, we determined the expression of Trp-catabolising enzyme genes in 
embryonic tissues, namely the visceral yolk sac and liver as well as the foetomaternal 
tissue, placenta (Section 4.3.4). The high expression of Tdo2 in early concepti in a 
previous report (Suzuki et al., 2001) could have been contributed to by the yolk sac, as 
yolk sac had the highest expression of Trp-catabolising enzyme genes, compared to the 
other tissues we tested. The expression of all three Trp-catabolising genes in the yolk sac 
might suggest that Trp catabolism is occurring actively in the yolk sac during 
development. Based on previous reports on the significance of Trp catabolism in 
preventing foetal rejection (Munn et al., 1998; Mellor et al., 2001), Trp catabolism in the 
embryonic tissues could be regulating the immune response at the foetal-maternal 
interface for precisely this role. However, this could be a collaborative function of the 
three Trp-catabolising enzymes and this would need to be further investigated. Although 
both placenta and endoderm yolk sac are responsible for transport of nutrients from the 
mother to the foetus, the types of nutrients transported by the two tissues differ. 
Immunoglobulins, as well as important nutrients such as cholesterol, lipids, iron, folic 
acid, retinoic acid and vitamin B12, are passed on to the foetus through the yolk sac 
(Jollie, 1990; Lloyd et al., 1996; Zohn and Sarkar, 2010; Brambell, 1966; Kozyraki and 
Gofflot, 2007). The yolk sac is also believed to be important for nutrient transfer during 
organogenesis (Ambroso et al., 1997; Beckman et al., 1998; Christensen and Birn, 2002). 
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In the placenta, on the other hand, glucose transporters (GLUTs), Ca2+ transporters and 
amino acid transporters have been reported, suggesting that it may play an essential role 
in the transport of these nutrients (Watson and Cross, 2005; Lager and Powell, 2012). It 
has been suggested that the transport of nutrients depends on the yolk sac in the earlier 
stages of development, after which this role is played by placenta, based on the high 
expression of certain genes in the early yolk sac which eventually decreases, while the 
expression of the same genes in the placenta is detected and climbs in later 
developmental stages (Freyer and Renfree, 2009; Jauniaux et al., 2004). However, this 
was not true of Tdo2 as its expression in the yolk sac was consistently higher than in the 
placenta even in the later developmental stages (16.5 to 18.5 dpc) (Fig. 4.14 and Fig. 
4.16).  Tdo2 could be playing a key role in the transport and catabolism of Trp during 
developmental stages, supporting organogenesis in the embryos. As both Ido1 and Ido2 
were expressed at similar levels to each other in the yolk sac, both enzymes also could be 
involved in this process. Similar to Tdo2, the levels of Ido2 were higher in the yolk sac 
than in the placenta. Whether its expression in the yolk sac is pointing to a role in 
nutrient transport or immunity is an interesting aspect for future investigation. Although 
we did not observe any gross phenotypical abnormalities in Tdo2-/-, Ido1-/- and Ido2-/- 
mouse offspring compared to their respective wild-types, a more in-depth analysis of the 
levels of glucose, cholesterol, lipids and other major nutrients will be crucial to better 
understanding the role of these enzymes in embryonic development. The mechanism 
through which they support embryonic development and the possible differences in the 
roles of each Trp-catabolising enzyme will also need to be further investigated.  
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In the placenta, Ido1, Ido2 and Tdo2 mRNA were all detectable. Tdo2 again had the 
highest expression. Unlike Tdo2, Ido1 was more highly expressed in the placenta than the 
yolk sac. To date, it has been believed that Ido1 plays a pivotal role in preventing 
allogeneic foetal rejection (Munn et al., 1998), as a significant decrease in the mean 
number of concepti in IDO-sufficient pregnant mice treated with the IDO inhibitor 1-
methyl-tryptophan (1-MT) was found. However, this study did not distinguish between 
IDO1 and IDO2 activity. 1-MT was later shown to inhibit both IDO1 and IDO2 (Austin et 
al., 2010; Yuasa et al., 2010). Therefore, while it has been established that IDO is a key 
player in preventing allogeneic foetal rejection in pregnancy, whether this role is driven 
by IDO1 or IDO2 remains an open question that requires further investigation. The 
immunomodulatory role of IDO in pregnancy also could be mediated more through the 
placenta than the yolk sac. 
Suzuki et al. (2001) speculated that it was TDO2 that was responsible for the increase in 
Trp catabolic activity in earlier embryonic stages (5.5 to 9.5 dpc) by demonstrating that 
the use of 1-MT did not significantly alter Trp-degrading activity in the earlier stages, but 
only in the later stages (12.5 dpc onwards). This is worthy of further study. 
The unavailability of appropriate anti-mouse-TDO2 antibodies impeded us from studying 
the localisation of TDO2 in embryonic and adult tissues, which could shed light on its 
possible role within the yolk sac and placenta. It would also be interesting to compare the 
localisation of TDO2 within the placenta to that of IDO1, as it may inform our 
understanding on the roles of IDO1 and TDO2 in embryonic development.  
Both Ido2 and Tdo2 mRNA were undetectable in embryonic liver, however. The absence 
of Trp-catabolising activity in embryonic liver has been documented in rats (Franz and 
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Knox, 1967). Although Trp-catabolising activity within neonatal liver was detectable in P7 
neonates following induction with hydrocortisone, basal Trp-catabolising activity without 
stimulation was only detected in 2-week old rats. It was rather surprising that although 
both IDO2 and TDO2 were highly expressed in adult murine livers, mRNAs coding for 
these proteins were undetectable in embryonic livers. In early neonatal liver (P1 – P3) of 
outbred QS mice, Tdo2 was detectable at very low levels, although Ido2 was not. 
Although Ido2 was detectable in in-bred Ido2+/+ mice in early neonatal liver (P2 and P3), 
the level of mRNA was very low. At all timepoints, the expression of Tdo2 in the liver was 
higher than that of Ido2. The inferred absence of Trp-catabolising enzymes in embryonic 
liver suggests that Trp degradation is not performed in the liver until much later after 
birth. Perhaps, during the embryonic stage, Trp catabolism is performed mainly, if not 
solely, by the placenta and the yolk sac. It would be interesting to investigate whether the 
activity of Tdo2 and Ido2 is triggered post-partum by an intrinsic factor or the feeding 
process (suckling, solid food). 
 
4.4.5 Expression of genes for tryptophan-catabolising enzymes in various transgenic 
mice deficient for one or two tryptophan-catabolising enzymes 
There is some published evidence suggesting that the expression of Ido2 is regulated by 
Ido1. In the epididymis, an upregulation of IDO2 was seen in Ido1-/- mice (Fukunaga et al., 
2012). There was also downregulation of regulatory T cells mediated by IDO1 in Ido2-/- 
mice (Metz et al., 2014). This points to a possible regulatory relationship between IDO1 
and IDO2. Whether TDO2 was involved in regulation of the other two Trp-catabolising 
enzymes in other tissues has not been explored to date.  
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In the liver, there were no differences in either Tdo2 or Ido2 expression between the 
various gene knockout mouse strains. The mRNA expression level of Tdo2 in the liver was 
unchanged in the single gene knockouts Ido1-/- and Ido2-/- as well as the double knockouts 
Ido1-/-Tdo2-/- and Ido2-/-Tdo2-/- relative to their respective wild-types, suggesting that Tdo2 
expression in the liver is neither dependent on, nor influenced by, the other two Trp-
catabolising enzymes. The same can be said for Ido2 in the liver, as both single and 
double gene knockout mouse livers had similar mRNA levels of Ido2 to those in their 
respective wild-types. This is consistent with the argument that IDO2 has a function apart 
from its Trp-catabolic activity, a role independent of TDO2.  
The presence of two Trp-catabolic enzymes in the same tissue did raise some questions 
about the possibility that these two proteins interact to maintain Trp homeostasis within 
the liver. However, the lack of a significant difference at the mRNA level, in the absence 
of the other enzyme, suggests that this would be unlikely. It needs to be noted, however, 
that the lack of differences in mRNA levels (i.e. transcription) may not necessarily denote 
lack of differences at the level of protein expression (i.e. translation). This is an aspect 
that needs further investigation. 
A significant downregulation of Ido2 mRNA, however, was seen in single Ido1-/- and 
double Ido1-/-Tdo2-/- kidney, brain and epididymis tissues. However, it is possible that the 
downregulation seen could be an artefact resulting from knocking out Ido1, as Ido2 is 
located immediately adjacent to Ido1 on chromosome 8. The absence of Ido1 in wild-type 
kidney and brain supports this argument. Since there was no Ido1 in the wild-type kidney 
and brain to begin with, any downregulation of Ido2 seen in the knockout tissues are very 
unlikely to be a functional effect caused by the absence of IDO1  
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The epididymis may be different, however, as both IDO1 and IDO2 are present there. 
Fukunaga et al. (2012) reported an upregulation of IDO2 in Ido1-/- mouse epididymis by 
Western Blot and IHC. Differences in mRNA levels were unreported. We, however, saw a 
downregulation of Ido2 mRNA in Ido1-/- epididymis. The limitation in the Fukunaga et al. 
(2012) study is the lack of Ido2-/- mice to validate their data. We demonstrated in the 
results, and discussed in the previous section, the importance of validating the specificity 
of IDO2 antibodies using Ido2-/- mouse tissues as negative control due to the recurrent 
issue of cross-reactivity. Therefore, in the absence of a negative control in the form of 
Ido2-/- tissues, the observation made regarding upregulation of IDO2 in Ido1-/- epididymis 
(Fukunaga et al., 2012) may not be truly representative of the condition in the tissue. 
When we obtained anti-IDO2 antibodies from the Yamamoto group and validated them, a 
non-specific band of a similar molecular weight to IDO2 was detected not only in Ido2+/+ 
liver lysates but also in Ido2-/- liver lysates. It is possible that the downregulation of Ido2 
seen in the kidney, brain and epididymis of mice deficient in IDO1 is caused by the 
disruption of regulatory elements of Ido2 genes, a possible by-product of deletion of a 
part of the Ido1 gene as the Ido1 and Ido2 genes are situated adjacent to each other. 
These regulatory elements, however, would also have tissue-specific roles. A different 
approach may be necessary to elucidate whether the downregulation of Ido2 in Ido1-/- 
and Ido1-/-Tdo2-/- (Figures 4.22) is caused by the absence of IDO1. An example of such an 
approach would be to determine IDO2 expression in the epididymis of mice treated with 
an IDO1-selective inhibitor or by utilising transient knockdown approaches such as siRNA. 
Metz et al. (2014) demonstrated an upregulation of Ido2 RNA in primary peritoneal 
macrophages from Ido1-/- tissues, stimulated with LPS. The pattern of Ido2 regulation in 
the absence of Ido1 could be a tissue-specific phenomenon that may also differ in 
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physiological compared to pathological conditions. Of the tissues analysed, almost all had 
two Trp-catabolising enzymes present except kidney, where only Ido2 was detected. The 
presence of only Ido2 mRNA in kidney tissues could imply that Ido2 may play a specialised 
role in the kidney. IDO2 protein, however, was not detectable in Ido2+/+ kidney tissues by 
either Western Blot of immunoprecipitated lysates or IHC on kidney sections. Metz et al. 
(2014), however, reported the presence of IDO2 in wild-type kidney by Western Blot, and 
this was absent in Ido2-/- mice. It is possible that the method we employed was not as 
sensitive as that of Metz and colleagues who used immunoprecipitation beads of higher 
sensitivity. Another consideration is the epitope at which the antibody is directed. The 
mouse monoclonal IgG1 antibody employed by Metz et al. on murine kidney lysates was 
generated by immunising mice with human IDO2, produced in HEK293T cells, and was 
recommended for human IDO2 detection. On the other hand, we used an IgG2A mouse 
monoclonal generated by immunising mice with murine C-9 terminus IDO2. The existence 
of alternatively-spliced transcripts for both human and mouse IDO2 genes that have been 
reported previously (Metz et al., 2007) could suggest that proteins encoded by these 
transcripts may interact with a subset of IDO2 antibodies. In such a case, there is a need 
to differentiate between the full-length protein and truncated proteins when assessing 
the presence of IDO2 in tissues by Western Blot or IHC. Elucidating whether the protein 
present in the kidney and epididymis is the full-length or truncated IDO2 protein would 
give us a better understanding of the possible roles of IDO2 within these tissues.  
In the testes, only Ido1 and Tdo2 were detected and there were no differences in the 
mRNA expression level of the respective genes in the single and double knockout mice 
relative to the respective wild-types. Despite an earlier report (Ball et al., 2007) claiming 
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the presence of IDO2 in the testes, the absence of mRNA transcript coding for full-length 
protein in the testes could imply either the presence of truncated proteins of uncertain 
enzymatic function, or cross-reactivity of the anti-IDO2 antibody used. 
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4.5 SUMMARY 
Although an isotype control is the most commonly used negative control in IHC analysis, 
we found that mouse gene knockout tissues were the most suitable negative control, 
differentiating specific antibodies from those that were not. Out of the five anti-IDO2 
antibodies we tested for specificity by Western Blot, the mouse monoclonal anti-IDO2 
antibody was the most specific, detecting a single band of the expected molecular weight 
in wild-type mouse liver lysate, which was absent in Ido2-/- lysates. However, it did not 
detect any IDO2 protein bands in the wild-type kidney lysates.  
IDO2 was found localised around the hepatocyte nuclei in the liver when detected using 
mouse monoclonal IDO2 antibody by an optimised IHC approach. However, the 
localisation of IDO2 in transfected HEK cells appeared cytoplasmic. Despite conferring 
high sensitivity by Western Blot, non-specific staining was evident by IHC in a number of 
other tissues, namely the brain, colon and testes, where a similar staining pattern was 
seen in Ido2-/- to that present in Ido2+/+ mice, while the isotype control showed negative 
staining. 
In the murine embryonic development series, Tdo2 was the most highly expressed gene 
in both the placenta and yolk sac. Whether the role of Tdo2 in murine embryos is purely 
nourishment and NAD+ production, or if it may also be playing a role in inducing immune 
tolerance to prevent foetal rejection, will need to be further investigated. Ido1 mRNA 
expression in the placenta and yolk sac was higher than that of Ido2. As Ido2 was present 
only at very low levels in the embryonic tissues, it is unlikely that Ido2 is playing a pivotal 
role in embryonic development. Despite being present in abundant amounts in adult 
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liver, neither Ido2 nor Tdo2 were present in embryonic liver and were only detectable in 
low levels in early neonates, suggesting that Trp metabolism is not performed by the liver 
until much later in murine development. Finally, the absence of the other Trp-
catabolising enzymes did not affect the expression levels of Ido2 within the liver. 
Although Ido2 was downregulated in Ido1-/- and Ido1-/-Tdo2-/- kidney, brain and 
epididymis, it is likely that these were artefacts as Ido1 was not present in wild-type 
kidney and brain in the first place. Whether the downregulation of Ido2 seen in Ido1-/- 
and Ido1-/-Tdo2-/- epididymis is due to the absence of IDO1 will need to be further 
investigated by using transient knockdowns or an siRNA approach. 
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CHAPTER 5: IDO2- AND TDO2-REGULATED PATHWAYS IN MURINE 
LIVER 
5.1 INTRODUCTION 
The tryptophan catabolic capacity of IDO2 and TDO2 via the kynurenine pathway has 
been well established (Knox and Auerbach, 1955; Ball et al., 2007; Metz et al., 2007). 
However, the roles these two enzymes may play outside this pathway and the expression 
of genes regulated by one or both of these enzymes have not been investigated before. 
Apart from regulation of dietary tryptophan and supplying NAD+ (Badawy, 1981), TDO2 
also has been suggested to play a role in facilitating immunotolerance in allogeneic liver 
transplantation (Schmidt et al., 2009) as well as in cancer (Pilotte et al., 2012). Increased 
anxiety also has been reported in mice deficient of TDO2 (Kanai et al., 2009) and an 
upregulation of TDO2 activity was observed in post-mortem analysis of the cortex of 
individuals with schizophrenia and bipolar disorder (Miller et al., 2006). In addition to the 
possible role of TDO2 in these conditions, only the differential regulation of downstream 
enzymes of the kynurenine and TPH pathway in the absence of TDO2 has been studied 
previously. The role of TDO2 outside of these two pathways has not been investigated 
before. 
The second tryptophan-catabolising enzyme present in human and murine liver is IDO2.  
In vivo, the tryptophan catabolic activity of IDO2 in the liver is relatively low as the Km of 
mouse IDO2 was more than 400 times higher than that of mouse IDO1 (Austin et al., 
2010), suggesting lower affinity of IDO2 towards tryptophan.  It has been proposed that 
some effects of IDO2 may be mediated through a mechanism unrelated to tryptophan 
catabolism/kynurenine production (Ball et al., 2014).  To date, the physiological roles of 
 170 
IDO2 have not been well established. Apart from some reports on the upregulation of 
IDO2 seen in human cancer cell lines (Lob et al., 2009; Witkiewicz et al., 2009), nothing 
more is known on the specific role of human IDO2. Metz and colleagues more recently 
suggested that IDO2 plays a role in contact hypersensitivity, one that is mechanistically 
distinct from IDO1 (Metz et al., 2014). Its possible role as an important mediator of 
autoantibody production in autoimmune diseases also has been discussed (Merlo et al., 
2014). However, nothing more is known about the role of IDO2 or the mechanism of its 
action. 
In this chapter, microarray analysis of differentially expressed genes in mice deficient for 
one or two genes coding for tryptophan-catabolising enzymes, relative to their respective 
wild-type strain, was undertaken. As two tryptophan-catabolising enzymes, IDO2 and 
TDO2, are expressed in the liver, the possibility of a redundancy in their roles needed to 
be considered. With this in mind, we aimed to investigate whether the absence of either 
or both of these enzymes affects a distinct or overlapping set of genes, which may 
provide insights into the interaction between TDO2 and IDO2, as well as alternative roles 
they may be playing in the liver. 
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5.2 METHODS 
5.2.1 Liver collection and homogenisation 
Liver was collected from Ido2+/+, Ido2-/-, Tdo2+/+, Tdo2-/-, Ido2+/+Tdo2+/+ and Ido2-/-Tdo2-/- 
mice and homogenised as described in Section 4.2.2. 
 
5.2.2 RNA extraction 
RNA extraction was performed as described in Section 4.2.3. Part of the RNA was used for 
cDNA synthesis (as described in Section 4.2.3) and the remainder was used for microarray 
analysis. 
 
5.2.3 RNA quality assessment using the Nanodrop and Bioanalyser 
The quality of RNA of each sample was assessed with a Nanodrop 2000 (Thermoscientific) 
and an RNA 6000 Nano Assay chip on an Agilent 2100 Bioanalyser as per the 
manufacturer’s instructions. Samples with 260:280 and 260:230 ratios of above 1.8 as 
well as RNA Integrity Number (RIN) of above seven were deemed acceptable for 
microarray analysis (Thompson et al., 2007; Schroeder et al., 2006).  
 
5.2.4 Illumina mouse (WG-6) microarray 
Samples (n>5) of each mouse strain were pooled for microarray analysis such that each 
individual mouse contributed an equivalent amount of RNA (200 ng) to the pooled 
sample with a final concentration of 100 ng/µL and total amount of 1000 – 1200 ng. 
Pooled samples were assayed by the Ramaciotti Centre for Genomics, UNSW, using the 
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Illumina mouse (WG-6) BeadChip array system according to the manufacturer’s 
instructions.  
5.2.5 Microarray data analysis 
Illumina microarray data were extracted using Genome Studio with the addition of a 
Partek plug-in to facilitate the analysis of data on Partek software. Data were analysed 
using Partek Genomics Suite 6.6 software to identify differentially-expressed genes. Each 
array from a gene knockout mouse strain was compared to its respective control strain 
and a differentially-expressed gene was defined as having a greater than 2-fold change. 
As each array represented pooled samples no statistical test was performed. Instead, 
selected genes, i.e. those having at least a two-fold change in expression, were further 
validated using RT-qPCR on samples from individual mice with appropriate statistical 
tests. Partek Pathway software was used for detecting the different pathways implicated 
by the global genes that were differentially regulated in the samples. 
 
5.2.6 RT-qPCR 
The expression of some of the genes differentially regulated in the microarray analysis 
was validated by RT-qPCR. The reaction (20 µL) contained 8 µL cDNA and 0.1 µmol/L of 
each primer in 1x KAPA SYBR Fast Universal qPCR Master Mix. Amplification was 
performed in a Rotorgene 3000 (Corbett Research) with 40 cycles of 95 °C for 15 sec 
followed by 60 °C for 45 sec. Ywhaz was used as the housekeeping gene. The relative 
expression of genes was calculated using the ΔΔCt method with normalisation to Ywhaz 
(Livak and Schmittgen, 2001; Jusof et al., 2013). The primer sequences for the genes are 
listed in Table 5.1. 
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Ywhaz 5’ TGTCACCAACCATTCCAACTTG 3’ 
5’ ACACTGAGTGGAGCCAGAAAGA 3’ 
Fam25c (2200001I15Rik) 5’ AAGCACGCTCTTCCAGTCTGAG 3’ 
5’ TCCACTGCGTGAACTGCTC 3’ 
Bcl7c 5’ GAATTCGGCACGAGGCTCA 3’ 
5’ TTCTCCCATCTCCGGACCTT 3’ 
Bmf 5’ GCGGGCGTATTTTGGAAACA 3’ 
5’ CAGGGTCCAGGGTGAAGAAC 3’ 
Cdc37 5’ CACCGGGTTGGGGATACAAA 3’ 
5’ GGTTCACCCTCTGCCTCAAA 3’ 
Cyp4a14 5’ TTGCTCACGAGCACACAGAT 3’ 
5’ TCTTCTTCCTGGCCTTCTGC 3’ 
Ehd3 5’ CACATCTAGGCTCCGAGCAG 3’ 
5’ GCAGTGCCCTATGGAGGTTT 3’ 
Acot1 5’ GGTGCCAACATCACCTTTGG 3’ 
5’ TTTCCCCAACCTCCAAACCA 3’ 
Acot3 5’ AGCTCTTGACCTTGTCTGTCTG 3’  
5’ AGTCAATGGGCAGGGAGTTG 3’ 
Acot4 5’ TGCGGTACATGCTTCGACAT 3’ 
5’ GCGGAATCATGGTCTGCTTG 3’ 
Lcn2 5’ AATGTCACCTCCATCCTGGTCA 3’ 
5’ CCCTGGAGCTTGGAACAAATG 3’ 
Saa1 5’ ATCACCAGATCTGCCCAGGA 3’ 
5’ CCTTGGAAAGCCTCGTGAAC 3’ 
Steap3 5’ ACCCAGGGTTAAGGAGAACCT 3’ 
5’ ACTCCAGCTCACCAGGTCTA 3’ 
Nrep (D0H4S114F) 5’ CAGGCCTGGTTCGCTACAA 3’ 
5’ ATGAAAGGCAGGAGTGGACC 3’ 
Gjb3 5’ CAGCCAGAGGGAGGCTTTAC 3’ 
5’ CTGCTAGCCACACTTGCTCT 3’ 
Moxd1 5’ ACAACGCAGAGTGGTCGATT 3’ 
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5’ CTTTCTCGCACACCAGAGGT 3’  
Igfbp1 5’  CGCCGACCTCAAGAAATGGA 3’  
5’ GACACACCAGCAGAGTCCAG 3’ 
G0s2 5’ CAAAGCCAGTCTGACGCAAG 3’ 
5’ ACACTGCCCAGCACGTATAG 3’  
Ankar 5’ ACCTTCCGGGAAAATTTAGCA 3’ 
5’ GAACGAGCATCATCCTTGGC 3’ 
Psmb5 5’  CCATGGGCACCATGATCTGT 3’ 
5’ CGTAAGCATACACGGAGCCA 3’  
Adam33 5’ AAACCGAGATGCCTTCCCCT 3’ 
5’ AGAATGTTGGGAGCTGGTAGCAC 3’ 
Gdf15 5’ ACTCAGGACACAAGCGACAT 3’ 
5’ GGGTCGCTGTTCAGGCATT 3’ 
8430408G22Rik 5’ GCCTGGATGACTACGTCAGG 3’ 
5’ GCCTGGATGACTACGTCAGG 3’ 
Table 5.1. Lists of primers for genes of interest validated by RT-qPCR. 
 
5.2.7 Statistical test 
Data were log-transformed and the unpaired t-test was used to detect significant 
differences in expression of an individual gene in the knockout strain relative to its 
equivalent wild-type using GraphPad Prism software. 
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5.3 RESULTS 
5.3.1 Genes differentially regulated in liver lysates of Ido2-/- mice relative to Ido2+/+ and 
their associated pathways.  
A total of 73 genes was found to be differentially regulated in the Ido2-/- liver relative to 
its equivalent wild-type (Ido2+/+) using microarray analysis. Of these, 10 genes have been 
withdrawn from PubMed Gene due to lack of sufficient evidence for their existence and 
were therefore not further considered. Of the remaining 63 genes that were found to be 
differentially regulated, 26 were upregulated (Table 5.2) and 37 downregulated (Table 
5.3) in Ido2-/- relative to Ido2+/+. The functions or nomenclatures of five of these have yet 
to be validated. A list of pathways that were implicated by the genes that were 
differentially-regulated was generated by Partek Pathway and the top 30 pathways are 
listed in Table 5.4. Pathways related to lipid metabolism (elongation, biosynthesis and 
degradation of fatty acids as well as peroxisome proliferator-activated receptor [PPAR] 
signalling pathway) were implicated in the absence of Ido2, as were the purine 
metabolism, asthma, JAK-STAT, p53, chemokine and cytokine-cytokine receptor signalling 
pathways. All these pathways were to some degree related to insulin resistance, 
oxidative stress, the immune response or inflammation. Although these pathways were 
implicated by the Partek analysis, only a small number of genes in each pathway was 
detected as being differentially regulated. For example, although there are 22 genes 
involved in encoding proteins for the fatty acid elongation pathway, only one was found 
by microarray to be differentially regulated. Similarly, in purine metabolism, only 2 genes 
were differentially regulated although 173 genes are involved in this pathway. 
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Fourteen out of the 26 upregulated genes were evaluated by RT-qPCR (Table 5.5), out of 
which seven genes (Xdh, Acot1, Cyp4a14, Ehd3, Gdf15, Igfbp1 and Fam25c) were found to 
be significantly upregulated in the Ido2-/- liver compared to the wild-type. Among the list 
of downregulated genes, the expression of six genes was assessed by RT-qPCR and only 
Moxd1 was significantly (p=0.0108) downregulated. Xdh, Ehd3 and Fam25c (all p<0.0001) 
were most significantly upregulated in Ido2-/- liver compared to wild-type, followed by 
Acot1 (p<0.01), Cyp4a14, Gdf15 and Igfbp1 (p<0.05) (Fig. 5.1). 
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Symbol Definition Chromosome 
Fold-Change 
(Ido2-/-  vs. 
Ido2+/+) 
1.  
Fam25c 
(2200001I15Rik) 
RIKEN cDNA 2200001I15 gene (2200001I15Rik), mRNA. Now known as 
Fam25c (family with sequence similarity 25, member C)  14 7.00087 
2.  Cyp4a14 Cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14), mRNA. 4 5.12023 
3.  Xdh Xanthine dehydrogenase (Xdh), mRNA. 17 3.7886 
4.  Ehd3 EH-domain containing 3 (Ehd3), mRNA. 17 3.6572 
5.  G0s2 G0/G1 switch gene 2 (G0s2), mRNA. 1 3.53331 
6.  Bcl7c 
B cell CLL/lymphoma 7C; associated with certain types of lymphoma and 
leukemiae 7 3.19183 
7.  8430408G22Rik RIKEN cDNA 8430408G22 gene (8430408G22Rik), mRNA. 6 3.01383 
8.  Ankar Ankyrin and armadillo repeat containing (Ankar), mRNA. 1 3.01383 
9.  Psmb5 Proteasome (prosome, macropain) subunit, beta type 5 (Psmb5), mRNA. 14 2.98575 
10.  Igfbp1 Insulin-like growth factor binding protein 1 (Igfbp1), mRNA. 11 2.72639 
11.  Gdf15 Growth differentiation factor 15 (Gdf15), mRNA. 8 2.54065 
12.  Tas2r125 Taste receptor, type 2, member 125 (Tas2r125), mRNA. 6 2.46006 
13.  Bmf BCL2 modifying factor  2 2.45616 
14.  Cox7a2l Cytochrome c oxidase subunit VIIa polypeptide 2-like 17 2.42212 
15.  Yipf4 Yip1 domain family, member 4 (Yipf4), mRNA. 17 2.39514 
16.  Cxcl1 Chemokine (C-X-C motif) ligand 1 (Cxcl1), mRNA. 5 2.27302 
17.  
Ppp1r3g 
(1600032L17Rik) 
Validated as Ppp1r3g (protein phosphatase 1, regulatory (inhibitor) subunit 
3G)  13 2.2632 
18.  Gjb3 Gap junction protein, beta 3 (Gjb3), mRNA. 4 2.2448 
19.  Supt16h Suppressor of Ty 16 homolog (S. cerevisiae) (Supt16h), mRNA. 14 2.19184 
20.  Lars2 Leucyl-tRNA synthetase, mitochondrial (Lars2), nuclear gene encoding mitoc 9 2.1552 
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21.  Krt1-2 Keratin 32 11 2.14519 
22.  Ms4a2 Membrane-spanning 4-domains, subfamily A, member 2 (Ms4a2), mRNA. 19 2.13687 
23.  Il13ra2 Interleukin 13 receptor, alpha 2 (Il13ra2), mRNA. X 2.12012 
24.  
Prob1 
(Gm1614) 
PREDICTED: gene model 1614, (NCBI) (Gm1614), mRNA. Validated as proline 
rich basic protein 1 (Prob1) 18 2.12001 
25.  Itga9 Integrin alpha 9 (Itga9), mRNA. 9 2.10595 
26.  Acot1 Acyl-CoA thioesterase 1 (Acot1), mRNA. 12 2.01911 
 
Table 5.2. Genes upregulated (n=26) in mouse liver lysates of Ido2-/- (pooled from n=6) relative to Ido2+/+ (also pooled from n=6), where genes 
are ranked according to decreasing fold-change values as determined by Illumina microarray analysis. mRNA expression of genes in bold font 
subsequently was assessed further by RT-qPCR. Data were extracted and analysed using Partek Genomics Suite 6.6 software
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Symbol Definition Chromosome 
Fold-Change 
(Ido2-/-  vs. 
Ido2+/+) 
1.  Adam33 A disintegrin and metallopeptidase domain 33 (Adam33), mRNA. 2 -6.77354 
2.  Cdc37 Cell division cycle 37 homolog (S. cerevisiae) (Cdc37), mRNA. 9 -5.49856 
3.  OTTMUSG00000010433 
Predicted gene, OTTMUSG00000010433 (OTTMUSG00000010433), 
mRNA. 4 -4.05319 
4.  Gadd45g 
Growth arrest and DNA-damage-inducible 45 gamma (Gadd45g), 
mRNA. 13 -3.8463 
5.  Moxd1 Monooxygenase, DBH-like 1 (Moxd1), mRNA. 10 -3.79386 
6.  Cish Cytokine inducible SH2-containing protein (Cish), mRNA. 9 -3.68348 
7.  Lrrc18 Leucine rich repeat containing 18 (Lrrc18), mRNA. 14 -3.5994 
8.  Lmln Leishmanolysin-like (metallopeptidase M8 family) (Lmln), mRNA. 16 -3.58725 
9.  Foxq1 Forkhead box Q1 (Foxq1), mRNA. 13 -3.34803 
10.  Degs2 
Degenerative spermatocyte homolog 2 (Drosophila), lipid desaturase 
(Degs2) 12 -2.79156 
11.  Hhex Hematopoietically expressed homeobox (Hhex), mRNA. 19 -2.70547 
12.  Hist1h1c Histone cluster 1, H1c  13 -2.65215 
13.  Mela Melanoma antigen 8 -2.60853 
14.  Tom1 Target of myb1 homolog (chicken) (Tom1), mRNA. 8 -2.59949 
15.  Phlda1 Pleckstrin homology-like domain, family A, member 1 (Phlda1), mRNA. 10 -2.56321 
16.  Slbp Stem-loop binding protein (Slbp), mRNA. 5 -2.46028 
17.  Lrrc3b Leucine rich repeat containing 3B (Lrrc3b), mRNA. 14 -2.44217 
18.  Cisd2 CDGSH iron sulfur domain 2 (Cisd2), mRNA. 3 -2.43887 
19.  Klf1 Kruppel-like factor 1 (erythroid) (Klf1), mRNA. 8 -2.41683 
20.  Ccr4 Chemokine (C-C motif) receptor 4 (Ccr4), mRNA. 9 -2.40598 
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21.  
Tmbim1 
(2310061B02Rik) 
Validated as (Tmbim1) transmembrane BAX inhibitor motif containing 1  
1 -2.39888 
22.  Pde6h Phosphodiesterase 6H, cGMP-specific, cone, gamma (Pde6h), mRNA. 6 -2.38854 
23.  EG241041 Predicted gene, EG241041 (EG241041), non-coding RNA. 1 -2.3572 
24.  Iqcf4 IQ motif containing F4 (Iqcf4), mRNA. 9 -2.35017 
25.  Axud1 AXIN1 up-regulated 1 (Axud1), mRNA. 9 -2.30655 
26.  Nhedc2 Na+/H+ exchanger domain containing 2 (Nhedc2), mRNA. 3 -2.27656 
27.  5033411D12Rik RIKEN cDNA 5033411D12 gene (5033411D12Rik), mRNA. 13 -2.26891 
28.  Mstn Myostatin (Mstn), mRNA. 1 -2.23966 
29.  C87499 Expressed sequence C87499 (C87499), mRNA. 4 -2.19228 
30.  
Ctse 
(C920004C08Rik) 
Validated as Ctse (cathepsin E) 
1 -2.16718 
31.  
Nrep 
(D0H4S114) 
DNA segment, human D4S114 (D0H4S114), mRNA. Now known as 
Nrep (Neuronal regeneration-related protein) 18 -2.14232 
32.  Per2 
Period homolog 2 (Drosophila) (Per2), mRNA. Also known as Period 
circadian clock 2 1 -2.14048 
33.  Asns Asparagine synthetase (Asns), mRNA. 6 -2.08855 
34.  Olfr97 Olfactory receptor 97 (Olfr97), mRNA. 17 -2.06431 
35.  LOC100039496 
Predicted: hypothetical protein LOC100039496 (LOC100039496), 
mRNA. 8 -2.03371 
36.  Dusp1 Dual specificity phosphatase 1 (Dusp1), mRNA. 17 -2.03146 
37.  Duoxa1 Dual oxidase maturation factor 1 (Duoxa1), mRNA. 2 -2.02541 
Table 5.3. Genes downregulated (n=37) in mouse liver lysates of Ido2-/- mice (pooled from n=6) relative to Ido2+/+ (also pooled from n=6), 
where genes are ranked according to decreasing fold-change values as determined by Illumina microarray analysis. mRNA expression of genes 
in bold font subsequently was evaluated further by RT qPCR. Data were extracted and analysed using Partek Genomics Suite 6.6 Software. 
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Pathway Name 
No. genes 
in list 
No.  in 
pathway 
1.  Caffeine metabolism 1 4 
2.  Maturity onset diabetes of the young 1 21 
3.  Fatty acid elongation 1 22 
4.  Biosynthesis of unsaturated fatty acids 1 23 
5.  Asthma 1 24 
6.  Jak-STAT signaling pathway 2 147 
7.  Alanine, aspartate and glutamate metabolism 1 30 
8.  Energy Metabolism 2 155 
9.  Circadian rhythm 1 31 
10.  Purine metabolism 2 163 
11.  Transcriptional misregulation in cancer 2 169 
12.  Chemokine signaling pathway 2 170 
13.  Fatty acid degradation 1 42 
14.  Proteasome 1 43 
15.  Aminoacyl-tRNA biosynthesis 1 44 
16.  Drug metabolism - other enzymes 1 45 
17.  Sphingolipid metabolism 1 46 
18.  NOD-like receptor signaling pathway 1 55 
19.  Legionellosis 1 56 
20.  Taste transduction 1 60 
21.  Cytokine-cytokine receptor interaction 2 238 
22.  p53 signaling pathway 1 67 
23.  Cardiac muscle contraction 1 68 
24.  Fc epsilon RI signaling pathway 1 69 
25.  MAPK signaling pathway 2 248 
26.  Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 1 70 
27.  Prolactin signaling pathway 1 71 
28.  RNA degradation 1 72 
29.  PPAR (peroxisome proliferator-activated 
receptor) signaling pathway 1 73 
30.  Salmonella infection 1 75 
Table 5.4. List generated by Partek Pathway of top 30 pathways implicated by genes 
differentially-regulated in Ido2-/- (n=6, pooled sample) relative to Ido2+/+ (n=6, pooled 
sample) mouse liver lysates. mRNA expression of some genes involved in the pathways 
indicated with bold font subsequently was analysed further by RT-qPCR.  
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Gene Changes 
relative to 
Ido2+/+ 
1.  Xdh + 
2.  Acot1 + 
3.  Cyp4a14 + 
4.  Ehd3 + 
5.  Gdf15 + 
6.  IgfbP1 + 
7.  Fam25c + 
8.  Moxd1 - 
9.  Cdc37 ns 
10.  G0s2 ns 
11.  Psmb5 ns 
12.  Ankar ns 
13.  Adam33 ns 
14.  Gjb3 ns 
15.  Acot3 ns 
16.  Acot4 ns 
17.  Nrep  ns 
18.  Bcl7c ns 
19.  Bmf ns 
20.  Ccr4 ns 
21.  8430408G22Rik ns 
22.  Saa1 ns 
23.  Lcn2 ns 
Table 5.5. Gene expression in Ido2-/- relative to Ido2+/+ mouse liver, evaluated by RT-
qPCR from the list of genes differentially regulated according to microarray analysis. 
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Figure 5.1. Genes that were significantly differentially regulated in Ido2-/- mouse liver 
relative to Ido2+/+ as assessed by RT-qPCR. Three asterisks denote p<0.0001, double 
asterisks 0.0001<p<0.001, whereas one asterisk denotes 0.001< p<0.05. N = 6 in each 
case. 
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5.3.2 Genes differentially regulated in liver lysates of Tdo2-/- mice relative to Tdo2+/+ 
and the pathways implicated.  
A total of 95 genes were differentially regulated in Tdo2-/- compared to Tdo2+/+ mouse 
liver as assessed by microarray analysis. Of these, 15 genes were either not defined or 
withdrawn from the Entrez Gene (NCBI database for gene-specific information) (Maglott 
et al., 2005), leaving 80 potential genes for further validation. Six out of the 80 
differentially-regulated genes in Tdo2-/- mice were either predicted genes that have yet 
to be validated or validated genes whose function or role have yet to be classified. 
When the list of differentially-regulated genes was assessed using the Partek Pathway 
software, lipid metabolism-related pathways were most commonly implicated in the 
absence of Tdo2, similar to what was observed in Ido2-/- animals (Table 5.8). Four out of 
70 genes associated with the PPAR signalling pathway were differentially regulated 
(Acot3, Acot4, Cyp7a1, Cyp4a14), while in the fatty acid elongation pathway, two out of 
21 genes were differentially regulated (Acot3 and Acot4). 
The expression of six out of the 54 upregulated genes (Table 5.6) was further analysed 
by RT-qPCR and only Cyp4a14 was found to be significantly upregulated using this 
technique. Of the 26 downregulated genes (Tdo2 included) (Table 5.7), the expression 
of three was further assessed and only Moxd1 was found to be significantly 
downregulated. In addition to these, the expression levels of seven genes that were 
differentially regulated in Ido2-/- were also analysed in the Tdo2-/- mice relative to the 
equivalent wild-type (Tdo2+/+) (Table 5.9). However, none of these was found to be 
differentially regulated in Tdo2-/- mouse liver. The expression patterns of both Cyp4a14 
and Moxd1 were similar to their expression in Ido2-/- mice, as Cyp4a14 was significantly 
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upregulated (p= 0.0488) and Moxd1 was significantly downregulated (p=0.0268) in 
Tdo2-/- mouse liver relative to its wild-type counterpart (Fig. 5.2). 
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Symbol Definition Chromosome 
Fold-Change 
(Tdo2-/-  vs. 
Tdo2+/+) 
1.  Accn5 Amiloride-sensitive cation channel 5, intestinal (Accn5), mRNA. 3 7.7863 
2.  Steap3 STEAP family member 3, mRNA. 1 4.59505 
3.  Acot3 Acyl-CoA thioesterase 3, mRNA. 12 4.34048 
4.  Rad54l2 
(Srisnf2l) Validated as Rad54l2 (RAD54 like 2 (S. cerevisiae)) 
9 4.23291 
5.  Cyp7a1 Cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1), 
mRNA. 
4 3.62802 
6.  Mr1 Major histocompatibility complex, class I-related 1 3.23201 
7.  Cyp4a14 Cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14), 
mRNA. 
4 3.1853 
8.  Myoz1 Myozenin 1 (Myoz1), mRNA. 14 3.09084 
9.  Nrep 
(D0H4S114) 
DNA segment, human D4S114 (D0H4S114), mRNA. Now known as 
Nrep (Neuronal regeneration-related protein). 
18 2.99895 
10.  Tmco2 Transmembrane and coiled-coil domains 2 (Tmco2), mRNA. 4 2.69164 
11.  Agk Acylglycerol kinase (Agk), mRNA. 6 2.65009 
12.  Bmf BCL2 modifying factor  2 2.56819 
13.  Edn2 Endothelin 2 (Edn2), mRNA. 4 2.55954 
14.  Rgs16 Regulator of G-protein signaling 16, mRNA. 1 2.50613 
15.  Rshl2a Radial spokehead-like 2A, mRNA. 17 2.47821 
16.  Prei4 Preimplantation protein 4, transcript variant 3, mRNA. 2 2.42365 
17.  Crtc2 
(4632407F12Rik) Validated as Crtc2 (CREB regulated transcription coactivator 2) 
3 2.39501 
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18.  Tiam2 T-cell lymphoma invasion and metastasis 2 (Tiam2), mRNA. 17 2.39175 
19.  Usp2 Ubiquitin specific peptidase 2 (Usp2), transcript variant 2, mRNA. 9 2.38705 
20.  D1Ertd622e DNA segment, Chr 1, ERATO Doi 622, expressed (D1Ertd622e), mRNA. 1 2.28648 
21.  Mmd2 Monocyte to macrophage differentiation-associated 2 (Mmd2), mRNA. 5 2.26695 
22.  Exph5 
(Slac2b) Validated as Exph5 (exophilin 5) 
9 2.24818 
23.  Pdk1 
(D530020C15Rik) Validated as Pdk1 (pyruvate dehydrogenase kinase, isoenzyme 1) 
2 2.23418 
24.  Cndp1 Carnosine dipeptidase 1 (metallopeptidase M20 family) (Cndp1), 
mRNA. 
18 2.20074 
25.  Per3 Period circadian clock 3  4 2.19626 
26.  2610020H08Rik RIKEN cDNA 2610020H08 gene 7 2.16727 
27.  Pcsk4 Proprotein convertase subtilisin/kexin type 4, mRNA. 10 2.14789 
28.  Pdk1 Pyruvate dehydrogenase kinase, isoenzyme 1, nuclear gene encoding m 2 2.14561 
29.  P2ry1 Purinergic receptor P2Y, G-protein coupled , mRNA. 3 2.14393 
30.  Hamp2 Hepcidin antimicrobial peptide 2, mRNA. 7 2.14239 
31.  LOC194360 PREDICTED: Mus musculus hypothetical LOC194360 (LOC194360), 
mRNA. Gm4744 predicted gene 4744 
6 2.13307 
32.  BC016495 cDNA sequence BC016495 (BC016495), mRNA. 19 2.13036 
33.  Sema4d Sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4D 
13 2.12925 
34.  Prmt8 Protein arginine N-methyltransferase 8 (Prmt8), mRNA. 6 2.12476 
35.  LOC666168 PREDICTED: Mus musculus similar to cytochrome P450, family 4, 
subfamily a, polypeptide  
4 2.10826 
36.  Olfr1212 Olfactory receptor 1212 (Olfr1212), mRNA. 2 2.10776 
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37.  Gm129 Gene model 129, (NCBI) (Gm129), mRNA. XM_907670 XM_920513 
XM_920520 XM_920 
3 2.09879 
38.  Ell3 Elongation factor RNA polymerase II-like 3 (Ell3), mRNA. 2 2.08376 
39.  Olfr1412 Olfactory receptor 1412 1 2.07623 
40.  Mll5 Lysine (K)-specific methyltransferase 2E 5 2.06649 
41.  Emp2 Epithelial membrane protein 2 (Emp2), mRNA. 16 2.05973 
42.  Plac9a 
(MGC41689) Plac9a (placenta specific 9a) 
14 2.05766 
43.  Lrtm1 Leucine-rich repeats and transmembrane domains 1, mRNA. 14 2.05602 
44.  Bhlhb9 Basic helix-loop-helix domain containing, class B9, mRNA. X 2.05379 
45.  Cyp2c54 Cytochrome P450, family 2, subfamily c, polypeptide 54, mRNA. 19 2.04421 
46.  Fam108b Family with sequence similarity 108, member B, mRNA. 19 2.04263 
47.  Serpina6 Serine (or cysteine) peptidase inhibitor, clade A, member 6, mR 12 2.03427 
48.  Acot4 Acyl-CoA thioesterase 4, mRNA. 12 2.0333 
49.  LOC100042018 PREDICTED: Mus musculus hypothetical protein LOC100042018 
(LOC100042018), mRNA. Gm3627 predicted gene 3627 
4 2.02483 
50.  Gjb3 Gap junction protein, beta 3, mRNA. 4 2.02265 
51.  Olfr813 Olfactory receptor 813, mRNA. 10 2.00893 
52.  Tnpo2 Transportin 2 (importin 3, karyopherin beta 2b), mRNA. 8 2.00813 
53.  Gm906 Gene model 906, (NCBI) (Gm906), mRNA. 13 2.00575 
54.  Rnf186 Ring finger protein 186, mRNA. 4 2.0041 
Table 5.6. Genes upregulated (n=54) in liver lysates of Tdo2-/- mice (pooled from n=5) relative to Tdo2+/+ mice (pooled from n=6), where genes 
are ranked according to the fold-change values as assessed by Illumina microarray analysis. mRNA expression of genes in bold font 
subsequently was assessed further by RT-qPCR. Data were extracted and analysed using Partek Genomics Suite 6.6 Software.  
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Symbol Definition Chromosome 
Fold-Change 
(Tdo2-/-  vs. 
Tdo2+/+) 
1.  
LOC666403 
PREDICTED: Mus musculus similar to ribosomal protein S2 
(LOC666403), misc RNA. 11 -18.0343 
2.  Tdo2 Tryptophan 2,3-dioxygenase, mRNA. 3 -11.1854 
3.  Saa2 Serum amyloid A 2, mRNA. 7 -7.74417 
4.  Saa1 Serum amyloid A 1, mRNA. 7 -5.85553 
5.  Tbkbp1 TBK1 binding protein 1, mRNA. 11 -5.02919 
6.  Polr2c Polymerase (RNA) II (DNA directed) polypeptide C, mRNA. 8 -5.02492 
7.  Selenbp2 Selenium binding protein 2, mRNA. 3 -4.26395 
8.  Erdr1 Erythroid differentiation regulator 1, mRNA. Y -4.15712 
9.  Lcn2 Lipocalin 2 (Lcn2), mRNA. 2 -3.66235 
10.  1700012A03Rik RIKEN cDNA 1700012A03 gene (1700012A03Rik), mRNA. 6 -3.45047 
11.  Atp4b ATPase, H+/K+ exchanging, beta polypeptide (Atp4b), mRNA. 8 -3.17338 
12.  Ep Hermansky-Pudlak syndrome 1 homolog 19 -2.80116 
13.  Rps3a Ribosomal protein S3a, mRNA. 3 -2.79031 
14.  
Hsd3b5 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 3 -2.77053 
15.  Sept12 Septin 12 (Sept12), mRNA. 16 -2.6386 
16.  Szt2 
(BC059842) 
Seizure threshold 2, mRNA 
4 -2.46092 
17.  Try4 trypsin 4 (Try4), mRNA. 6 -2.41999 
18.  AU018091 Expressed sequence AU018091 (AU018091), mRNA. 7 -2.35656 
19.  Moxd1 Monooxygenase, DBH-like 1 (Moxd1), mRNA. 10 -2.28549 
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20.  Syk Spleen tyrosine kinase (Syk), mRNA. 13 -2.24069 
21.  Olfr414 Olfactory receptor 414 (Olfr414), mRNA. 1 -2.19227 
22.  
Gab2 
Growth factor receptor bound protein 2-associated protein 2 (Gab2), 
mRNA. 7 -2.1782 
23.  Lbp Lipopolysaccharide binding protein (Lbp), mRNA. 2 -2.12514 
24.  Setbp1 
(C130092E12) 
Validated as Setbp1 (SET binding protein 1) 
18 -2.06874 
25.  Apcs Serum amyloid P-component (Apcs), mRNA. 1 -2.0158 
26.  B4galnt3 Beta-1,4-N-acetyl-galactosaminyl transferase 3 (B4galnt3), mRNA. 6 -2.0082 
 
Table 5.7. Genes downregulated (n=26) in mouse liver lysates of Tdo2-/- mice (pooled from n=5) relative to Tdo2+/+ (pooled from n=6), where 
genes are ranked according to the fold-change values as analysed by Illumina microarray analysis. mRNA expression of genes in bold font 
subsequently was assessed further by RT-qPCR. Data were extracted and analysed using Partek Genomics Suite 6.6 Software. 
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Pathway Name 
No. genes 
in list 
No.  in 
pathway 
1.  PPAR signaling pathway 4 70 
2.  Fatty acid elongation 2 21 
3.  Biosynthesis of unsaturated fatty acids 2 22 
4.  Steroid hormone biosynthesis 3 80 
5.  beta-Alanine metabolism 2 27 
6.  Metabolic pathways 11 1131 
7.  Fatty acid degradation 2 41 
8.  Tryptophan metabolism 2 41 
9.  Lysine degradation 2 45 
10.  Fc epsilon RI signaling pathway 2 68 
11.  Retinol metabolism 2 80 
12.  Arachidonic acid metabolism 2 83 
13.  Fc gamma R-mediated phagocytosis 2 84 
14.  NF-kappa B signaling pathway 2 88 
15.  Primary bile acid biosynthesis 1 14 
16.  HIF-1 signaling pathway 2 103 
17.  Butanoate metabolism 1 22 
18.  Osteoclast differentiation 2 118 
19.  Collecting duct acid secretion 1 24 
20.  Propanoate metabolism 1 26 
21.  RNA polymerase 1 26 
22.  Histidine metabolism 1 28 
23.  Circadian rhythm 1 31 
24.  Linoleic acid metabolism 1 45 
25.  Tuberculosis 2 172 
26.  Arginine and proline metabolism 1 47 
27.  Valine, leucine and isoleucine degradation 1 47 
28.  Fatty acid metabolism 1 48 
29.  Glycerolipid metabolism 1 55 
30.  Ovarian steroidogenesis 1 57 
 
Table 5.8. List of top 30 pathways implicated by genes differentially-regulated in Tdo2-/- 
(n=5) relative to Tdo2+/+ (n=6) liver lysates. mRNA expression of some genes involved in 
the pathways shown with bolded font subsequently was evaluated further by RT-qPCR. 
The list was generated using microarray data analysed using Partek Pathway software. 
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 Gene Changes 
relative to 
Tdo2+/+ 
1.  Cyp4a14 + 
2.  Moxd1 - 
3.  Acot3 ns 
4.  Steap3 ns 
5.  Nrep  ns 
6.  Acot4 ns 
7.  Gjb3 ns 
8.  Lcn2 ns 
9.  Saa1 ns 
10.  Xdh ns 
11.  Ehd3 ns 
12.  Gdf15 ns 
13.  Fam25c  ns 
14.  IgfbP1 ns 
15.  G0s2 ns 
16.  Acot1 ns 
Table 5.9. Gene expression in Tdo2-/- relative to Tdo2+/+, analysed by RT-qPCR from the 
list of genes differentially regulated by microarray analysis. 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2. Cyp4a14 (p=0.0488) and Moxd1 (p=0.0268) were significantly differentially 
regulated in Tdo2-/- mouse liver lysates relative to Tdo2+/+, where p<0.05, as assessed by 
RT-qPCR. N ≥ 5 in each case. 
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5.3.3 Global gene expression in liver lysates of Ido2-/-Tdo2-/- mouse liver relative to 
Ido2+/+Tdo2+/+ and the pathways implicated  
A total of 123 global genes were differentially regulated in Ido2-/-Tdo2-/- mouse liver 
relative to its wild-type counterpart. However, only 111 genes were verifiable in 
Pubmed Gene. The remaining 12 genes were either not found or withdrawn from the 
database due to insufficient evidence. Two out of 66 upregulated genes (Table 5.10) 
were further validated by RT-qPCR and both Lcn2 and Saa1 were found to be 
significantly upregulated (Fig 5.3). From the list of genes downregulated in liver, three 
out of 45 genes were further validated (Table 5.11). Nrep and Acot4 were significantly 
downregulated (Fig 5.3) in Ido2-/-Tdo2-/- mice as compared to their wild-type 
counterparts. The expression levels of an additional eight genes that were differentially 
regulated in either Ido2-/- or Tdo2-/- mice were also assessed in these double knockout 
animals (Table 5.13) and none of the genes tested were found to be significantly 
differentially regulated in Ido2-/-Tdo2-/- relative to Ido2+/+Tdo2+/+. Although Cyp4a14 was 
upregulated in the liver tissue deficient for Ido2 and Tdo2 individually, this upregulation 
was not observed in liver tissue of mice deficient in both Ido2 and Tdo2. 
Pathways that were implicated by the differentially-regulated genes were again lipid 
metabolism-related genes, namely fatty acid elongation and biosynthesis of 
unsaturated fatty acids pathways. In the former pathway, three (Elovl6, Acot3 and 
Acot4) out of 20 genes were differentially regulated. Three out of 70 genes related to 
the PPAR signalling pathway were also implicated due to the downregulation of Cyp7a1 
as well as Acot3 and Acot4 (Table 5.12). Other noteworthy pathways that were 
implicated by the differentially regulated genes in the Ido2-/-Tdo2-/- mouse liver were the 
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cytokine-related pathways such as the Jak-STAT signalling pathway and the malaria 
pathway.
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Symbol Definition Chr 
Fold-Change (Ido2-
/-Tdo2-/-  vs. 
Ido2+/+Tdo2+/+) 
1.  Saa2 Serum amyloid A 2, mRNA. 7 18.0424 
2.  Lcn2 Lipocalin 2, mRNA. 2 18.0381 
3.  Saa1 Serum amyloid A 1, mRNA. 7 13.4714 
4.  Orm2 Orosomucoid 2 4 6.16559 
5.  Trpa1 Transient receptor potential cation channel, subfamily A, member 1  1 6.07971 
6.  Hcrt Hypocretin, mRNA. 11 6.07137 
7.  Tnfsf15 Tumor necrosis factor (ligand) superfamily, member 15, mRNA. 4 5.73186 
8.  Jdp2 Jun dimerization protein 2, mRNA. 12 5.35209 
9.  Taar7e Trace amine-associated receptor 7E, mRNA. 10 4.75828 
10.  Hhatl Hedgehog acyltransferase-like, mRNA. 9 4.69441 
11.  Accn5 Amiloride-sensitive cation channel 5, intestinal, mRNA. 3 4.6359 
12.  Saa3 Serum amyloid A 3, mRNA. 7 4.36359 
13.  7420426K07Rik RIKEN cDNA 7420426K07 gene, mRNA. 9 3.89435 
14.  Thbs2 Thrombospondin 2 (Thbs2), mRNA. 17 3.14326 
15.  Bhlhb4 Basic helix-loop-helix domain containing, class B4, mRNA. 2 3.13176 
16.  Incenp Inner centromere protein, mRNA. 19 3.12555 
17.  Myom1 Myomesin 1, mRNA. 17 3.10907 
18.  Mt1 Metallothionein 1, mRNA. 8 3.07366 
19.  Rnase10 Ribonuclease, RNase A family, 10 (non-active), mRNA. 14 3.05756 
20.  Bglap1 Bone gamma carboxyglutamate protein 1, transcript variant 1, mRNA 3 3.03914 
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21.  Kctd1 Potassium channel tetramerisation domain containing 1, mRNA. XM_97 18 2.99579 
22.  Ureb1 Also known as Huwe1 (HECT, UBA and WWE domain containing 1) X 2.95686 
23.  Atat1 
(2610110G12Rik) 
Validated as Atat1 (alpha tubulin acetyltransferase 1) 
17 2.94559 
24.  Ptbp2 Polypyrimidine tract binding protein 2  3 2.81686 
25.  Il23a Interleukin 23, alpha subunit p19, mRNA. 10 2.7915 
26.  Myt1 Myelin transcription factor 1, mRNA. 2 2.68917 
27.  Phf14 
(4932409F11Rik) 
Validated as Phf14 (PHD finger protein 14) 
6 2.68316 
28.  Adam33 A disintegrin and metallopeptidase domain 33, mRNA. 2 2.60281 
29.  Prr7 Proline rich 7 (synaptic), mRNA. 13 2.56205 
30.  Col23a1 Collagen, type XXIII, alpha 1 11 2.56146 
31.  Cd276 CD276 antigen, mRNA. 9 2.5208 
32.  Rhbdd3 Rhomboid domain containing 3, mRNA. 11 2.51229 
33.  Fam64a 
(6720460F02Rik) 
RIKEN cDNA 6720460F02 gene (6720460F02Rik), mRNA. Also known as 
Fam64a (family with sequence similarity 64, member A) 11 2.50221 
34.  4932443I19Rik PREDICTED: RIKEN cDNA 4932443I19 gene, transcript variant 2 
(4932443I19Rik) 8 2.49155 
35.  Lrrc30 Leucine rich repeat containing 30, mRNA. 17 2.46812 
36.  Actc1 Actin, alpha, cardiac muscle 1, mRNA. 2 2.44374 
37.  Srek1 
SRRP86 
Also known as Srek1 (splicing regulatory glutamine/lysine-rich protein 1) 
13 2.43596 
38.  Pif1 PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) (Pif1), mRNA. 9 2.43347 
39.  Orly Validated as Orly (oppositely-transcribed, rearranged locus on the Y) Y 2.41987 
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(4930529H12Rik) 
40.  Klhl24 
(LOC100046372) 
Validated as Klhl24 (kelch-like 24) 
16 2.41608 
41.  Lrp11 Low density lipoprotein receptor-related protein 11, mRNA. 10 2.39417 
42.  Apcs Serum amyloid P-component, mRNA. 1 2.38877 
43.  Pmch Pro-melanin-concentrating hormone, mRNA. 10 2.38749 
44.  Scara5 Scavenger receptor class A, member 5 (putative), mRNA. 14 2.34509 
45.  Vps37b Vacuolar protein sorting 37B (yeast), mRNA. 5 2.30027 
46.  Bcl6 B-cell leukemia/lymphoma 6, mRNA. 16 2.2668 
47.  Nmnat2 Nicotinamide nucleotide adenylyltransferase 2, mRNA. 1 2.25532 
48.  Zfp353 Zinc finger protein 353, mRNA. 8 2.25321 
49.  Mtvr2 Mammary tumor virus receptor 2, transcript variant 2, mRNA. 19 2.20975 
50.  Slc41a2 Solute carrier family 41, member 2, mRNA. 10 2.17968 
51.  Olfr780 Olfactory receptor 780, mRNA. 10 2.17843 
52.  Pnlip Pancreatic lipase, mRNA. 19 2.17612 
53.  Rnuxa RNA U, small nuclear RNA export adaptor, mRNA. 18 2.17186 
54.  Recql5 RecQ protein-like 5, mRNA. 11 2.17092 
55.  Enho 
(2310040A07Rik) 
Validated as Enho (energy homeostasis associated) 
4 2.14905 
56.  Reg3g Regenerating islet-derived 3 gamma, mRNA. 6 2.10547 
57.  Olfr11 Olfactory receptor 11, mRNA. 13 2.10102 
58.  Rilpl1 Rab interacting lysosomal protein-like 1, mRNA. 5 2.09711 
59.  Pira6 Paired-Ig-like receptor A6, transcript variant 2, mRNA. 7 2.09638 
60.  Nnmt Nicotinamide N-methyltransferase 9 2.08966 
 198 
61.  Olfml3 Olfactomedin-like 3, mRNA. 3 2.0817 
62.  Olfr460 Olfactory receptor 460, mRNA. 6 2.06781 
63.  Plekhg3 
(BC030417) 
Validated as Plekhg3 (pleckstrin homology domain containing, family G) 
12 2.05746 
64.  Myo1f Myosin IF, mRNA. 17 2.04977 
65.  Cdh3 Cadherin 3, transcript variant 1, mRNA. 8 2.02131 
66.  BC048671 cDNA sequence BC048671 (BC048671), mRNA. 6 2.00031 
Table 5.10. Genes upregulated (n=66) in liver lysates of Ido2-/-Tdo2-/- mice (pooled from n=6) relative to Ido2+/+Tdo2+/+ mice (pooled from n=6), 
where genes are ranked according to the fold-change values as evaluated by Illumina microarray analysis. mRNA expression of genes in bold 
font subsequently was assessed further by RT-qPCR. Data were extracted and analysed using Partek Genomics Suite 6.6 Software. 
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Symbol Definition Chr 
Fold-Change (Ido2-
/-Tdo2-/-  vs. 
Ido2+/+Tdo2+/+) 
1.  Tdo2 Tryptophan 2,3-dioxygenase, mRNA. 3 -12.7669 
2.  Selenbp2 Selenium binding protein 2, mRNA. 3 -4.39624 
3.  Rps3a Ribosomal protein S3a, mRNA. 3 -4.23152 
4.  Sucnr1 Succinate receptor 1, mRNA. 3 -4.09805 
5.  
Cib3 
PREDICTED: Calcium and integrin binding family member 3, 
transcript varian 8 -3.99612 
6.  Acot3 Acyl-CoA thioesterase 3, mRNA. 12 -3.26252 
7.  Thrsp Thyroid hormone responsive 7 -3.17541 
8.  Krt79 Keratin 79, mRNA. 15 -3.13334 
9.  LOC669658 PREDICTED: similar to melanoma antigen, mRNA. 18 -3.08308 
10.  
Hsd3b5 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 3 -2.91359 
11.  Nrep 
(D0H4S114) 
DNA segment, human D4S114 (D0H4S114), mRNA. Now known as 
Nrep (Neuronal regeneration-related protein). 18 -2.84185 
12.  Ces1 Carboxylesterase 1, mRNA. 8 -2.69296 
13.  Elovl6 ELOVL family member 6, elongation of long chain fatty acids (yeast)  3 -2.64572 
14.  Hamp2 Hepcidin antimicrobial peptide 2, mRNA. 7 -2.6271 
15.  Sult1c2 Sulfotransferase family, cytosolic, 1C, member 2 17 -2.61046 
16.  Dbp D site albumin promoter binding protein, mRNA. 7 -2.60059 
17.  Ppp1r3g 
1600032L17Rik 
Validated as Ppp1r3g (protein phosphatase 1, regulatory (inhibitor) 
subunit 3G) 13 -2.54774 
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18.  9130409I23Rik RIKEN cDNA 9130409I23 gene, mRNA. 1 -2.48669 
19.  Ptgds Prostaglandin D2 synthase  2 -2.44528 
20.  Cish Cytokine inducible SH2-containing protein, mRNA. 9 -2.44116 
21.  Krtap4-16 
OTTMUSG00000002196 
Predicted gene, OTTMUSG00000002196, mRNA. Also known as 
Krtap4-16 (keratin associated protein 4-16) 11 -2.3801 
22.  Rgs16 Regulator of G-protein signaling 16, mRNA. 1 -2.29596 
23.  Acot4 Acyl-CoA thioesterase 4, mRNA. 12 -2.28633 
24.  
Pdk1 
Pyruvate dehydrogenase kinase, isoenzyme 1, nuclear gene 
encoding m 2 -2.2666 
25.  Aacs Acetoacetyl-CoA synthetase, mRNA. 5 -2.23187 
26.  Cyp7a1 Cytochrome P450, family 7, subfamily a, polypeptide 1, mRNA. 4 -2.22223 
27.  Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3, mRNA. 11 -2.22062 
28.  Ccrn4l CCR4 carbon catabolite repression 4-like (S. cerevisiae), mRNA. 3 -2.1556 
29.  Gstm6 Glutathione S-transferase, mu 6 3 -2.15109 
30.  Mtfr1l 
2410166I05Rik Validated as Mtfr1l (mitochondrial fission regulator 1-like) 4 -2.13669 
31.  Mod1 Malic enzyme, supernatant, mRNA. 9 -2.13567 
32.  A530017F20 PREDICTED: Gm2447 predicted gene 2447 3 -2.11981 
33.  Necab1 N-terminal EF-hand calcium binding protein 1, mRNA. 4 -2.10211 
34.  Srebf1 Sterol regulatory element binding factor 1, mRNA. 11 -2.08173 
35.  Olig1 Oligodendrocyte transcription factor 1, mRNA. 16 -2.07964 
36.  Pnpla3 Patatin-like phospholipase domain containing 3, mRNA. 15 -2.05922 
37.  Ugt2a3 UDP glucuronosyltransferase 2 family, polypeptide A3, mRNA. 5 -2.05416 
38.  Nudcd2 NudC domain containing 2, mRNA. 11 -2.0449 
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39.  Nampt Nicotinamide phosphoribosyltransferase, mRNA. 12 -2.03617 
40.  
Slc17a8 
Solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransport 10 -2.0341 
41.  
Serpina7 
Serine (or cysteine) peptidase inhibitor, clade A (alpha-1 
antiproteinase, X -2.03341 
42.  Bdh2 3-hydroxybutyrate dehydrogenase, type 2, mRNA. 3 -2.03296 
43.  Cd1d1 CD1d1 antigen, mRNA. 3 -2.02001 
44.  Acly ATP citrate lyase, mRNA. 11 -2.0157 
45.  Ces5 Carboxylesterase 5, mRNA. 8 -2.00567 
 
Table 5.11. Genes downregulated (n=45) in liver lysates of Ido2-/-Tdo2-/- mice (pooled from n=6) relative to Ido2+/+Tdo2+/+ mice (pooled from 
n=6), where genes are ranked according to the fold-change values as assessed by Illumina microarray analysis. mRNA expression of genes in 
bold font subsequently was assessed further by RT-qPCR. Data were extracted and analysed using Partek Genomics Suite 6.6 Software. 
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Pathway Name 
No. genes 
in list 
No.  in 
pathway 
1.  Fatty acid elongation 3 20 
2.  Biosynthesis of unsaturated fatty acids 3 21 
3.  Nicotinate and nicotinamide metabolism 3 27 
4.  Metabolic pathways 16 1126 
5.  Primary bile acid biosynthesis 2 13 
6.  Butanoate metabolism 2 21 
7.  Steroid hormone biosynthesis 3 80 
8.  Drug metabolism - other enzymes 2 44 
9.  Glycerolipid metabolism 2 54 
10.  Synthesis and degradation of ketone bodies 1 7 
11.  Metabolism of xenobiotics by cytochrome 
P450 2 62 
12.  Drug metabolism - cytochrome P450 2 63 
13.  Bile secretion 2 68 
14.  PPAR signaling pathway 2 72 
15.  Chemical carcinogenesis 2 86 
16.  Vitamin digestion and absorption 1 23 
17.  Ascorbate and aldarate metabolism 1 26 
18.  Citrate cycle (TCA cycle) 1 31 
19.  Pentose and glucuronate interconversions 1 33 
20.  Nicotine addiction 1 36 
21.  Pyruvate metabolism 1 37 
22.  Fat digestion and absorption 1 37 
23.  Porphyrin and chlorophyll metabolism 1 40 
24.  Tryptophan metabolism 1 42 
25.  Jak-STAT signaling pathway 2 147 
26.  Malaria 1 43 
27.  Cell adhesion molecules (CAMs) 2 151 
28.  Sphingolipid metabolism 1 46 
29.  ABC transporters 1 46 
30.  Mineral absorption 1 46 
Table 5.12. List of top 30 pathways implicated by genes differentially regulated in Ido2-/-
Tdo2-/- (n=6) relative to Ido2+/+Tdo2+/+ (n=6) mouse liver lysates. mRNA expression of 
some genes involved in the pathways, indicated with bold font, subsequently was 
assessed further by RT-qPCR. The list was generated using microarray data analysed 
with Partek Pathway software. 
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 Gene Changes 
relative to 
Ido2+/+Tdo2+/+ 
1.  Lcn2 + 
2.  Saa1 + 
3.  Acot4 - 
4.  Nrep (previously known as D0H4S114) - 
5.  Xdh ns 
6.  Ehd3 ns 
7.  Gdf15 ns 
8.  Fam25c (previously known as 2200001I15Rik) ns 
9.  IgfbP1 ns 
10.  Acot1 ns 
11.  Acot3 ns 
12.  Cyp4a14 ns 
Table 5.13. Gene expression in Ido2-/-Tdo2-/- relative to Ido2+/+Tdo2+/+ mouse liver, 
analysed by RT-qPCR from the list of genes differentially regulated in microarray 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3. Saa1 and Lcn2 were significantly upregulated while Acot4 and Nrep were 
significantly downregulated in Ido2-/-Tdo2-/- mouse liver lysates relative to 
Ido2+/+Tdo2+/+as determined by RT-qPCR. A single asterisk denotes statistical 
significance of p<0.05 whereas triple asterisks denote statistical significance of 
p<0.0001. N = 6 in each case. 
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5.3.4 Overlapping gene expressions in Ido2-/-, Tdo2-/- and Ido2-/- Tdo2-/- mice relative to 
their equivalent wild-types. 
Upon validation by RT-qPCR, the expression of only two genes were differentially 
regulated in the liver of both Ido2-/- and Tdo2-/- single knockouts, where Cyp4a14 was 
upregulated (Fig. 5.4) and Moxd1 was downregulated (Fig. 5.5). Very surprisingly, no 
genes were differentially expressed in all the three transgenic mouse strains deficient 
for one or two tryptophan-catabolising genes tested (relative to their respective wild-
types), i.e. Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- (Fig. 5.6). 
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Fig. 5.4. Cyp4a14 was upregulated in the liver of both Ido2-/- and Tdo2-/- single knockouts 
(n>5 each group) as determined by RT-qPCR. This upregulation, however, was not seen in 
the Ido2-/-Tdo2-/- double knockouts (Fig. 5.3). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.5. Moxd1 was downregulated in the liver of both Ido2-/- and Tdo2-/- single knockouts 
(n>5 each group) as determined by RT-qPCR. However, this gene was not differentially 
regulated in the Ido2-/-Tdo2-/- double knockouts (Fig. 5.3). 
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Fig. 5.6. Venn diagram depicting differentially-regulated genes in liver lysates of single  
Ido2-/- and Tdo2-/- as well as Ido2-/-Tdo2-/- double knockout mouse strains based on RT-
qPCR analysis. 
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5.4 DISCUSSION 
To validate the findings of the microarray analysis, the mRNA levels of genes that were 
differentially regulated (in microarray) in the liver lysates of mice deficient for one or 
two Trp-catabolic enzymes were assessed by RT-qPCR. Although we were interested to 
assess the protein levels and/or activity of the differentially regulated genes that were 
validated by RT-qPCR, time constraints meant that this could not be pursued. Therefore, 
in this section, the changes in mRNA levels will be discussed as indicative of changes in 
protein expression and/or activity. However, the above caveat needs to be kept in mind.  
 
5.4.1 Differentially-regulated genes in Ido2-/- mouse liver lysates relative to the wild-
type counterparts (Ido2+/+) 
The upregulation of eight (Xdh, Acot1, Cyp4a14, Gdf15, Igfbp1, Moxd1, Ehd3 and 
Fam25c) metabolism-related enzymes (Table 5.4) in the absence of Ido2-/- indicates a 
potentially significant role for Ido2 in maintenance of the normal metabolism of various 
elements in murine liver.  
Xanthine dehydrogenase (Xdh) was one of the genes upregulated in Ido2-/- mouse liver 
relative to Ido2+/+. XDH, one of the interconvertible forms of xanthine oxidoreductase 
(XOR), is an NAD-dependent cytosolic dehydrogenase. Both XDH and xanthine oxidase 
(XO) are capable of metabolising hypoxanthine to xanthine, which is then converted to 
uric acid (Pacher et al., 2006). In vivo, XOR exists predominantly as XDH (Hille and 
Nishino, 1995; Hille, 2006) and is converted to XO by sulphydryl oxidation or limited 
proteolysis (Pacher et al., 2006; Zhang et al., 1998). Conversion of XDH to XO has been 
 208 
documented in ischaemia, atherosclerosis and inflammation (Tan et al., 1995; Houston 
et al., 1999; White et al., 1996). While both NAD+ and O2 can reduce XOR, XDH has a 
greater affinity for NAD+ as its electron acceptor, generating NADH, while the converse 
is true for XO, with superoxide anions being the by-product (Nishino, 1994). Both human 
XDH and XO also have been shown to oxidise accumulated NADH and hypoxanthine, 
generating reactive oxygen species in the presence of oxygen. However, XDH prefers 
NADH as its reducing agent whereas XO favours hypoxanthine (Zhang et al., 1998). It 
also is known that the NADH generated by XDH can eventually be consumed by XDH 
itself to regenerate NAD+ (Harris and Massey, 1997). NAD+ is a common denominator 
between the kynurenine and purine pathways, since the former generates NAD+ as one 
of its final products whereas XDH activation is dependent on NAD+ and is upregulated 
by it. It is possible that the observed upregulation of Xdh in Ido2-/- mouse liver relative 
to Ido2+/+ is indirectly caused by an elevation in XO or NAD+. However, if IDO2 plays a 
role in generating NAD+ it is likely that NAD+ deficiency, rather than accumulation, is 
observed in the absence of the enzyme. It previously has been reported that the 
absence of IDO2 did not cause any significant change in serum kynurenine levels (Metz 
et al., 2014), which suggests that it is likely that no changes in NAD+ levels will be 
observed in the absence of IDO2.  
A product of the XO-mediated reaction, superoxide anion radical, has been speculated 
to act as a cofactor that activates IDO1 in enterocytes, since the presence of the XO 
substrates hypoxanthine, inosine and adenosine was shown to increase IDO1 activity 
(Taniguchi et al., 1977). One possibility is that the relationship of XO with IDO2 is similar 
to that postulated between XO and IDO1, where products of XO activity, namely 
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superoxide anion radicals, result in increased activity of the IDO1 enzyme. The absence 
of IDO2 enzyme appears to lead to upregulation of XDH, which could attempt to 
compensate for the lack of IDO2 activity by driving the synthesis of its cofactor, 
superoxide anion radical. However, there is no evidence that superoxide can affect the 
expression of Ido1 or Ido2. Furthermore, the claim that the superoxide anion radical is a 
physiological IDO1 cofactor was refuted by a recent publication (Maghzal et al., 2008). 
Maghzal and colleagues demonstrated that although inosine upregulated IDO1 activity, 
this was entirely dependent on the presence of methylene blue in the cell-free assay 
system and, when an XO inhibitor, oxypurinol, was added to the reaction, IDO1 activity 
was unaffected. This and other evidence showed that superoxide anion radical was not 
acting as a cofactor of the IDO1 enzyme in cells. It was suggested that cytochromeb5 was 
the physiological co-factor for IDO1. Subsequently, Austin and colleagues showed 
parallels with the activation of IDO2 in a cell-free system (Austin et al., 2010). Therefore, 
there are no grounds for postulating that the upregulation of Xdh seen in Ido2-/- mouse 
liver is related to the superoxide anion radical-generating characteristic of XOR.  
In fact, the relationship between XDH and IDO2 may not be within the kynurenine 
pathway but rather through an independent alternative pathway (Figure 5.7). 
Hypoxanthine, one of the substrates of XDH (the gene upregulated in the absence of 
IDO2), was found increased at rest and after exercise in the plasma of obese subjects, 
relative to their healthy, normal body weight counterparts (Saiki et al., 2001) (Figure 
5.7). Xdh mRNA and activity also were found upregulated in obese mice (Cheung et al., 
2007). Regulatory T cells have been shown to play an important role in averting obesity, 
whereas macrophages are key mediators of inflammation and insulin resistance in 
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obesity (Feuerer et al., 2009; O'Rourke et al., 2012). In mouse models of obesity, 
increased numbers of CD8+ effector T cells, reduced numbers of CD4+ regulatory T cells 
and accumulation of macrophages in adipose tissue were noted (Nishimura et al., 2009; 
Yang et al., 2010). The former study also showed reduced cell counts of CD8+ and CD4+ T 
cells in peripheral blood. An important player in the activation and differentiation of 
regulatory T cells, which in turn suppress antigen-specific T cells, is IDO1 (Baban et al., 
2009; Mellor and Munn, 2008; Sharma et al., 2007). This IDO1-dependent T cell 
regulation requires IDO2, since in the absence of IDO2 proliferation of T cells is not 
suppressed (Metz et al., 2014). It is interesting to speculate whether this role of IDO2 in 
IDO1-dependent T cell regulation may lead to obesity (Fig. 5.7). Given the relationship 
between IDO2 and Tregs, it seems important to ascertain its possible role in contributing 
to the onset of obesity, a condition in which Tregs are reportedly decreased and 
hypoxanthine levels elevated (Nishimura et al., 2009; Saiki et al., 2001; Yang et al., 
2010). In addition to impaired activation of regulatory T cells as previously reported 
(Metz et al., 2014), levels of Tregs could be decreased in the plasma and/or liver in the 
absence of IDO2. Although Metz and colleagues found no difference in the numbers of 
Tregs in the spleen and lymph nodes in their experimental contact sensitivity model 
(Metz et al., 2014), it would be worth investigating whether their numbers are reduced 
in peripheral blood, adipose tissue and liver of Ido2-/- mice. Absence of IDO2 conceivably 
could contribute to the onset of obesity, through the dysregulation of Treg functions. 
This putative onset of obesity could then be marked by an increase in hypoxanthine 
levels, and consequently Xdh levels (Figure 5.7).  
 211 
Another interesting feature of XOR is the induction of Xdh mRNA expression and the 
consequent conversion of XDH to XO, increasing XO activity, by proinflammatory 
cytokines like IFNγ, LPS, TNF, IL-1 and IL-6 (Reiners et al., 1990; Terao et al., 1992; 
Ghezzi et al., 1984; Ghezzi et al., 1986; Rinaldo et al., 1994; Pfeffer et al., 1994). IL-1, IL-6 
and TNF are increased in the plasma and adipose tissues of obese humans (Jung and 
Choi, 2014; Ouchi et al., 2011) while, in addition to these cytokines, IFNγ also was found 
elevated in the visceral adipose tissue of obese humans (O'Rourke et al., 2009). Here, 
then, we speculate that the absence of IDO2 could be triggering the onset of obesity-
related inflammation concurrent with increases in proinflammatory cytokines, such as 
IFNγ, IL-1, IL-6 and TNF, which in turn could be upregulating Xdh (Fig. 5.7). Whether the 
upregulation of Xdh seen in the liver of Ido2-/- mice is contributed to by any of the 
proinflammatory cytokines will need to be further investigated by assessing their 
protein levels. Although no upregulation of these cytokines in liver was detected at the 
molecular level by microarray, it is worth considering that the cytokines might be 
produced elsewhere and carried in the circulation to the liver. 
Hyperuricaemia, a product of increased XO activity, has been noted to be correlated 
with insulin resistance as well as dyslipidaemia (Facchini et al., 1991; Zavaroni et al., 
1993; Pacher et al., 2006). These latter observations also are consistent with our 
hypothesis that the absence of IDO2 might trigger obesity, through T cell dysregulation 
(as discussed above) and release of inflammatory mediators that switch on XDH/XO, 
which could contribute to insulin resistance and dyslipidaemia (Fig. 5.7). This, however, 
will need to be further investigated by analysing inflammatory biomarkers, insulin and 
triglyceride levels in IDO2-deficient mice. Although in a previous report the absence of 
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IDO2 attenuated skin inflammatory responses and IFNγ, TNF and IL-6 levels in the ear 
(Metz et al., 2014), this could be a tissue-specific phenomenon. The expression of these 
inflammatory factors should be analysed at the protein level in liver tissues and blood 
samples of IDO2-deficient mice, but there was insufficient time to do this during this 
project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 213 
 
 
 
 
 
 
 
 
 
Fig. 5.7. Possible mechanism through which IDO2 deficiency leads to Xdh 
upregulation, and its implications. XO, xanthine oxidase; Xdh, xanthine dehydrogenase; 
IFNγ, interferon gamma; TNF, tumour necrosis factor; Tregs, regulatory T cells. Numbers 
in the diagram refer to the supporting references listed below. Blue solid lines denote 
established findings, green dashed lines implied outcomes and red dotted lines 
postulated relationships that have not been studied to date. 
1. (Saiki et al., 2001)  
2. (Feuerer et al., 2009; O'Rourke et al., 2012; Nishimura et al., 2009; Yang et al., 2010)  
3. (Baban et al., 2009; Mellor and Munn, 2008; Sharma et al., 2007)  
4. (Metz et al., 2014)  
5. (Reiners et al., 1990; Pfeffer et al., 1994)  
6. (Facchini et al., 1991; Pacher et al., 2006; Zavaroni et al., 1993)  
7. (Jung and Choi, 2014; Ouchi et al., 2011)  
8. (Cheung et al., 2007) 
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Another two genes that were differentially regulated in Ido2-/- mouse liver lysates relative 
to Ido2+/+ were also related to lipid metabolism and/or decreased insulin bioavailability. 
Cyp4a14 and Acot1, both upregulated in the absence of IDO2, are respectively involved in 
fatty acid degradation and biosynthesis of unsaturated fatty acid. These are lipid 
metabolic processes modulated by the PPARα signalling pathway. Ligand-activated 
transcription factors, PPARs trigger the transcription of genes involved in a number of 
processes such as inflammation, as well as lipid and glucose metabolism (Patsouris et al., 
2006). Most commonly, PPARs induce proliferation of peroxisomes, an organelle involved 
in fatty acid oxidation (Issemann and Green, 1990). The CYP4 family of cytochrome P450s 
catalyses metabolism of saturated branched chain and unsaturated fatty acids by ω-
hydrolysis. In hepatocytes, the products are transported into peroxisomes as either free 
fatty acids or dicarboxylic acids following the hydrolysis, after which they are esterified by 
acyl-CoA synthetase. Upregulation of Cyp4a14 mRNA has been reported in obese and/or 
nutritionally diabetic (Type II) mice (Cheng et al., 2008; Enriquez et al., 1999). However, 
this PPARα-dependent gene was suggested to play a protective role in liver inflammation, 
where its upregulation was shown to increase lipid turnover and prevent steatohepatitis, 
a condition marked by inflammation and accumulation of fat in the liver (Ip et al., 2003). 
Cyp4a14 expression also is increased in immune-deficient mice that lack mature T and B 
lymphocytes (Nyagode et al., 2012). The study by Nyagode and colleagues, however, did 
not differentiate between regulatory and cytotoxic T cells, which makes it difficult to 
ascertain whether the upregulation of Cyp4a14 is related to the downregulation of Tregs 
specifically. As mentioned previously, a defect in IDO1-mediated T cell regulation was 
observed in IDO2-deficient mice (Metz et al., 2014). Unfortunately, a literature search did 
not yield much useful information on the effect of pro-inflammatory cytokines on 
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Cyp4a14. However, LPS, an endotoxin, does induce Cyp4a14 expression in a TLR4-
dependent manner in specific mouse strains (Chaluvadi et al., 2009) and this effect could 
be mediated through cytokines such as TNF, IL-1, IL-6, IL-8, the production of which is 
known to be stimulated by LPS (Segura et al., 2002; Harris et al., 2007). As Cyp4a14 is 
increased in obese and/or diabetic mice as well as in immune deficient mice, we 
speculate that the upregulation of Cyp4a14 could be caused by a dysregulation of T cells 
in this mouse strain, concurrent with an onset of obesity, a condition marked by release 
of proinflammatory cytokines and reduced levels of T cells in the blood (Jung and Choi, 
2014; Nishimura et al., 2009). The upregulation of Cyp4a14 in the absence of IDO2 also 
could be a biomarker for a possible obesity-related inflammation occurring in the liver of 
Ido2-/- mice. However, as an increase of Cyp4a14 mRNA expression in murine liver also 
was shown to prevent steatohepatitis – fatty liver disease – its upregulation in the liver of 
IDO2-deficient mice may play a protective role in averting the putative inflammation or 
the worsening of it. Our speculation of the onset of obesity-related inflammation in the 
absence of IDO2 contradicts an earlier report which suggested that the absence of IDO2 
ameliorates inflammation, in the skin at least (Metz et al., 2014). In the face of these 
contradictory results, one has to consider that the phenomenon may be tissue-specific 
and requires more examination at the molecular, and especially protein, levels to acquire 
better understanding. 
After fatty acids or dicarboxylic acids are esterified, they are hydrolysed further by acyl-
CoA thioesterases (ACOTs) (Hardwick, 2008). Acot1, a gene upregulated in Ido2-/- mouse 
liver, codes for ACOT1 (cytosolic acyl-coenzyme A thioesterase I), previously referred to 
as CTE-1 or ACH2. This enzyme hydrolyses long chain fatty acids into free fatty acids and 
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coenzyme A (CoA). In diabetic heart, an accumulation of long chain acyl CoA is seen. 
ACOT1 renders protection against cardiac dysfunction in the diabetic heart by reducing 
long chain fatty acid CoA overload by hydrolysing them (Yang et al., 2012). In the liver, 
Acot1 is upregulated when treated with PPAR agonists (Yamada et al., 1994; Lindquist et 
al., 1998; Hunt et al., 1999) and in diabetic rats (Kurooka et al., 1971), suggesting that 
ACOT1 could be participating in lipid disposal by channelling free fatty acids to ω-
oxidation when experiencing fatty acid overload (Yi et al., 2013; Pashaj et al., 2013; Hunt 
and Alexson, 2002). It previously was reported that PPARα deficiency contributes to 
improved protection against diet-induced glucose intolerance and insulin resistance 
(Finck et al., 2005; Tordjman et al., 2001). Whether ACOT1 plays a similar protective role 
in diabetic or pre-diabetic liver to that reported in the heart (Yang et al., 2012), by 
removing long chain acyl-CoAs, thereby suppressing PPARα signalling, is not yet known 
but is certainly a possibility. Collectively, these observations illustrate that PPARα 
signalling can induce expression of ACOT1, which subsequently suppresses the activity of 
the pathway by removing the long chain acyl CoA agonists of PPARα. An insufficiency in 
PPARα signalling pathway activity has been shown to circumvent glucose intolerance and 
insulin resistance (Finck et al., 2005; Tordjman et al., 2001). This indicates that ACOT1 
possibly plays a protective role against the lipid overload that may occur when PPARα 
signalling is activated. Therefore, the upregulation of Acot1 detected in the liver of Ido2-/- 
mice could be pointing to a possible activation of PPARα signalling. However, as ACOT1 
then feeds back negatively to suppress this PPARα signalling, it is more likely that its 
upregulation indicates a protective response to circumvent the long-chain fatty acid 
overload and onset of insulin resistance and glucose intolerance that otherwise would 
have been triggered by the activation of the PPARα signalling pathway (Fig. 5.8). Although 
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there were no differences in the expression of other genes regulated by this signalling 
pathway in the liver of Ido2-/- mice relative to WT, this does not necessarily mean that the 
PPARα signalling pathway is unaffected by Acot1. It is possible that although their mRNA 
expression was unaffected in the liver of IDO2-deficient mice, the activity or the 
localisation of the proteins regulated by this pathway could be altered. Therefore, it 
would be relevant to analyse expression of proteins regulated by the PPARα signalling 
pathway to better understand the mechanism behind the upregulation of Acot1 and the 
involvement of PPARα signalling in this tissue.  
Thus, expression of Cyp4a14 and Acot1, both coding for proteins involved in protective 
responses against diabetes (Cheng et al., 2008; Enriquez et al., 1999; Yang et al., 2012), 
was increased in the liver of Ido2-/- mice. This could be a marker of inflammation leading 
to dyslipidaemia, eventually resulting in diabetes or obesity in these mice when older. 
However, due to time constraints, we were not able to measure plasma lipid or glucose 
levels or analyse cytokines in the liver tissue of these mice to confirm this possibility. 
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Fig. 5.8. Possible mechanism through which Acot1 is upregulated in the liver of IDO2-
deficient mice, and its implications. PPARα, peroxisome proliferator-activated receptors 
alpha; Acot1, acyl CoA thioesterase 1; SOD, superoxide dismutase; FA, fatty acid; ROS, 
reactive oxygen species. Changes that have been demonstrated in liver and heart are 
indicated. Numbers on the diagram refer to the supporting references given below. Blue 
solid lines denote established findings and red dotted lines possible relationships that 
have not been studied to date. 
1. (Konstandi et al., 2013)  
2. (Hunt et al., 1999; Lindquist et al., 1998; Yang et al., 2012)  
3. (Yang et al., 2012)  
4. (Jagasia and McNulty, 2003) 
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Gdf15, also found upregulated in Ido2-/- mouse liver lysates relative to Ido2+/+, is the 
murine orthologue of the human macrophage inhibitory cytokine-1 (MIC-1). MIC-
1/GDF15 were discovered as a divergent member of the transforming growth factor β 
(TGFβ) superfamily (Bootcov et al., 1997). Although constitutively its expression is low, 
GDF15 is induced in malignancy or injury, leading to speculation about its possible role in 
inflammation (Fairlie et al., 1999; Welsh et al., 2003; Zimmers et al., 2006). More 
recently, its expression also was reported in adipocytes and it was shown to enhance the 
release of adiponectin, suggesting a possible role for this cytokine in modulation of 
adipose tissue function and insulin-sensitivity (Ding et al., 2009). Proinflammatory factors 
such as phorbol myristate acetate (PMA), IL-1, TNF and macrophage colony-stimulating 
factor (M-CSF), as well as the anti-inflammatory factor TGF-β, were shown to stimulate 
MIC-1 in human culture-derived macrophages (Fairlie et al., 1999; Bootcov et al., 1997). 
However, IFNγ and LPS were found to exert no effect on the expression of this protein. It 
has been suggested that its induction by proinflammatory cytokines acts as a protective 
factor, limiting later phases of macrophage activation (Bootcov et al., 1997; Xu et al., 
2006), suggesting that it could contribute to the aversion of inflammation. IDO2 has been 
implicated in inflammation, since skin contact hypersensitivity responses were reduced in 
mice deficient for IDO2 (Metz et al., 2014). Increased levels of GDF15 also have been 
reported in rheumatoid arthritis and cancer (Brown et al., 2007; Brown et al., 2003; 
Brown et al., 2006; Koopmann et al., 2006) while IDO2 was shown to be critical for 
progression of autoimmune arthritis (Merlo et al., 2014).  
Reports of Ido2-/- mice exhibiting ameliorated inflammatory responses in skin contact 
hypersensitivity (Metz et al., 2014) and alleviation of rheumatoid arthritis (Merlo et al., 
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2014) suggest that the absence of IDO2 mitigates inflammatory responses. This conflicts 
with our report on the upregulation of Gdf15 in liver lysates of Ido2-/- mice relative to its 
WT, which would be consistent with the occurrence of inflammation in the absence of 
IDO2. As speculated previously, this difference might indicate tissue-specific roles of 
IDO2, which could depend on the balance of other pro- and anti-inflammatory factors. 
More recently, GDF15 was proposed as a marker for obesity and diabetes (Hong et al., 
2014; Kempf et al., 2012) as there were markedly higher levels of serum GDF15 in obese 
than non-obese humans as well as in Type II diabetic patients compared to their healthy 
counterparts (Ding et al., 2009; Dostalova et al., 2009). Therefore, the upregulation of 
Gdf15 seen in Ido2-/- relative to Ido2+/+ mouse liver also could be indicative of obesity or 
Type II diabetes in older mice, with an underlying inflammation.      
Two other genes that were differentially regulated in the liver tissue of Ido2-/- mice are 
Igfbp1 and Moxd1. Both genes were reported to be markers of reduced insulin 
bioavailability (Jee et al., 2007; Zhang et al., 2007a). Insulin-like growth factors (IGFs) are 
involved in maintaining glucose homeostasis by inhibiting glucose-stimulated insulin 
secretion at higher concentrations (Hill et al., 1997) and stimulating insulin release at 
lower concentrations (Guler et al., 1989). This action is modulated by IGFBPs (insulin-like 
growth factor binding proteins) through the sequestration of IGFs (Firth and Baxter, 
2002), limiting their hypoglycaemic effects. Proinsulin and insulin were shown to both 
play a role in suppressing hepatic IGFBP1 and levels of this protein were reduced in obese 
and Type II diabetic humans (Conover et al., 1992; George et al., 2002; Kamoda et al., 
2006). In Type I diabetes, insulin secretion is reduced and hence an upregulation of 
IGFBP1 has been reported (Hedman et al., 2004). The upregulation of Igfbp1 seen in the 
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liver of Ido2-/- mice could be hinting at the possibility of reduced levels of insulin and/or 
proinsulin. However, this observation does not agree well with the upregulation of the 
other genes, Cyp4a14 and Gdf15, which were implicated in Type II diabetes, although 
XDH has been associated with both Type I and II diabetes (Butler et al., 2000; Desco et al., 
2002).  
Interestingly, the proinflammatory factors IL-1β, IL-6 and TNF were found to induce 
IGFBP1 secretion in mice as well as in a human hepatoma cell line (Samstein et al., 1996; 
Fan et al., 1996; Fan et al., 1995). The upregulation of Igfbp1 in the liver lysates of Ido2-/- 
mice could indicate the presence of proinflammatory factors that trigger inflammation, 
which could eventually lead to obesity and/or diabetes. However, deeper investigation 
will need to be undertaken before this relationship can be established. 
Unlike Igfbp1, which has been studied extensively since the 1970s, very little is known 
about Moxd1, a gene whose expression was downregulated in the liver of Ido2-/- mice, as 
it was discovered only 17 years ago (Chambers et al., 1998). The literature shows that 
Moxd1 expression was decreased in mice with reduced insulin bioavailability (Jee et al., 
2007). Thus, downregulation of Moxd1 and upregulation of Igfbp1 both occur in cases of 
reduced insulin bioavailability, which is characteristic of diabetes and/or obesity, 
consistent with their expression pattern in IDO2-/- mice.  
Collectively, the absence of IDO2 switched on a number of genes that were reported to 
be inducible by pro-inflammatory factors such as IFNγ, TNF, IL-1 and IL-6. The cytokines 
IFNγ, TNF and IL-1 are secreted by macrophages (Darwich et al., 2009; Beuscher et al., 
1990; Stow et al., 2009) whereas IL-6 is secreted secondary to the synthesis of the former 
two cytokines by either macrophages or local stromal cells (Uhlar and Whitehead, 1999; 
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Martin and Dorf, 1991). The fact that macrophages commonly express a number of the 
genes seen upregulated in the liver of Ido2-/- mice is indeed interesting, considering that 
expression of IDO2 is readily detectable in these immune cells. The liver contains a high 
number of Kupffer cells of the macrophage lineage. Whether the secretion of 
proinflammatory cytokines is defective in IDO2-deficient macrophages can be further 
investigated. Although these pro-inflammatory factors were not differentially regulated 
when assessed by microarray, it is worth considering that such changes may occur at the 
protein level as they may be synthesised extrahepatically and transported into the liver. 
The genes Xdh, Cyp4a14 and Gdf15, expression of which was upregulated in the liver of 
Ido2-/- mice relative to the WT, were implicated previously in type II diabetes and/or 
obesity, although Xdh also has been implicated in Type I diabetes, as was Igfbp1. While 
Moxd1 has not been implicated directly in diabetes, its downregulation in mice with 
reduced insulin bioavailability is consistent with a role for this gene in diabetes-related 
conditions. Collectively, this could be pointing to a possible role of IDO2 in regulating 
inflammation, a process that can result in Type II diabetes or obesity. However, this will 
need to be further confirmed by measuring cytokine levels in the serum as well as 
glucose, insulin, lipid, fatty acid and cholesterol levels in the Ido2-/- mice relative to 
Ido2+/+, which has not been studied to date. Although previously no significant 
differences were found in plasma glucose levels of Ido2-/- mice relative to its WT, this was 
analysed in mice ranging from 8 to 23 weeks old (Bakmiwewa, 2011). Plasma glucose 
levels in a group of older mice (>30 weeks) may be a better indicator of the glycaemic 
status in these mice. The mechanism through which the absence of IDO2 might result in 
these conditions also would need to be investigated. Although there were no significant 
differences between the body weights of Ido2-/- and WT mice up to 12 weeks of age (HJ 
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Ball, personal communication), it is possible that any dyslipidaemia that might be 
occurring in the Ido2-/- animals has not by that age translated into changes in body 
weight, considering that the differentially regulated genes have been implicated in 
maturity onset, rather than juvenile, diabetes (Pacher et al., 2006; Enriquez et al., 1999; 
Hur, 2014). It would be interesting to determine body weight as well as blood glucose, 
insulin, cholesterol and lipid levels in older mice to determine whether any differences 
are evident. 
The upregulation of Ehd3 and Fam25c, however, does not seem to fall into any of the 
potential disease categories discussed above. Ehd3 has been implicated in endocytic 
recycling and tubular structures, directing their motility (Galperin et al., 2002). It also has 
been suggested to play a role in cardiac membrane protein trafficking and physiology 
(Curran et al., 2014). In mice, Ehd3 has been detected only in the brain and kidney 
(Galperin et al., 2002). The upregulation of Ehd3 in the absence of IDO2 will require 
further in-depth analysis. The least understood protein in the list is Fam25c, which is a 
predicted sequence with no reports on its structure or role having been made thus far. 
 
5.4.2 Differentially-regulated genes in Tdo2-/- mouse liver lysates relative to the wild-
type counterparts (Tdo2+/+) 
Upon validation of the microarray results by RT-qPCR, only Cyp4a14 and Moxd1 were 
differentially regulated in Tdo2-/- liver lysates compared to Tdo2+/+. As discussed in the 
previous section (Section 5.4.1), Cyp4a14 is involved in fatty acid degradation and an 
upregulation of this enzyme is seen in diabetic and obese mice, whereas Moxd1 is 
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downregulated in rats with decreased insulin bioavailability, suggesting the possibility of 
a form of dyslipidaemia resulting in an onset of obesity and/or diabetes in Tdo2-/-. 
However, as there was no difference in the expression of the other lipid metabolism-
related genes that were upregulated in Ido2-/-, if any dyslipidaemia is occurring in Tdo2-/-, 
it would be less severe than that previously postulated to occur in Ido2-/-, relative to their 
respective wild-types, and likely occurring through a different pathway. 
 
5.4.3 Differentially-regulated genes in liver lysates of Ido2-/- Tdo2-/- murine liver relative 
to Ido2+/+ Tdo2+/+  
In Ido2-/-Tdo2-/- liver, Saa1 and Lcn2 were significantly upregulated, while Acot4 and Nrep 
were significantly downregulated, relative to Ido2+/+ Tdo2+/+. 
SAA1 is an acute phase apolipoprotein (Kushner, 1982), expressed primarily in the liver as 
a response to infection or inflammation (Marhaug and Dowton, 1994; Baumann et al., 
1984; Marhaug et al., 1983; Benson and Cohen, 1979; Meek and Benditt, 1986). An 
elevation of SAA1 levels is seen in obese women and correlates positively with their body 
mass indices (BMI) (Yang et al., 2006). Correlation between excess body fat and metabolic 
as well as cardiovascular diseases has been well documented, although this link is not 
clear at the level of the molecular and cellular interactions (Yang et al., 2006). Increased 
expression of proinflammatory cytokines such as TNF and IL-6 was observed in adipose 
tissue of obese humans and mice, indicating an ‘inflamed’ tissue (Lehrke and Lazar, 2004; 
Emanuela et al., 2012; Nishimura et al., 2009). The expression of human SAA1 is inducible 
by IL-1, IL-6 and TNF (Thorn and Whitehead, 2002; Hagihara et al., 2004; Thorn et al., 
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2004; Thorn et al., 2003). As none of these factors were upregulated at the mRNA level 
when analysed by microarray, we must consider the possibility that they are produced 
elsewhere, as discussed earlier. Elevated levels of SAA1 in the liver tissue of Ido2-/-Tdo2-/- 
suggest an underlying inflammation in the liver of these mice. As the liver is the main site 
of SAA1 production, inflammation could be occurring elsewhere, and circulating 
cytokines could be triggering the transcription of Saa1 in the liver. The presence of 
inflammation in Ido2-/- mice would need to be confirmed by examining protein levels of 
inflammatory cytokines in the liver and plasma. While no significant difference between 
the weight of the Ido2-/-Tdo2-/- and Ido2+/+Tdo2+/+ mice was observed in both genders up 
to 12 weeks of age (HJ Ball, personal communication), in the case that an inflammatory 
pathology is observed through liver histology or analysis of inflammatory markers, there 
will need to be investigation as to whether this inflammation translates into obesity or 
diabetes in mature animals. Interestingly, Saa1 was not upregulated in the Ido2-/- mouse 
liver lysates relative to their equivalent wild-type. Although we speculated that onset of 
inflammation may be occurring in the liver of IDO2-deficient mice, the lack of Saa1 
upregulation in their liver suggests that the mechanism through which inflammation 
might be occurring in Ido2-/- and Ido2-/-Tdo2-/- may differ.  
Complementing Saa1 expression is the upregulation of another gene, Lcn2, coding for an 
inflammatory marker and acute phase protein, lipocalin-2 (LCN), in the mutant mice 
deficient in genes coding for both Trp-catabolising enzymes. Expression of LCN2, also 
known as neutrophil gelatinase-associated lipocalin, is stimulated by IL-1β, IL-6 and TNF 
in hepatocytes, similar to SAA1 (Borkham-Kamphorst et al., 2011). However, it was also 
shown that in the absence of Lcn2, the levels of the same proinflammatory cytokines 
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were elevated, suggesting that while Lcn2 expression is induced by IL-1β, IL-6 and TNF 
(Borkham-Kamphorst et al., 2013), the synthesis of LCN2 acts in a negative feedback 
manner protecting the liver from further injury by suppressing the expression of these 
cytokines. This finding is further consolidated by the observation that the absence of 
LCN2 (Lcn2-/- mice) resulted in worsening of insulin resistance and glucose homeostasis, 
increasing inflammation in the tissue, leading to the proposal of a protective role for 
LCN2 during inflammation (Guo et al., 2010). In addition to this, Lcn2 also has been 
reported to be upregulated in the adipose and liver tissue of genetically obese mice 
(Zhang et al., 2008). Similar to Saa1, despite being upregulated in Ido2-/-Tdo2-/- liver 
compared to Ido2+/+Tdo2+/+, there were no significant differences in the levels of Lcn2 in 
the liver of Ido2-/- mice relative to its wild-type.  First and foremost, whether ‘true’ 
inflammation is occurring in these liver tissues deficient for two Trp-catabolising enzymes 
will need to be confirmed by liver histology as well as analysis of LCN2 and inflammatory 
cytokine protein expression. As speculated previously, despite the possible inflammatory 
onsets that could be occurring in the liver tissues of both Ido2-/- and Ido2-/-Tdo2-/- mice, 
the inflammation-related genes that were dysregulated in these animals differ, suggesting 
that the mechanisms through which inflammation might occur are likely to be distinct. 
Two genes that were downregulated in Ido2-/-Tdo2-/- liver compared to their equivalent 
wild-types were Acot4 and Nrep. Although both ACOT1 and ACOT4 hydrolyse fatty acids 
to form free fatty acids, they hydrolyse different types of fatty acid chains. Described for 
the first time in 2005 (Westin et al., 2005), the latter is responsible for catabolising 
medium chain fatty acids such as succinyl CoA into free fatty acids via ω-oxidation, 
whereas the former does so more with long chain fatty acids via β-oxidation (Hunt et al., 
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2012; Westin et al., 2005). There are no reports on factors that regulate ACOT4. 
Therefore, the downregulation of Acot4 in Ido2-/-Tdo2-/- mouse liver in contrast to the 
upregulation of Acot1 seen in single Ido2-/- is perplexing, in view of the differential 
regulation of other inflammation-related genes. We can only speculate that some form of 
dysregulation of lipid metabolism could be occurring. However, the process that is 
leading to this difference in regulation will need to be studied in detail before any 
conclusions can be made concerning the mechanisms involved. 
Nrep, also known as D0H4S114 and P311, was reported to be expressed constitutively in 
hepatocytes, liver sinusoidal endothelial cells and in activated hepatic stellate cells  
(Guimaraes et al., 2015).  Apart from its earlier reported roles in neuronal regeneration 
(Fujitani et al., 2004) and distal lung generation (Zhao et al., 2006), Nrep also has been 
shown to upregulate a number of genes involved in lipid synthesis and metabolism, 
increase cellular cholesterol and triglyceride level and induce lipid droplet accumulation 
mediated by retinoic acid  (Leung et al., 2008). Plasma Nrep is downregulated 
postprandially in rats fed with an olive oil-rich diet (Martinez-Beamonte et al., 2011). This 
could be suggesting a role for NREP in regulating lipid homeostasis in the liver. If the 
downregulation of Nrep seen in Ido2-/-Tdo2-/- mouse liver relative to Ido2+/+Tdo2+/+ is also 
seen at the protein level, the decrease could be a protective response to control the 
production of cholesterol and triglyceride. Again, due to time constraints, we were not 
able to confirm the expression of Nrep at the protein level. Further investigations will 
need to be done to determine whether dyslipidaemia and inflammation occur in Ido2-/-
Tdo2-/- mouse liver. 
 
 228 
5.4.4 Genes that were differentially expressed in Ido2-/-, Tdo2-/- and Ido2-/- Tdo2-/- 
mouse liver relative to the equivalent wild-types. 
There were only two genes (Cyp4a14, Moxd1) whose differential expression was similar 
in the liver lysates of both Ido2-/-and Tdo2-/- mice relative to their equivalent WT (Fig. 5.9). 
Other genes such as Xdh, Acot1, Gdf15, Igfbp1, Ehd3 and Fam25 were upregulated only in 
the liver of Ido2-/- mice. Similarly, Saa1, Lcn2, Acot4 and Nrep were differentially 
regulated only in the liver of Ido2-/-Tdo2-/- mice, with no changes in expression in either 
Ido2-/- or Tdo2-/- animals. Therefore, it is likely that the mechanism through which TDO2 
and IDO2 may exert their putative effects on inflammation, lipid and/or glucose 
metabolism are different. Upon RT-qPCR validation, there were a greater number of 
genes that were differentially regulated in the absence of IDO2 than there was in the 
absence of TDO2 or IDO2 and TDO2 together. This could be suggesting that the absence 
of IDO2 may exert a greater effect on inflammation in the liver, if there is any, than the 
absence of either TDO2 alone or both IDO2 and TDO2. Whether this inflammation is 
actually occurring and if it could lead to obesity or Type II diabetes will need to be further 
investigated by looking at cytokine levels in these genetically-modified mice, as well as 
insulin, glucose and lipid metabolism.  
Surprisingly, there was no common gene that was regulated in a similar manner in all the 
three transgenic mouse strains deficient for one or two Trp-catabolising enzymes (Fig. 
5.6). This further consolidates the view that while the absence of TDO2 and IDO2 
individually may result in similar outcomes, such as obesity and/or diabetes as postulated 
here, the mechanism leading to this outcome differs between the two cases.  
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5.4.5 RT-qPCR assessment of genes differentially expressed according to microarray 
analysis in IDO2- and/or TDO2-deficient mice 
Despite the relatively high number of genes reported to be differentially regulated in the 
liver lysates of Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- mice relative to their equivalent wild-types 
by microarray analysis, only a fraction was further assessed by RT-qPCR due to time 
constraints. Out of these re-assessed genes, only a small number was validated, as shown 
in Table 5.14. 
Mouse strain  Percentage of genes 
assessed by RT-qPCR  
(total number of genes 
assessed by RT-qPCR / 
total number of genes 
differentially regulated 
in microarray analysis) 
Percentage of genes 
validated by RT-qPCR 
(total number of genes 
validated by RT-qPCR / 
total number of genes 
differentially regulated 
in microarray analysis) 
Percentage genes 
with the same 
outcome in RT-
qPCR analysis as 
microarray analysis 
Ido2-/- 31.7 % (20/63) 12.7 % (8/63) 40.0 % (8/20) 
Tdo2-/- 11.2 % (9/80) 2.5 % (2/80) 22.2 % (2/9) 
Ido2-/-Tdo2-/- 4.5 % (5/111) 3.6% (4/111) 80.0 % (4/5) 
Table 5.14. Percentage of genes assessed by RT-qPCR from the total number of genes 
differentially regulated by Illumina microarray analysis 
In some cases, a difference was seen in the fold expression of genes differentially 
expressed in the liver of Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- mice relative to their equivalent 
wild types by RT-qPCR analysis that did not attain statistical significance. As we were 
using pooled samples in microarray analysis, what seemed like a substantial change in 
gene expression in the liver of Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- mice relative to their 
equivalent wild-type was not statistically significant in fold-change when assessed in 
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samples from individual animals by RT-qPCR. Such was the case for G0s2, Psmb5 and Ccr4 
expression in Ido2-/-, Acot3, Nrep and Saa1 in Tdo2-/- and Acot3 in Ido2-/-Tdo2-/- mice 
relative to their respective wild-type. In some cases, the presence of an individual mouse 
outlier within the pooled sample may have resulted in the detection of falsely 
‘upregulated’ or ‘downregulated’ genes by microarray analysis.  
Finally, there were quite a number of genes with very low expression, which could 
contribute to ‘noise’ in microarray analysis. A small change in these genes can cause large 
differences in fold expression when assessed by microarray analysis. Bcl7, Bmf and Cdc 
are some of these genes that were expressed at very low levels in liver lysates when 
analysed by RT-qPCR, yet were indicated as being differentially regulated by microarray 
analysis. 
These observations reiterate the need to further assess genes that are apparently 
differentially-regulated in microarray samples, in order to validate the expression 
patterns observed. Initially this can be achieved by RT-qPCR. This is even truer when 
performing microarray analysis using pooled samples, a common procedure given the 
high cost of the process. Using pooled samples for microarray analysis and validating the 
differentially-regulated genes by RT-qPCR is perhaps the most cost-effective method to 
study global gene expression in various conditions. 
 
 
 
 231 
5.4.6 Pathways implicated in mice deficient for one or two Trp-catabolising enzymes 
Although quite a number of pathways were implicated in Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- 
mouse liver lysates, the percentage of genes differentially regulated in each pathway 
(number of genes differentially regulated in the pathway / total number genes involved in 
the pathway) in these genetically-modified mice was rather low. The question why the 
absence of IDO2, TDO2 or both only affects the expression of a low number of genes per 
pathway, while the others remain unaffected, requires deeper investigation. Certainly, 
there is considerable redundancy between pathways as defined by the Partek analysis 
software and, indeed, between signal transduction pathways in biological systems. For 
example, based on the genes differentially regulated in the liver of Ido2-/-Tdo2-/- mice, the 
“malaria pathway” was implicated by the Partek Pathway software. However, this 
“pathway” comprises a number of other pathways such as JAK-STAT and Trp metabolism, 
both of which were separately listed as involved pathways by the software.  
Only a small number of genes from each individual pathway was implicated in the 
absence of IDO2 and TDO2, and most of the genes affected by the absence of one or two 
of the enzymes differed. While this could be a result of the different backgrounds of  
Ido2-/-, Tdo2-/- and their equivalent wild-type strains, it also could be suggesting that the 
absence of either could be inducing distinct key inflammatory mediators, which then 
affect the expression of different genes from a variety of pathways. This suggests that the 
mechanisms through which either IDO2 or TDO2 contribute to inflammation (if this does 
occur) also are likely to be different.  
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5.5 SUMMARY 
In conclusion, the absence of either of the tryptophan-catabolising enzymes seems to 
impact upon the expression of genes that have been implicated in inflammation, 
dyslipidaemia, diabetes and/or obesity (Fig 5.9), suggesting that IDO2 and TDO2 could be 
involved in lipid homeostasis and inflammation in the liver.
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Fig. 5.9. Diagram summarising the validated, differentially-regulated genes in Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- relative to their respective wild-
types, and their roles. The diagram was taken from PPAR signalling pathway illustration of Kyoto Encyclopedia of genes and genome (KEGG).  
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CHAPTER 6: GENERAL DISCUSSION & FUTURE DIRECTIONS 
6.1 GENERAL DISCUSSION 
Tryptophan is an essential amino acid. Trp-catabolic enzymes play a prominent 
immunomodulatory role in the physiological process of pregnancy, protection against 
infections, as well as in the pathophysiology of a number of autoimmune conditions such 
as cancer, asthma and rheumatoid arthritis (Schmidt et al., 2009; Szanto et al., 2007; 
Hayashi et al., 2004; Pilotte et al., 2012; Uyttenhove et al., 2003; Munn et al., 1998). Their 
roles in other physiological processes are as yet incompletely understood. 
Very little is known about the biological roles of the most recently discovered Trp-
catabolic isozyme, IDO2, although it has been implicated in inflammatory responses as 
well as in autoimmune disorders (Merlo et al., 2014; Metz et al., 2014).  IDO2, the 
existence of which was first reported by Dr Helen Ball (Ball et al., 2007), from our 
laboratory, has been the main focus in this project. Discovered in 2007 in mice as the 
paralogue of IDO1 and later detected in other mammals such as humans, chimpanzees, 
dog, cow and rats, the characteristics and role of mammalian IDO2 remain to be 
explored. The presence of two other Trp-degrading enzymes, TDO2 and IDO1, led 
researchers to question whether the roles of these enzymes are redundant, if they 
possess overlapping functions, or have their own specialised function distinct from the 
other Trp-catabolic enzymes. Understanding this will be fundamental in the field of Trp 
research.  
The zebrafish was viewed as the canonical vertebrate due to its position in the 
evolutionary timeline. It also possesses several features that make it easy to study, 
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including optical transparency of its embryos, ex utero fertilisation and rapid breeding 
with high numbers of offspring. Due to the presence in the zebrafish of only one ido gene, 
which is more similar to Ido2 than Ido1 (Yuasa et al., 2007), this animal model appeared 
very suitable for the study of the possible role of IDO2 in development. 
The low Trp-catabolic activity of IDO2 has led investigators to speculate that it also may 
possess a role independent of its enzymatic activity (Fatokun et al., 2013; Yuasa et al., 
2009; Metz et al., 2007). Downregulation of functional IDO2 has been reported in 
macrophages from Ido1-/- mice, while an upregulation in IDO2 expression was described 
in IDO1-deficient epididymis (Metz et al., 2014; Fukunaga et al., 2012). Apart from these 
dysregulations, the relationship between TDO2, IDO1 and IDO2 has not been extensively 
investigated. 
While the role of IDO1 in preventing allogeneic foetus rejection in pregnancy is widely 
agreed upon, the role of TDO2 in pregnancy is still under debate (Munn et al., 1998; 
Suzuki et al., 2001). Despite being expressed in the placenta, the role of the third Trp-
catabolic isozyme, IDO2, in pregnancy remains to be explored (Metz et al., 2007; Ball et 
al., 2009). 
During this project, we first developed a convenient and simple human IFNγ bioassay that 
can be adapted for use in different applications such as testing human biological samples 
for the pro-inflammatory cytokine. This assay is based on the ability of the cytokine to 
induce the expression of IDO1 in human endothelial cells. We then acquired useful 
information on the expression patterns of genes coding for Trp-catabolic enzymes during 
development in zebrafish and mouse (Table 6.1). In addition, we investigated the 
distribution of IDO2 within various murine tissues. We also examined the intracellular 
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expression of both IDO1 and IDO2 in a transfected cell system. The expression of genes in 
the absence of one or two Trp-degrading enzymes also was uncovered by studying the 
mRNA expression of Tdo2, Ido1 and Ido2 in different tissues from a variety of transgenic 
mouse strains, Ido1-/-, Ido2-/- and Tdo2-/-. Furthermore, Ido1-/-Tdo2-/- and Ido2-/- Tdo2-/- 
and their equivalent WT mice were generated to acquire additional data on the 
expression of genes coding Trp-catabolic enzymes in the absence of two (of the three) 
enzymes. Finally, we assessed global gene expression in liver tissue deficient in IDO2, 
TDO2, or both. 
  
6.1.1 Distribution and role of IDO2 in development of genes coding for Trp-catabolising 
enzymes  
In this project, we ascertained the distribution of genes coding for Trp-catabolising 
enzymes in both murine and zebrafish developmental series. When the distributions of 
tdo2a, tdo2b and ido of zebrafish were compared to those of the genes coding Trp-
catabolic enzymes in mouse (Tdo2, Ido1 and Ido2), differences in the distribution patterns 
between the TDO and IDO homologues were evident (Fig. 6.1).  
TDO2 in the liver has been shown to be pivotal for the normal regulation of dietary Trp 
(Knox and Auerbach, 1955) as well as to confer tolerogenic properties to the liver, 
modulating immunotolerance in transplantation (Schmidt et al., 2009). In the zebrafish, 
tdo2a and tdo2b both were expressed in the liver from 4 dpf (Fig. 3.6). As the liver 
develops by 3 dpf, with medial expansion by 4 dpf (Field et al., 2003), it can be postulated 
that the expression of tdo2a and tdo2b in the liver is concurrent with the maturation of 
the liver in zebrafish embryos. In contrast, the expression of both Ido2 and Tdo2 mRNA 
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was undetectable in murine embryonic liver (Fig. 4.17), despite being detected at 
relatively high levels in adult livers, suggesting that Trp degradation in murine embryos is 
not activated at the embryonic stage, in the liver at least. The functions of TDO2 and IDO2 
in murine liver are switched on perhaps only after birth. Genes coding Trp-catabolic 
enzymes were detected in zebrafish liver from 4 dpf onwards, after hatching occurs (~3 
dpf). While no synonymy between zebrafish hatching and mouse birth has been 
established, it would be interesting to investigate the factors that switch on the genes 
coding Trp-catabolic enzymes in the zebrafish and mouse.  
Genes coding Trp-catabolising enzymes also were found in zebrafish intestine, where 
tdo2a was distributed throughout (seen at 3 dpf) and tdo2b localised in the posterior 
intestine (visible at 4 dpf) (Fig. 3.6). This is consistent with gut development, where the 
lumen of the intestine is evident by 3 dpf, followed by differentiation of intestinal 
epithelium (~4 dpf) and compartmentalisation of the tract into three distinct sections, 
intestinal bulb, mid-intestine and posterior intestine (by 5 dpf) (Ng et al., 2005). This 
pattern could be suggesting that the Trp-catabolic genes are switched on as part of the 
development of the intestine and may even be necessary for normal intestinal 
development and functioning, similar to the situation in the liver.  
The knocking down of ido and tdo2a genes in zebrafish embryos did not yield reliable 
information on the role of these genes in embryonic development due to the unsuitability 
of the morpholino approach for studying the role of these genes in zebrafish embryos 
since they are expressed relatively late during development (3 dpf onwards). However, 
the localisation and onset of gene expression suggest that the expression of these Trp-
catabolic enzymes is concurrent with liver and intestinal development/maturation.  
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The only intestinal Trp-catabolising enzyme reported thus far is IDO1, which is found 
constitutively in the jejunum and ileum (small intestine) of rabbit and mouse (Higuchi and 
Hayaishi, 1967; Dai and Zhu, 2010), while also being upregulated in inflammatory 
diseases of the gut in mouse and human (Ciorba, 2013; Ohyama et al., 2007; Clarke et al., 
2009). Although Metz and colleagues reported Ido2 mRNA in the colon, another 
publication was not able to detect any in the same tissue (Metz et al., 2007; Fukunaga et 
al., 2012). While we, too, were able to detect Ido2 mRNA in the colon, specific IDO2 
protein staining was undetectable in this tissue (Fig. 4.8). The presence of TDO2 in the 
adult mouse intestine has not been reported. As neither IDO2 nor TDO2 protein have 
been reported in the intestine thus far, we speculate that these two Trp-catabolic 
enzymes may be absent in embryonic gut as well. While we cannot rule out the possibility 
that IDO1 is expressed in embryonic gut, we speculate that, like IDO2 and TDO2 that were 
only expressed postnatally, IDO1 may be expressed only after birth. However, this needs 
to be confirmed by direct measurements of protein expression.  
In the murine developmental series, the genes coding for Trp-degrading enzymes were 
detected in the yolk sac and placenta (Table 6.1). Therefore, it is quite possible that the 
murine Trp-catabolising homologues, while providing nutrients to the embryo through 
the yolk sac, also have evolved to play an immunomodulatory role in development, as 
was the case of IDO1 in murine placenta (Munn et al., 1998). It is rather unlikely that the 
zebrafish homologues of Trp-degrading enzymes play this role in embryonic development 
as fertilisation and maturation of embryos occur ex utero. However, whether these 
enzymes play a role in immune responses to foreign material or infection requires further 
investigation as the genes coding for these enzymes were detected in the liver and 
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intestine, tissues that are involved in not only metabolic and digestive processes but also 
in immune responses (Forn-Cuni et al., 2015; Goldsmith and Jobin, 2012). While all three 
genes coding for Trp-degrading enzymes were detected in murine yolk and placenta, 
Tdo2 was the most highly expressed. While it is IDO1 that has been implicated in inducing 
local immune suppression to prevent allogeneic foetal rejection in mice, the high 
expression of Tdo2 mRNA in the yolk sac and placenta indicates that Tdo2 also could be 
playing roles in murine embryonic development. Whether these roles are related to 
nutrient supply, immunomodulation, or both, warrants further investigation. The absence 
of TDO2, IDO1 or IDO2, or both IDO1 and TDO2 or IDO2 and TDO2, proteins did not affect 
breeding outcomes significantly (HJ Ball, personal communication). This suggests that 
while genes coding for these enzymes are detected in key embryonic developmental 
tissues, these proteins are not essential for normal syngeneic pregnancy, where 
compensatory mechanisms may make up for the absence of Trp-catabolic enzymes. It has 
been shown, however, that IDO is necessary to prevent foetal rejection in allogeneic 
pregnancies of IDO-sufficient parents (Munn et al., 1998). However, no distinction 
between IDO1 and IDO2 activity was made in this experiment. When parents were IDO1-
deficient, no significant differences in pregnancy failure rates were seen in either 
allogeneic or syngeneic foetuses (Baban et al., 2004). Baban and colleagues suggested 
that in IDO1-deficient parents compensatory mechanisms may exist to make up for the 
absent immunomodulatory role of IDO1 in pregnancy. This compensatory mechanism 
may be IDO2-related considering that 1-MT, the inhibitor used in the former study, was 
reported to inhibit both IDO1 and IDO2 (Metz et al., 2007). Although the mRNA levels of 
Ido2 were relatively low in both yolk sac and placenta of WT mice, this does not 
necessarily imply a lack of role for IDO2 in immunomodulation in pregnancy. It is worth 
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considering that maternal IDO2 from other tissues may contribute to facilitate immune 
tolerance during pregnancy. Breeding rates of syngeneic pregnancies in Ido2-/-, Tdo2-/- 
and Ido2-/-Tdo2-/- mice were studied and no differences were found (H. Ball, personal 
communication). The role of IDO2 and TDO2 in allogeneic pregnancy rates in either IDO2- 
and/or TDO2-deficient mice should be examined next. Whether the absence of these 
enzymes during embryonic development affects the mice as they age, predisposing them 
to other conditions, also should be further examined. Furthermore it will be interesting to 
investigate whether the functions of the three Trp-catabolic proteins in these tissues 
overlap or if they play different, specialised roles. The factors that trigger the expression 
of the genes coding Trp-degrading proteins in these tissues also are worth identifying. 
It is quite striking to observe that the expression patterns of the tdo2s in zebrafish were 
different to those in embryonic and adult mouse. As discussed previously (Section 3.4.1), 
tdo2b was initially duplicated from tdo2a in an ancestor of teleosts but was eventually 
lost in many fish lineages. The absence of TDO2 in mammalian intestine could be 
suggesting that although TDO contributed to Trp-catabolising activity in the intestine in 
early evolution, this role was eventually performed by IDO1 alone, which is the Trp-
degrading enzyme expressed highly in the intestine of mouse and humans (Yamazaki et 
al., 1985; Yoshida et al., 1980). While these early reports did not distinguish between 
IDO1 and TDO2, the Trp-degrading enzyme reported in the murine intestine had a broad 
substrate specificity and required the presence of methylene blue for its activity, both of 
which are characteristic of IDO1. This led researchers to conclude that IDO1 is responsible 
for Trp catabolism in intestinal tissues, ruling out a role for extra-intestinal TDO2 or IDO2. 
 242 
However, TDO2, to date, has not been conclusively proven to be absent in the intestine 
by assessment of its molecular or protein expression.   
Although the ido gene in zebrafish is the murine orthologue of IDO2, it was undetectable 
in zebrafish liver while murine IDO2 is expressed strongly in mouse liver. On the other 
hand, zebrafish ido was expressed throughout the intestine, a distribution pattern similar 
to IDO1 in mammalian intestine. Therefore, while being structurally more similar to IDO2, 
the zebrafish IDO homologue exhibited greater similarity to mammalian IDO1 in terms of 
its distribution pattern. Also, zebrafish ido mRNA was detected constitutively only in the 
intestine while mammalian Ido2 (coding for full-length IDO2 protein) has been reported 
in the liver, colon, kidney, brain and epididymis (Ball et al., 2007; Metz et al., 2007). 
Human IDO activity was detected readily in post mortem small intestine, lung, 
epididymis, and placenta (Yamazaki et al., 1985). The wider distribution of IDOs in 
mammals also indicates that the role of the two enzymes in the more complex 
mammalian system could be more extensive and diverse than the role of the homologue 
in the fish.  
While the zebrafish appears a promising experimental model for the study of Trp-
degrading enzymes, especially the IDO2 homologue, the challenges in gene knockdown or 
knockout approaches in zebrafish remain a major concern. With high rates of off-target 
effects, one has to carefully pick a suitable knockdown/knockout approach with the least 
probability of off-target effects, as well as approaches suitable for studying genes that are 
expressed at later time points in development. This is discussed further in Section 6.4. 
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6.1.2 IDO2 distribution within murine tissue 
Taking into account the differential distribution of IDO2 intracellularly in transfected HEK 
cells and WT liver sections, with the former appearing cytoplasmic and the latter 
perinuclear, it could be speculated that the distribution pattern of the protein may differ 
according to tissue type. Of course, the apparent difference in intracellular localisation 
also could be related to the fact that the HEK cells were transfected, or to species 
differences. Although the distribution of IDO2 in transfected HEK cells did not change 
when incubated in different concentrations of Trp, whether this is also the case in vivo 
should be investigated to acquire more understanding of the distribution of IDO2 in 
physiological circumstances. In vivo, we found that, at physiological Trp levels, IDO2 was 
localised perinuclearly in liver hepatocytes. This distribution pattern could suggest a role 
for IDO2 in signal transduction, perhaps affecting the expression of other genes through a 
transduction pathway. While this is purely speculative, it would be worth investigating 
given the precedent set by another haem enzyme, haem oxygenase 1 (HO-1), which 
possesses nuclear distribution in its truncated form (Lin et al., 2007). While HO-1 itself is 
not a conventional transcription factor, its nuclear localisation suggested a possible 
signalling role for the enzyme. Upon trans-signal array analysis, this faster migrating HO-1 
was found to activate a number of transcription factors such as AP-1, STAT1 and NF-κB 
(Lin et al., 2007). It would also be interesting to investigate the distribution pattern of 
IDO2 in primary hepatocytes in Trp-rich conditions in vivo. One way to investigate IDO2 
expression in hepatocytes in Trp-rich conditions in vivo could be by studying by IHC the 
distribution patterns of IDO2 in the liver of Tdo2-/- mice relative to Tdo2+/+ mice, since the 
plasma level of Trp is elevated (~10x) in TDO2-deficient mice (Kanai et al., 2009).  
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Although Ido2 mRNA was detectable in a number of tissues, namely, the liver, kidney, 
brain, epididymis and colon (Ball et al., 2007; Fukunaga et al., 2012; Metz et al., 2007), 
there was no specific protein staining detected in any of these organs, except liver, when 
tissues from Ido2-/- mice were used as negative controls (Table 6.1). The Ido2-/- mice have 
exons 9 and 10 deleted, resulting in the absence of full-length IDO2 protein and 
enzymatic activity (Metz et al., 2014).  The existence of alternatively spliced Ido2 mRNA 
transcripts (Ball et al., 2009; Metz et al., 2007) suggests that there is the potential for 
variant forms of IDO2 proteins, with at least one less active form having been described 
(Metz et al, 2014).  If a variant IDO2 protein is recognized by an IDO2 antibody, but does 
not contain exon 9 onwards, then it is possible that it will still be detectable in the Ido2-/- 
mice.  Thus our results suggest that while specific staining of full-length protein is only 
apparent in the liver, other tissues may still possess variant IDO2 proteins that are 
recognisable by anti-IDO2 antibodies. It would be a methodological milestone to be able 
to generate different antibodies that differentiate between the full-length and truncated 
IDO2 proteins. Only the full-length IDO2 protein is considered likely to possess Trp-
catabolic activity (albeit possessing only low activity), as truncated IDO2 protein 
possessed only a small fraction of the Trp-catabolic activity of the full length protein 
(Metz et al., 2014). However, the presence of substantial amounts of mRNA transcripts in 
the kidney, brain, epididymis and colon but no specific IDO2 staining (when tissues from 
Ido2-/- mice were used as negative controls) forces us to consider other roles the possible 
alternative protein forms of IDO2 may play in these tissues. While mRNA transcripts 
coding for full-length IDO2 protein were undetectable in embryonic liver (Section 4.3.4.3), 
an alternatively spliced Ido2 variant that may encode IDO2 isoforms was found in these 
livers (data not shown). Whether these splice forms of Ido2 mRNA code alternative IDO2 
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proteins that possess actions independent of its enzymatic activity remains to be 
explored. 
 
 6.1.3 Expression of genes in the liver of IDO2- and/or TDO2-deficient mice 
While a number of genes were differentially regulated (Fig. 6.1), as determined by 
microarray analysis, in liver lysates of mice deficient for one or two Trp-catabolic enzymes 
only a few genes were differentially regulated in the liver lysates of all the three 
transgenic mice analysed, Ido2-/-, Tdo2-/- and Ido2-/-Tdo2-/- (Section 5.3.4), when validated 
by RT-qPCR. It is intriguing that the genes differentially regulated in the liver of single 
Ido2-/- and double Ido2-/-Tdo2-/- were different and no one gene was differentially 
regulated in the liver of both mouse models (Section 5.4.4). This could suggest that TDO2 
may in some way be necessary for the dysregulation of the genes differentially regulated 
in IDO2-deficient mice and, in the absence of both TDO2 and IDO2, the expression of 
those genes was not affected. Similarly, the expression of the two genes that were 
dysregulated in the liver of Tdo2-/- mice, in which IDO2 is constitutively expressed, namely 
Cyp4a14 and Moxd1, was unaffected in the liver of Ido2-/-Tdo2-/- mice. The converse may 
also be possible, where IDO2 is necessary for the dysregulation of Cyp4a14 and Moxd1 
seen in TDO2-deficient mice. This will need to be investigated in more detail by analysing 
by RTqPCR and IHC the expression of a greater number of genes found dysregulated in 
the liver of Tdo2-/- mice by microarray. Despite the possible interdependence of TDO2 
and IDO2 in the liver, it is worth considering that the mechanism through which the 
postulated inflammation is triggered, or metabolic processes are perturbed, in the liver of 
these mice differs as there were only two genes that differentially regulated in a similar 
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manner in the liver of both Tdo2-/- and Ido2-/- mice (Section 5.4.4). There were no genes 
similarly regulated in all the three mutant mice deficient for one or two Trp-degrading 
enzymes, which is consistent with this speculation. mRNA expression of neither Ido2 nor 
Tdo2 was affected in the absence of the other in various murine tissues (liver, brain, 
kidney, testes and epididymis) (Section 4.3.5). However, whether either is required to 
dysregulate other genes in the absence of their counterpart necessitates further 
investigation. While a downregulation of Ido2 was seen in the kidney, brain and 
epididymis of Ido1-/- and Ido1-/-Tdo2-/- mice, such a dysregulation was not seen in the 
liver, where Ido2 is detected constitutively (Table 6.1). This is an interesting observation. 
It is possible that the expression of Ido2 is only affected by the absence of IDO1 in tissues 
in which IDO1 was constitutively expressed. In tissues where IDO1 is not constitutively 
expressed, i.e. the liver, such regulation of Ido2 mRNA may not occur, as indeed might be 
expected. However, the attenuation of Ido2 mRNA expression in the kidney of Ido1-/- and 
Ido1-/-Tdo2-/- mice is an anomaly to this hypothesis as its expression is downregulated 
despite the absence of constitutive expression of IDO1 and TDO2 in this tissue (Section 
4.3.5.2).  
Collectively, as we were unable to detect specific IDO2 protein staining in WT kidney, 
brain and epididymis, IDO1 regulation of IDO2 in these tissues will be challenging to study 
at the level of protein expression (Table 6.1). Perhaps, while the mRNA is present 
constitutively, the expression of IDO2 protein is only triggered in certain pathological 
conditions, due to stimulation by specific factors, as yet unidentified. Given the proposed 
roles of IDO2 in inflammation (Metz et al., 2014), perhaps the expression of IDO2 protein 
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in these tissues from WT, Ido1-/- and Ido2-/- mice in inflammatory conditions would be 
worth investigating. 
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6.2 FUTURE DIRECTIONS 
The findings of this project have opened new doors on the roles of Trp-catabolic enzymes, 
especially in murine models, giving leads to possible alternative roles of IDO2 and TDO2 
physiologically and pathophysiologically. 
1. We discovered the expression patterns of genes coding Trp-degrading enzymes in a 
zebrafish developmental series. While the roles of these enzymes in zebrafish 
physiology remain to be uncovered, their expression patterns suggest that they may 
have roles different to those in mammalian systems, exemplified here by the mouse. 
The roles of Trp-catabolic enzymes in zebrafish embryos and adult fishes should be 
investigated using a permanent genome-editing approach such as TALENs or CRISPR-
Cas (Gupta and Musunuru, 2014; Hwang et al., 2013a; Clark et al., 2011). Essential 
amino acids (which need to be acquired from the diet) in fish are similar to those in 
mammals, with Trp being necessary for the optimal growth of some species of fish, 
though not all (Ketola, 1982). Despite this similarity, understanding the roles of these 
enzymes in the development of zebrafish can provide information on the roles of 
these enzymes in early evolution. As we speculate that the roles of the Trp-catabolic 
enzymes in fish differ from those in mammals, it would be interesting to investigate 
whether there was divergence in the roles of these enzymes throughout evolution. 
2. The expression of the Trp-catabolic enzymes TDO2, IDO1 and IDO2 should be 
confirmed at the protein level in murine developmental tissues (yolk sac and 
placenta). The Trp-catabolic activities of these enzymes also should be assessed. The 
roles of TDO2 and IDO2 in adult mice, separated from those during mouse 
development, could be investigated by a conditional knockout approach where 
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genes coding for Trp-catabolic enzymes would be only knocked out during adulthood 
by administration or feeding of factors that activate regulatory elements that clip the 
genes (Friedel et al., 2011). This approach can also be used to induce knockouts in 
specific cell types. The conditional knockout method may be more specific, with 
fewer off-target effects, than utilising either siRNA or selective inhibitors for TDO2 
and IDO2. No difference in breeding numbers was found in Ido2-/- or Tdo2-/- litters 
(data not shown), suggesting that if the enzymes have roles in syngeneic embryonic 
development, other mechanisms may exist to compensate for the lack of these 
enzymes during development.  Breeding rates of allogeneic foetuses from parents 
deficient for TDO2 and IDO2 should be observed and compared to those of TDO2-, 
IDO1- and IDO2-sufficient parents in whom the Trp-catabolic activity is antagonised 
by conditional knockout given the precedent that IDO was necessary for allogeneic 
pregnancies in IDO-sufficient parents, although this did not distinguish between 
IDO1 and IDO2 (Baban et al., 2004). Breeding rates of syngeneic offsprings of IDO1, 
IDO2 and TDO2-sufficient parents whose Trp-catabolic activity was ablated by 
selective inhibitors also could be acquired to better elucidate the possible role of 
these enzymes in pregnancy. 
3. IDO2 protein was detectable only in liver and, in the absence of IDO2, a number of 
inflammation- and metabolism-related genes were differentially regulated in this 
tissue (Section 5.3.1). The biological significance of this observation merits further 
study. It was suggested (Section 5.4.1) that these changes in young mice might flag 
the early stages of an inflammatory response that might in turn induce a metabolic 
dysregulation with some similarities to Type 2 diabetes. Assessment of inflammatory 
markers in the plasma and different cell populations, especially immune cells, of 
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IDO2-deficient mice as well as the histology of the liver at different age points may 
provide essential information on the health status of the mice in the absence of 
IDO2. Examining similar parameters in Tdo2-/- and Ido2-/- Tdo2-/- mice also may 
provide pivotal information on the consequences of the absence of IDO2 and TDO2 
for the normal physiology of mice. 
4. We speculated (Section 5.4.1) that the absence of IDO2 results in dysregulation of 
inflammatory mediators, which could lead eventually to obesity or diabetes. If 
changes in pro-inflammatory factors were confirmed, switching off their expression 
either by long-acting neutralising antibodies or conditional knockout could help us 
elucidate the changes that are triggered in the absence of IDO2. Assessment of 
obesity and diabetes also should be done in older mice (>20 wks of age) by 
examining their plasma lipid, glucose, cholesterol and body weights. 
5. Another possibility is to study the expression of IDO2 in immune/inflammatory 
models in Ido2-/- and WT mice, e.g. models of liver transplantation, viral hepatitis, 
alcohol-induced steatohepatitis or non-alcoholic fatty liver disease, all of which 
involve, to some extent, inflammation of the liver. This may provide some valuable 
insights into the role of IDO2 in acute or chronic liver injury/inflammation as well as 
immunotolerance in transplantation. 
6. It has been established previously that, in vivo, Trp-rich conditions activate TDO2 
(Knox and Auerbach, 1955), while IDO1 expression is inhibited by elevated serum Trp 
and stimulated more by immunological signals (Yoshida et al., 1980). However, the 
regulation of IDO2 by Trp in vivo has not been investigated as yet. While studying the 
distribution of IDO2 in different Trp concentrations was attempted in this project 
(Section 4.3.3), it only could be tested in HEK cells transfected with mouse Ido2 
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plasmids and not in primary hepatocytes as Ido2 signals in the latter plunged 
dramatically within the first 24 hours. Also, other factors that regulate IDO2 
expression are not known. Examining the activity and distribution of IDO2 in various 
tissues when fed Trp-rich or –deficient diets would be a good approach. However, it 
must be recalled that Ido2 mRNA expression did not change in Tdo2-/- mice (Section 
4.3.5), which have elevated serum Trp concentrations (Kanai et al., 2009). 
Understanding the expression of IDO2 in the presence of different concentrations of 
its primary substrate, Trp, could help us better understand the role of IDO2 in 
murine physiology. 
7. Although the analysis of gene expression of Trp-catabolic enzymes in the colon was 
not pursued, since we did not detect any specific IDO2 protein staining there 
(despite the presence of mRNA), the mRNA expression of the Trp-degrading enzymes 
in the intestine of Ido1-/-, Ido2-/-, Tdo2-/-, Ido1-/-Tdo2-/-, Ido2-/- Tdo2-/- mice and their 
equivalent WTs is worth investigating. IDO1 has been reported in the human and 
mouse intestine (Yoshida et al., 1980; Yamazaki et al., 1985) while Ido2 mRNA has 
been detected in both human (Metz et al., 2007) and mouse colon (Section 4.3.2). 
Any findings of IDO2 expression in the colon can be compared with the expression of 
zebrafish Trp-catabolic enzymes (Section 3.2.2). Global gene expression in the colon 
of mice deficient for IDO1 or IDO2 also could be investigated to ascertain whether 
the two enzyme isoforms play an interdependent role in this tissue. 
8. Truncated IDO2 protein, coded for by the splice form of Ido2 mRNA, has been 
reported and was shown to possess a much lower Trp-catabolic activity than the full 
length protein (Ball et al., 2009; Metz et al., 2014). It has been speculated that this 
truncated protein may possess alternative biological roles despite diminished 
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enzymatic activity. Sequencing of ‘non-specific’ proteins detectable by mouse IDO2 
antibodies, especially in tissues in which staining by IHC was evident, could be 
pursued. If indeed the non-specific protein detected is the truncated form of IDO2 
protein, uncovering its role in mouse physiology by knocking out its expression using 
a conditional knockout approach might yield interesting outcomes. 
9. While we validated by RT-qPCR the mRNA expression of some of the genes found by 
microarray analysis to be dysregulated in the liver of mice deficient for IDO2, TDO2, 
or both, we were not able to validate the mRNA levels of many other genes found 
differentially regulated in this analysis due to time constraints. We also were not 
able to confirm the dysregulation of the genes at the protein level. Ascertaining the 
expression of proteins of the genes found dysregulated by RT-qPCR should be 
pursued as it can provide insight into whether the absence of IDO2, TDO2 or both 
affects the expression of other genes at the posttranslational level. The expression of 
other genes, especially those related to the ones found differentially regulated in the 
liver of Ido2-/- and/or Tdo2-/- mice by RT-qPCR, should be assessed to uncover more 
players in the possible pathophysiology of the liver in the absence of IDO2, TDO2 or 
both. 
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6.3 FINAL CONCLUSION 
Collectively, these findings show a difference in the expression patterns of TDO and IDO 
homologues in zebrafish and mouse, which suggests differences in the roles of these 
homologues in embryonic development of the two species. In the adult mouse, IDO2 was 
found localised perinuclearly in hepatocytes. In the absence of the enzyme a number of 
inflammatory mediator-induced genes were differentially regulated, suggesting the 
possibility of a pre-inflammatory state in the liver in the absence of IDO2 in young adult 
mice. In the absence of both TDO2 and IDO2, a divergent set of inflammation-related genes 
was differentially regulated, suggesting mechanistic differences in how inflammation might 
be induced in these models. We speculate on a possible role for IDO2 in mediating 
inflammation and that, in the absence of the protein, inflammation-driven obesity and/or 
diabetes may result.
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Zebrafish (Section 3.3.2) tdo2a tdo2a ido 
i. Expressed in the liver and 
throughout the intestine. 
ii. Expressed from 3 dpf 
onwards 
iii. Possible role not ascertained 
as morpholino approach was 
unsuitable for knockdown 
i. Expressed in the liver and 
posterior intestine 
ii. Expressed 4 dpf onwards 
iii. Possible role not ascertained 
due to unsuitability of 
morpholino approach 
i. Expressed throughout the 
intestine 
ii. Expressed from 3 dpf onwards 
iii. Despite increased mortality in 
ido morphants, which was 
rescueable by the injection of 
ido RNA transcript, it was later 
deemed likely to be an off-
target effect of the 
morpholino 
Mouse Tdo2 Ido1 Ido2 
Embryonic (Section 4.3.4) i. mRNA expressed highly in yolk 
sac and placental tissue in a 
developing murine embryo. 
Among the three genes coding 
for Trp-catabolising enzymes, 
Tdo2 was expressed the 
highest. No expression 
detectable in murine liver 
while neonatal liver expressed 
very low levels of Tdo2 gene. 
i. mRNA expressed at low levels 
in yolk sac and placenta 
i. mRNA expressed at low levels 
in yolk sac and placenta. 
Expression levels were also 
lower than Ido1. mRNA coding 
for full length protein was 
undetectable in both 
embryonic and neonatal liver 
 
Adult    
Cellular and intracellular 
distribution 
(Section 4.3.2 and 4.3.3) 
i. Neither cellular nor 
intracellular localisation of 
TDO2 in tissues were 
examined due to the lack of a 
suitable antibody 
i. Cellular distribution of IDO1 
was not studied as it has been 
investigated thoroughly by 
previous researchers (Britan 
et al., 2006; Ball et al., 2007; 
i. For cellular distribution, IDO2 
protein detected in the liver, 
distributed perinuclearly in 
hepatocytes, which was 
different to the distribution 
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Dai and Zhu, 2010; Fukunaga 
et al., 2012). 
ii. Intracellular localisation of 
IDO1 showed cytoplasmic 
distribution in HEK cells 
transfected with plasmid 
containing Ido1 cDNA. 
reported by an earlier group 
(Fukunaga et al., 2012). Colon, 
brain, testis and kidney tissues 
exhibited non-specific staining 
that was present in both WT 
and Ido2-/- mice, challenging 
the findings of previous 
publications (Ball et al., 2007; 
Fukunaga et al., 2012).  
ii. IDO2 also exhibited 
cytoplasmic expression 
intracellularly in HEK cells 
transfected with plasmid 
carrying Ido2 cDNA. 
Expression in liver, kidney, brain, 
epididymis and testis tissue of 
different mutant mice deficient 
for one or two Trp-catabolising 
enzymes and their equivalent WT 
(Ido2-/-, Ido2+/+, Ido1-/-, Ido1+/+, 
Tdo2-/-, Tdo2+/+, Ido2-/-Tdo2-/-, 
Ido1-/-Tdo2-/- and 
Ido1+/+Ido2+/+Tdo2+/+) (Section 
4.3.5) 
i. Tdo2 mRNA was detectable in 
the liver, brain and testis of all 
the genetically-modified 
mouse strains except in Tdo2-/-
, Ido2-/-Tdo2-/- and Ido1-/-Tdo2-
/-  
ii. Tdo2 mRNA was not 
differentially regulated in the 
above mentioned tissues in 
mouse strains deficient for 
either IDO1 or IDO2, 
suggesting that the absence of 
the two genes does not affect 
the expression of Tdo2. 
i. Ido1 mRNA expression was 
found in the testis and 
epididymis of all mouse strains 
except Ido1-/- and Ido1-/-Tdo2-/-  
ii. The mRNA levels were 
unaffected in these tissues 
from mice deficient for IDO2 
and/or TDO2. 
i. Ido2 mRNA was detected in 
the liver, kidney, brain, testis 
and epididymis in all mouse 
strains except Ido2-/-and Ido2-/-
Tdo2-/-. 
ii. Ido2 mRNA levels were 
attenuated in the kidney, 
brain and epididymis of Ido1-/- 
and Ido1-/-Tdo2-/- mice, 
suggesting a possible 
downregulation of Ido2 mRNA 
in the absence of Ido1. 
Possibility that the effects 
seen are artefact also was 
considered. 
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Assessment of global gene 
expressions by microarray in liver 
lysates of Ido2-/-, Ido2+/+, Tdo2-/-, 
Tdo2+/+, Ido2-/-Tdo2-/- and 
Ido1+/+Ido2+/+Tdo2+/+) 
(Chapter 5) 
i. Absence of TDO2 in Tdo2-/- 
lead to the upregulation of 
Cyp4a14 and downregulation 
of Moxd1. 
ii. Cyp4a14 is a PPARα signalling 
pathway-dependent gene, 
involved in lipid and fatty acid 
metabolism while also 
implicated in a 
hepatoprotective role in 
ameliorating inflammation in 
the liver. 
iii. Moxd1 was reportedly 
downregulated in mice with 
reduced insulin bioavailability. 
This suggests a possible role 
for TDO2 in lipid metabolism. 
i. Not studied i. Xdh, Acot1, Cyp4a14, Gdf15, 
Igfbp1, Moxd1, Ehd3 and 
Fam25c were differentially 
regulated in liver tissue of 
Ido2-/- mice relative to Ido2+/+. 
ii. Xdh, Acot1, Cyp4a14, Gdf15 
Igfbp1, Ehd3 and Fam25c 
were all upregulated in IDO2-
deficient mice whereas Moxd1 
was downregulated.  
iii. Xdh, Acot1, Cyp4a14, Gdf15 
and Igfbp1 were all implicated 
in inflammatory responses 
while also reported in obesity 
and obesity-related diabetes. 
Proinflammatory cytokines 
such as IFNγ, TNF, IL-1 and IL-6 
have been shown to 
upregulate some of these 
genes.  
iv. Moxd1 was downregulated in 
Ido2-/- relative to Ido2+/+ mice, 
similar to its reduction in liver 
lysates of Tdo2-/- mice relative 
to the WT. 
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i. In the absence of both TDO2 and IDO2 in the liver, four genes were found differentially regulated, 
namely, Saa1, Lcn2, Acot4 and Nrep. 
ii. Both Saa1 and Lcn2 were downregulated in liver lysates of Ido2-/-Tdo2-/- relative to 
Ido1+/+Ido2+/+Tdo2+/+. Both these genes code for acute-phase proteins that are upregulated by TNF, IL-1 
and IL-6. Both SAA1 and LCN2 also have been implicated in inflammation and obesity. The lack of such 
upregulation in mice deficient for only one Trp-catabolising enzyme, IDO2 or TDO2, could be suggesting 
that the presence of at least one Trp-degrading enzyme is necessary to avert acute inflammatory 
responses, if inflammation is indeed occurring in the liver of these mice. 
 
Table 6.1 Summary of all findings 
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Fig. 6.1 Diagrammatic summary of findings  
Zebrafish image taken from (Haffter et al., 1996) and murine embryo image from 
(Mikkola and Orkin, 2006). The image of the liver was taken from 
(http://www.pinkjooz.com/index.php/virtual-liver-product-by-iisc-professor-patented-
in-us/)  
LPS - lipopolysaccharide; IFNγ - interferon gamma; TNF - tumour necrosis factor; IL-1 - 
interleukin 1; IL-6 - interleukin 6; IL-4 - interleukin 4; Xdh - xanthine 
oxidoreductase/dehydrogenase; Acot1 - acyl CoA thioesterase 1; Igfbp1 - insulin-like 
growth factor binding protein 1; Gdf15 - growth differentiation factor 15; Cyp4a14 - 
cytochrome P450 family 4, subfamily a, polypeptide 14; Moxd1 – monooxygenase DBH-
like 1; Saa1 – Serum amyloid A 1; Lcn2 – Lipocalin 2 
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